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I Executive summary (English) 
1 Introduction 
The purpose of the project was to produce a report on the current state of play of the 
2003 Council Recommendation (CR) of 18 June 2003 on the prevention and reduction 
of health-related harm associated with drug dependence. The CR mentions the 
following main objectives: 
» Member States should, in order to provide for a high level of health protection, set 
as a public health objective the prevention of drug dependence and the reduction 
of related risks, and develop and implement comprehensive strategies accordingly. 
» Member States should, in order to reduce substantially the incidence of drug-
related health damage (such as HIV, hepatitis B and C and tuberculosis) and the 
number of drug-induced deaths, make available, as an integral part of their overall 
drug prevention and treatment policies, a range of different services and facilities, 
particularly aiming at risk reduction; to this end, bearing in mind the general ob-
jective, in the first place, to prevent drug abuse. 
» Member States should consider measures, in order to develop appropriate evalua-
tion to increase the effectiveness and efficiency of drug prevention and the reduc-
tion of drug-related health risks. 
This report is the 2nd progress report on the implementation of the Council Recom-
mendation on the prevention and reduction of health-related harm associated with 
drug dependence, and covers all 27 EU countries, the acceding country Croatia and the 
candidate countries: The former Yugoslav Republic of Macedonia, Iceland, Montenegro 
and Turkey. It consists of the updated overview of the implementation of the Council 
Recommendation, including country profiles, as well as analyses of regional and EU 
trends in epidemiology, and assesses the availability of, access to and coverage of 
harm reduction measures. It provides country overviews on harm reduction policies, 
services and facilities (country profiles). In addition, the available scientific evidence 
regarding interventions to prevent and reduce health-harms associated with drug 
dependence was analysed. The epidemiological background data, using data available 
at the EMCDDA, as well as other relevant information, and trends from 2003 to 2011 
were analysed as well as main trends in availability and coverage of harm reduction 
measures introduced by the Council. The main output is a set of conclusions regarding 
the follow-up of the Council Recommendation, based on the application and combina-
tion of the scientific effectiveness of interventions and the availability and coverage.  
The general literature review on harm reduction measures presented in the previous 
report has been updated using recent comprehensive reviews. Significant recent 
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studies have been added and the relevant websites have been searched for interna-
tional guidelines. For areas not covered by recent reviews, four systematic literature 
reviews have been carried out (“peer naloxone programmes”, “needle exchange 
programmes in prison”, “prison release management” and “measures to influence the 
route of administration”). All data available at the EMCDDA (all standard tables and 
structured questionnaires collected by the EMCDDA, via the REITOX network), were 
scanned for relevant information related to description of the CR-implementation and 
then extracted. For the analysis of epidemiological trends, data presented in the 
EMCDDA Statistical Bulletin have been used, additionally. Data mainly refer to the time 
period 2003 to 2010/2011. Country profiles focusing on drug-related harm (reduc-
tion) were elaborated based on the analysis of the information available at the 
EMCDDA, the national reports on the drug situation from 2003 to 2011 and the 
EMCDDA country overviews for each country. They were sent out to the REITOX Focal 
Points to carry out a gap-survey in the course of which they were asked to add infor-
mation, if necessary, and to comment on the information presented (response rate 26 
of 32 countries). An online-survey for policy makers and a consultation of stake-
holders were designed to gather further information on the implementation of harm 
reduction. The EC contacted the permanent representatives of each country asking for 
the nomination of one responsible person for the CR to fill in the survey for policy 
makers (response rate 31 of 32 countries). Based on a systematic selection strategy, a 
total of 123 institutions from 32 countries were contacted during the stakeholder 
survey (response rate 43 field organisations from 24 countries). 
For the interpretation of this report’s results, the following limitations have to be taken 
into account: Data availability made a very good progress in the time-span from 2003 
to 2010. Thanks to the continuous efforts of the EMCDDA for the harmonisation and 
expansion of the data collection, a lot of comparable data are available to describe the 
epidemiology of the drug situation and harm reduction measures. Unfortunately, data 
for time-series are not available for all countries; even basic data to analyse drug-
related harm and availability of measures of harm reduction are missing in some 
countries. It has to be taken into account that absolute numbers (e. g. number of 
drug-induced deaths) are influenced by the quality of the respective monitoring 
system too. Therefore country-specific comparisons have to be made with caution and 
should be completely avoided for some countries. Another limitation of the present 
work is that the view of policy makers and stakeholders is based on the answers of 
single persons (answering often for a big country). This makes their statements 
subjective expert opinions. Therefore the data gathered are appropriate to give a 
general impression but not for direct country comparisons. 
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2  Evaluation of the Council Recommen-
dation on harm reduction 
Epidemiologic situation: Concerning drug-related harm it can be stated that a signifi-
cant reduction of HIV infections among IDUs in most countries was achieved, but 
infection rates of hepatitis C are still high in many countries. Recent HIV-outbreaks in 
Greece and Romania show that HIV infection rates can increase rapidly under specific 
conditions, including low coverage of harm reduction measures. High rates of HCV 
infection can be seen as an indicator for the risk of a HIV-outbreak. It was not possible 
to reduce drug-induced deaths (deaths due to overdoses) since 2003 in most coun-
tries, although the coverage of OST increased. On one hand, measures to improve 
retention rates in OST and to avoid interruptions (e. g. prison, attempts to become 
drug free with no adequate indication) are necessary. On the other hand interventions 
focusing on overdose risk like drug consumption rooms and peer naloxone pro-
grammes should be considered. Prison release is a risk factor for drug-induced deaths 
and therefore adequate throughcare including prison release management and con-
tinuation of OST in prison and over the period of release is crucial. 
Effectiveness of harm reduction measures: Strong scientific evidence exists for the 
effectiveness of opioid substitution treatment (OST) to reduce the infection risk in 
connection with drug-related infectious diseases (DRID) as well as mortality. Interrup-
tions of OST are a risk factor for drug-induced deaths. Challenges for the future are to 
clarify how coverage can be increased further (e. g. avoid waiting lists), how interrup-
tions can be avoided and how OST concerning substances and regimes can be diversi-
fied to meet the needs of different subgroups of opioid addicts. For syringe provision 
through specialised programmes (NSP) there is strong scientific evidence concerning 
the reduction of infection risk (e. g. HIV, HCV, HBV) too. Challenges are the improve-
ment of coverage and dealing with other routes of administration than injecting. There 
is strong evidence concerning the effectiveness of harm reduction (e. g. OST and NSP) 
in prison. Information, education and communication are effective when the setting is 
appropriate and messages are provided in an adequate form by trustable persons. One 
possibility to assure the right setting is outreach work. Since peers are the most 
trustable persons in many aspects peer involvement, which has proven to be effective, 
is a good strategy. In the last decade evidence on heroin assisted treatment as a 
second line intervention, drug consumption rooms and peer naloxone programmes 
have increased significantly. Based on this evidence, it can be assumed that these 
interventions are effective, but that they should be further monitored and evaluated. 
Vaccination for hepatitis B, treatment of HIV, HBV and HCV in IDUs are effective 
measures. The treatment for HCV is a particularly effective instrument of infection 
prevention for others, too. Drug Checking is considered an integrated service that 
always combines chemical analysis with advice or counselling. Although there is no 
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new evidence on the effectiveness of Drug Checking programmes, it might be worth 
conducting new studies; on the one hand, because Drug Checking/counselling might 
be a reaction to the emergence of new psychoactive substances on the markets, on the 
other hand, because professionalisation took place concerning testing and counselling 
methods during the last few years. The possible benefit of measures to avoid shifting 
from other routes of administration to injecting drug use (IDU) and to foster shifting 
from IDU to other routes of administration is pointed out in scientific literature. 
However, there is hardly any evidence on concrete projects 
Implementation of harm reduction measures and impact of the CR: The situation 
concerning harm reduction measures improved a lot in most countries. The Coverage 
of OST and NSP has considerably increased but especially NSP is still far away from full 
coverage in all countries. While OST is now available in many prisons, NSP is not. 
Therefore, prisons are still a high risk environment for infections with HIV or HCV and 
a driving factor for infectious diseases among injecting drug users (IDUs). Therefore, 
improvements in the prison setting are very urgent. Heroin assisted treatment as a 
second line intervention, Drug Checking, peer naloxone programmes and drug con-
sumption rooms are implemented in a few countries, only. In times of economic crises, 
the financing of the status quo and the expansion of harm reduction is an important 
issue in all countries. In some EU 12 states (e. g. Bulgaria and Romania) harm reduction 
projects were initially funded by the “Global Fund to Fight AIDS, Tuberculosis, and 
Malaria”. There are now problems to ensure national funding.  
The impact of the CR can be judged as substantial especially in the countries joining 
the EU in 2004 or later (EU 12). Further support from EU level is requested from 
organisations involved in harm reduction. A clear new statement on harm reduction 
can help to foster the expansion of harm reduction measures. These EU-
recommendations should also include, in particular, new measures like drug consump-
tion rooms and peer naloxone programmes related to the reduction of drug-induced 
death and give a special focus to prisons (OST, NSP and adequate throughcare). In 
addition, the new recommendations should cover new areas like housing, social re-
integration and occupation because these are the main factors for stabilisation (or de-
stabilisation if lacking). However, existing harm reduction measures, such as OSP and 
NSP as the backbone of any harm reduction strategy, need to be strengthened. 
3 Conclusions and suggestions for follow up  
Based on the literature review and the analysis of the situation concerning harm 
reduction, the following concrete recommendations and priorities have been elabo-
rated. These recommendations implicate activities on different levels: EU-policy-level, 
national-policy-level and the level of practical implementation in the field: 
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The Council Recommendation (CR) helped foster harm reduction in the EU, but the 
coverage is still far from sufficient in most areas. This calls for political strengthening 
of harm reduction which can be achieved by a new or revised CR. 
Priority A: reduction of drug-induced deaths 
Reasoning: It was not possible to reduce the number of drug-induced deaths since 
2003. 
Target: Significant reduction of the number of drug-induced deaths in the next ten 
years. 
Proposed measures: Improvement of the coverage (for specific subgroups of opioid 
addicts, low threshold access to opioid substitution treatment (OST), comprehensive 
health insurance covering OST) and organisation of opioid substitution treatment 
(avoid interruptions, avoid waiting lists), facilitate the use of emergency services, peer 
naloxone programmes, integration of services (especially prison and treatment release 
management), drug consumption rooms, outreach, peer involvement and family 
support. 
Relevance for public health: drug-induced deaths remain one of the major causes of 
death among young adults which calls for immediate action. In particular, easy to 
adopt and cost-effective measures, such as facilitating the use of emergency services, 
should be addressed and supported on European level in order to save young lives.  
Priority B: improvement of harm reduction in prison 
Reasoning: The coverage of harm reduction measures in prison lies far behind the 
coverage outside prison. Therefore prison is a high risk environment for injecting drug 
users (IDUs) to get infected with drug-related infectious diseases. Prison release 
without adequate throughcare is one main risk factor for drug-induced deaths. 
Target: Harm reduction measures in prison should be assured as a comprehensive 
response, equivalent to the community in the next ten years. 
Proposed measures: Opioid substitution treatment (OST), syringe provision through 
specialised programmes (introduction in all prisons), release management, through-
care into and out of prison (regarding OST continuity), housing for released prisoners, 
health assessments including infection prevention. 
Relevance for public health: Harm reduction in prison is still very rare or limited in 
Europe leading to high infections rates and increased mortality after prison release. 
Around 15 percent of all drug related deaths could be avoided only with adequate 
prison release management (Frisher et al. 2012)1. High infection rates (e. g. HIV, 
hepatitis) of the prisons’ population threaten health of general population too: Good 
                                                                                                                                         
1  
In 2005, 1.506 drug users died in England from ‘overdose’ or poisoning, drug abuse or drug dependence. 
Around 15% of these deaths occur in people after release from prison. Those fatalities might be avoided with 
adequate and coordinated prison release management (Department of Health 2007; Frisher et al. 2012). 
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prison health is good public health (WHO 2007). Action in this field promises instant 
results and can be implemented cost-effectively (e. g. syringe provision through 
specialised programmes).  
Priority C: reduction of harm caused by drug-related infections 
Reasoning: Existing harm reduction measures have been sufficient to decrease HIV 
prevalence in injecting drug users (IDUs) significantly in most countries covered with 
this research. Recent HIV outbreaks show that this situation can change very fast when 
harm reduction is not appropriate. Hepatitis C (HCV) rates are still on a high level and 
will lead – if the reaction is not adequate – to enormous individual (e. g. death due to 
consequences of HCV) and public costs. 
Target: Significant reduction of HCV prevalence among IDUs in the next five years, 
significant reduction of HIV incidence in countries with high rates or increasing trends 
(Bulgaria, Estonia, Latvia, Lithuania, Greece, Portugal, Romania) in the next five years, 
treatment (especially HCV treatment) of infected IDUs shall reach full coverage in the 
next five years (treatment should be available for anyone in need of it), HBV vaccination 
of IDUs shall reach full coverage in the next five years. 
Proposed measures: See priority B, improvement of the coverage of syringe provision 
through specialised programmes (NSP), HIV and HCV treatment programmes, im-
provement of HCV surveillance, hepatitis B vaccination programmes, outreach, peer 
involvement and family support. 
Relevance for public health: Infection diseases are one of the major drug-related 
diseases and can be easily and cost-effectively influenced by widely available syringe 
provision through specialised programmes. It has been proven that OST is associated 
with a 50 percent reduction of HIV infection among IDUs (MacArthur et al. 2012). HIV 
and HCV treatment decrease the risk of infections for others and are therefore cost-
effective interventions to avoid individual harm and prevent further infections, which 
could lead to a substantial health burden for drug users and the society as whole. 
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II Résumé analytique (Français) 
1  Introduction 
L’objectif de ce projet était de produire un rapport sur la situation actuelle de la 
Recommandation du Conseil (CR) du 18 Juin 2003 sur la prévention et la réduction des 
méfaits pour la santé liés à la toxicomanie. La CR mentionne les objectifs généraux 
suivants: 
» atteindre un haut niveau de protection de la santé, de faire de la prévention de la 
toxicomanie et de la réduction des risques annexes un objectif en matière de santé 
publique et d'élaborer et de mettre en oeuvre des stratégies globales en consé-
quence. 
» diminuer de façon significative l'incidence des effets nocifs de la drogue sur la 
santé (VIH, hépatite B et C, tuberculose, etc.) et le nombre de décès liés à la 
drogue, de prévoir, comme partie intégrante de leurs politiques globales de 
prévention et de traitement de la toxicomanie, un éventail d'interventions diverses, 
notamment en vue de réduire les risques et, par conséquent, sans perdre de vue 
l'objectif général qui est, avant tout, d'empêcher la toxicomanie. 
» élaborer une évaluation pertinente destinée à accroître l'efficacité et l'efficience de 
la prévention de la toxicomanie et de la réduction des risques pour la santé induits 
par les drogues. 
Ce rapport est le 2e sur l’état d’avancement concernant la mise en œuvre de la Re-
commandation du Conseil sur la prévention et la réduction des méfaits pour la santé 
liés à la toxicomanie, et couvre tous les 27 pays de l’UE, la Croatie (pays en voie 
d’adhésion) et les pays candidats: l’ancienne République yougoslave de Macédoine, 
l’Islande, Le Monténégro et la Turquie. Il consiste en un aperçu général de la mise en 
œuvre de la Recommandation du Conseil, incluant les profils de pays, ainsi que les 
analyses des tendances épidémiologiques des Régions et des Pays de l’UE, l’évaluation 
de la disponibilité, de l’accès ainsi que de la couverture des mesures de réduction des 
méfaits. Il fournit des aperçus des pays sur les politiques de réduction des méfaits, les 
services et les installations (Profil des pays). De plus, les preuves scientifiques dispo-
nibles concernant les interventions pour empêcher et diminuer les risques sanitaires 
liés à la toxicomanie ont été analysées. Les données de base épidémiologiques, qui 
utilisent les données disponibles de l’OEDT, ainsi que d’autres informations perti-
nentes, et les tendances de 2003 à 2011 ont été analysées, tout comme les principales 
tendances de disponibilité et de couverture des mesures de réduction des risques 
introduites par le Conseil.  
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Le principal résultat est une série de conclusions portant sur le suivi de la Recomman-
dation du Conseil, basé sur l’application et la combinaison de l’efficacité scientifique 
des interventions ainsi que sur la disponibilité et la couverture.  
La documentation générale sur les mesures de réduction des méfaits présentée dans le 
rapport précèdent a été mise à jour en utilisant des études récentes. Des recherches 
sur les directives internationales ont aussi été effectuées sur des sites web pertinents. 
Pour les domaines non-couverts par les études récentes, quatre analyses documen-
taires systématiques ont été effectuées (“programmes de Naloxone administrée par les 
pairs”, “programmes d’échange d’aiguille dans les prisons”, “gestion des libérations”, 
“mesures pour influencer le changement de voie d’administration”). Toutes les don-
nées disponibles à l’OEDT (tous les tableaux et les questionnaires structurés recueillis 
par l’OEDT, via le réseau REITOX), ont été scannées, afin de trouver des informations 
pertinentes pour la description de la mise en œuvre de la CR, puis extraites. Pour 
l’analyse des tendances épidémiologiques, les données présentées par le bulletin 
statistique de l’OEDT ont également été utilisées. Les données font principalement 
référence à la période 2003 à 2010/2011. Les profils des pays se concentrant sur les 
dommages liés à la drogue (diminution) ont été élaborés à partir de l’analyse des 
informations disponibles à l’OEDT, des rapports nationaux sur le problème de la 
drogue de 2003 à 2011 et des aperçus de chaque pays fait par l’OEDT. Ils ont été 
envoyés aux points focaux du REITOX afin de procéder à un sondage au cours duquel 
ils devaient ajouter de l’information, si nécessaire, et commenter les informations 
présentées. (Taux de réponse 26 pays sur 32). Un questionnaire en ligne pour les 
décideurs et une consultation des parties prenantes ont été conçus afin de rassembler 
des informations supplémentaires sur la mise en place de la diminution des risques. La 
CE a demandé aux représentants de chaque pays de nommer une personne respon-
sable de la CR qui remplira le questionnaire pour les décideurs. (Taux de réponse de 
31 pays sur 32). A partir d’une stratégie de sélection systématique, 123 institutions au 
total, sur les 32 pays, ont été contactées pendant  l’enquête (Taux de réponse de 43 
organisations sur le terrain sur 24 pays). 
Pour l’interprétation des résultats de ce rapport, les limites suivantes doivent être 
prises en compte: La disponibilité des données a fait un progrès important sur la 
période 2003-2010. Grace aux efforts continus de l’OEDT pour l’harmonisation et 
l’expansion de la collecte de données, beaucoup de données comparables sont 
disponibles pour décrire la situation épidémiologique des drogues et les mesures de 
diminution des méfaits. Malheureusement, les données pour les séries temporelles ne 
sont pas disponibles pour tous les pays ; même certaines données de base pour 
l’analyse des risques liés à la drogue et pour les mesures de diminution des risques 
manquent pour certains pays. Il faut également prendre en compte le fait que les 
nombres absolus (par exemple le nombre de décès liés à la drogue) sont influencés par 
la qualité du système de suivi. C’est pourquoi les comparaisons spécifiques entre pays 
doivent être réalisées avec prudence et doivent même être évitées pour certains pays. 
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Une autre limite du présent ouvrage est que la perception des décideurs et des inter-
venants est basée sur les réponses d’une seule personne (qui répond souvent pour un 
grand pays). Cela fait, de leurs déclarations, des avis subjectifs d’experts. En consé-
quence, les données collectées sont appropriées pour donner une impression générale 
mais pas pour une comparaison directe entre pays.  
2  Evaluation de la Recommandation du 
Conseil sur la réduction des méfaits 
Situation épidémiologique: En ce qui concerne les risques liés à la drogue, on peut 
affirmer qu’une baisse significative du nombre d’infection au VIH parmi les UDI dans la 
plupart des pays a été réalisée, mais que les taux d’infections de l’hépatite C sont 
toujours très élevés dans beaucoup de pays. Les récentes épidémies de VIH en Grèce et 
Roumanie montrent que les taux d’infections au VIH peuvent augmenter rapidement 
sous certaines conditions spécifiques, incluant la faible couverture des mesures de 
réduction des méfaits. Les taux élevés de VHC peuvent être vus comme un indicateur 
de risque de déclenchement de VIH. Il n’était pas possible de réduire les décès direc-
tement liés à la drogue (décès dus à une overdose) depuis 2003 dans la plupart des 
pays, même si la couverture des TSO a augmenté. D’un côté, les mesures 
d’amélioration des taux de rétention et le fait d’éviter les interruptions dans les TSO 
(par exemple: dans les prisons, tentatives pour se libérer de la drogue sans indication 
adéquate) sont nécessaires. D’un autre côté, les interventions qui se concentrent sur 
les risques d’overdose comme les salles de consommation de drogues et les pro-
grammes de Naloxone administrée par les pairs, doivent être pris en considération. Les 
libérations constituent un facteur de risque pour les overdoses et de ce fait une prise 
en charge adéquate, incluant la gestion des libérations et la continuation des TSO en 
prison et tout au long de la période de libération, est cruciale. 
Efficacité des mesures de réduction des méfaits: De solides preuves scientifiques 
existent pour l’efficacité des traitements de substitution d’opioïdes (TSO) afin de 
réduire le risque d’infection en relation avec les maladies infectieuses liées à la con-
sommation de drogue (DRID) ainsi que la mortalité. Les interruptions des TSO sont un 
facteur à risque pour les décès directement liés à la drogue. Les défis pour l’avenir 
seront de clarifier comment la couverture peut être étendue d’avantage (par ex. en 
évitant les listes d’attente), comment les interruptions peuvent être évitées et comment 
les TSO concernant les substances et régimes peuvent être diversifiés afin de répondre 
aux besoins des différents sous-groupes dépendants aux opioïdes. Pour la distribution 
des seringues par le biais de programmes spécialisés (NSP) il y a également de solides 
preuves scientifiques concernant la réduction du risque d’infection (Par ex: VIH, VHC, 
VHB). Les défis sont l’amélioration de la couverture et le traitement par d’autres voies 
d’administration que l’injection. Il y a de solides preuves concernant l’efficacité de la 
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réduction des méfaits (par ex: TSO et NSP) en prison. L’information, l’éducation et la 
communication sont effectives lorsque l’environnement est approprié and lorsque les 
messages sont fournis de manière adéquate par des personnes de confiance. Une 
possibilité d’assurer un bon environnement est le travail de proximité. Les pairs étant 
les personnes les plus dignes de confiance dans de multiples aspects, l’implication de 
ces derniers, qui s’est avéré être effective, est une bonne stratégie. Au cours de la 
dernière décennie, les preuves de traitement avec prescription d’héroïne comme 
traitement de deuxième ligne, les salles de consommation de drogue et les pro-
grammes de Naloxone administrée par les pairs ont considérablement augmentés. A 
partir de cela, nous pouvons en déduire que ces interventions sont efficaces, mais 
qu’elles devraient être surveillées et évaluées d’avantage. La vaccination contre 
l’hépatite B, le traitement contre le VIH, VHC et VHB dans les UDI sont des mesures 
efficaces. Le traitement pour le VHC est également un instrument particulièrement 
efficace pour la prévention des infections des autres maladies. Le contrôle des drogues 
est considéré comme un service intégré combinant une analyse chimique avec conseils 
et soutien. Bien qu’il n’y ait pas de nouvelles preuves sur l’efficacité des programmes 
de contrôle des drogues, cela vaudrait peut-être la peine de conduire de nouvelles 
études; d’une part, parce que le contrôle des drogues/consultations peuvent être une 
réaction aux substances psychoactives émergentes sur le marché, ou d’autre part, 
parce que la professionnalisation a eu lieu concernant les méthodes de test et de 
conseil au cours des dernières années. Les avantages possibles liés aux mesures mises 
en place pour éviter de passer d’autres routes d’administration à l’injection de drogue 
ou à celles mises en place pour favoriser le passage de l’UDI à d’autres routes 
d’administration sont soulignés dans la littérature scientifique. Toutefois, il n’y a guère 
de preuve provenant de projets concrets.  
Mise en œuvre des mesures de réduction des risques et impact de la CR: La situation 
concernant les mesures de réduction des risques s’est beaucoup améliorée dans la 
plupart des pays. La couverture des TSO et des NSP a considérablement augmenté 
mais les NSP notamment sont encore loin d’une couverture totale dans tous les pays. 
Tandis que les TSO sont maintenant disponibles dans un grand nombre de prisons, 
nous ne pouvons pas en dire autant des NSP. Par conséquent, l’univers carcéral est 
toujours un environnement présentant un risque élevé d’infection par le VIH ou VHC et 
un facteur déterminant pour les maladies infectieuses parmi les utilisateurs de drogues 
injectables (UDI). C’est pourquoi les améliorations de l’environnement carcéral sont 
très urgentes. Le traitement avec prescription d’héroïne comme traitement secondaire, 
le contrôle des drogues, le programme de Naloxone administrée par les pairs et les 
salles de consommation de drogues ne sont qu’implantés dans peu de pays. En 
période de crise économique, le financement du statu quo et l’extension de la réduc-
tion des méfaits est un enjeu important dans tous les pays. Dans certains pays de 
l’UE 12 (la Bulgarie ou la Roumanie par exemple) les projets de réduction des méfaits 
étaient initialement financés par le “Global Fund to Fight AIDS, Tuberculosis, and 
Malaria”. Il existe maintenant des problèmes concernant le financement national. 
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L’impact de la CR peut être jugé comme substantiel particulièrement pour les pays qui 
ont rejoint l’UE en 2004 ou plus tard (UE 12). Les organisations impliquées dans la 
réduction des risques demandent un soutien supplémentaire au niveau de l’UE. Un 
nouvel exposé précis sur la réduction des risques peut aider à favoriser 
l’épanouissement des mesures de réduction des risques. Ces recommandations de l’UE 
devront inclure en particulier les nouvelles mesures, comme les salles de consomma-
tion de drogues et les programmes de Naloxone administrée par les pairs, liées à la 
réduction des décès dus aux drogues et mettre un accent particulier sur les prisons 
(TSO, NSP et autres prises en charge adéquates). De plus, ces nouvelles recommanda-
tions devront couvrir de nouveaux domaines comme le logement, la réinsertion sociale 
et l’emploi car ce sont les facteurs principaux de stabilité. Toutefois, les mesures 
existantes, concernant la réduction des risques comme les TSO et NSP comme épine 
dorsale de toute stratégie de réduction des risques, devront être renforcées.  
3 Conclusions et suggestions de suivi  
A partir de la documentation existante et de l’analyse de la situation concernant la 
réduction des méfaits, les recommandations et priorités suivantes ont été élaborées. 
Ces recommandations impliquent des activités à différents niveaux: au niveau des 
politiques de l’UE, au niveau de la politique nationale et au niveau de la mise en œuvre 
pratique dans les domaines suivants:  
La Recommandation du Conseil (CR) a aidé à favoriser la réduction des risques dans 
l’UE, mais la couverture demeure encore insuffisante dans la plupart des secteurs. Ceci 
exige un renforcement politique de réduction des méfaits qui peut être atteint par une 
nouvelle CR (ou révisée).  
Priorité A: Réduction des décès liés à la drogue (surdose) 
Raisonnement: Il n’était pas possible de réduire le nombre de décès liés à la drogue 
depuis 2003. 
Objectif: Réduction significative du nombre de décès liés à la drogue dans les 10 
prochaines années. 
Mesures proposées: Amélioration de la couverture (pour des sous-groupes spécifiques 
de dépendants aux opioïdes, abaissement du seuil d’accès aux traitements des 
substituts d’opioïdes (TSO), un système d’assurance malade complet couvrant les TSO) 
et de l’organisation des traitements des substituts d’opioïdes (éviter les interruptions 
et les listes d’attente), faciliter l’utilisation des services d’urgences, des programmes 
de Naloxone administrée par les pairs, l’intégration de services (spécialement dans les 
prisons et gestion des libérations), les salles de consommation de drogue, la sensibili-
sation, l’implication des pairs et le support familial. 
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Intérêt pour la santé publique: Les décès dus à la drogue restent l’une des premières 
causes de décès parmi les jeunes adultes, ce qui exige des mesures immédiates. Les 
mesures faciles à adopter et avec une bonne rentabilité, comme l’utilisation d’urgence, 
devraient être ad+ressées tout particulièrement et supportées au niveau Européen afin 
de sauver de jeunes vies.  
Priorité B: Amélioration de la réduction des méfaits en prison 
Raisonnement: La couverture des mesures pour la réduction des méfaits en prison est 
très inférieure à celle en dehors des prisons. Par conséquent, la prison est un environ-
nement à risque pour les utilisateurs de drogues d’injection (UDI) de se faire infecter 
par des maladies liées à la drogue. La libération sans prise en charge adéquate est un 
des facteurs de risques de décès liés à la drogue.   
Objectif: Les mesures de réduction des méfaits en prison devront être assurées telle 
une réaction complète, équivalente à celles de la communauté dans les dix prochaines 
années.  
Mesures proposées: Les traitements de substitution aux opioïdes (TSO), la distribution 
de seringues à travers des programmes spécialisés (introduction dans toutes les 
prisons), gestion des libérations, la prise en charge dans et en dehors de la prison 
(concernant la continuité des TSO), le logement pour les prisonniers libérées et les 
évaluations de santé incluant la prévention des infections. 
Intérêt pour la santé publique: La réduction des méfaits en prison est toujours très 
rare, voir limitée en Europe, ce qui entraine des taux d’infection élevés et une mortalité 
en augmentation après une libération. Environ 15 % de toutes les morts liées à la 
drogue pourraient être évitées seulement avec une gestion des libérations plus adé-
quate.  (Frisher et al. 2012)2. Les taux d’infection élevés (par exemple VIH, hépatite) de 
la population carcérale menace également la santé de la population générale. Un 
système carcéral sain est bon pour la santé publique (WHO 2007). Des actions dans ce 
domaine promettent des résultats instantanés et peuvent être mis en place de manière 
rentable (par exemple: la distribution de seringues à travers un programme spécialisé).  
Priorité C: réduction des méfaits causés par les maladies infectieuses liées à la drogue 
Raisonnement: Les mesures existantes de réduction des méfaits ont été suffisantes 
pour diminuer la prévalence du VIH dans la catégorie des utilisateurs de drogues 
d’injection (UDI) de manière significative dans la plupart des pays couverts par cette 
recherche. Les récentes épidémies de VIH montrent que cette situation peut changer 
très rapidement lorsque la réduction des risques n’est pas appropriée. Les taux 
d’Hépatite C (VHC) sont toujours très élevés ce qui entraînera – si la réaction n’est pas 
                                                                                                                                         
2  
En 2005 il y avait 1,506 consummateurs de drogues en Angleterre qui mouraient d`empoisonnement ou d`une 
surdose, d`abus de drogues ou la dépendance aux drogues. À peu près 15 pour cent de ces morts peuvent etre 
attribués aux personnes récemment liberés de prison. Une gestion de la sortie de prison adéquatement 
appliquée et coordinée pourrait contribuer à éviter ces décès (Department of Health 2007; Frisher et al. 2012). 
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adéquate – d’énormes coûts individuels (par exemple la mort du aux conséquences du 
VHC) et publics. 
Objectif: Dans les cinq prochaines années: une réduction significative de la prévalence 
de VHC parmi les UDI, une réduction significative de l’incidence du VIH dans les pays 
aux taux élevés ou en augmentation (Bulgarie, Estonie, Lettonie, Lituanie, Grèce, 
Portugal, Roumanie), le traitement des UDI infectés (en particulier le traitement VHC) 
devra atteindre une couverture totale (le traitement devra être disponible à toute 
personne qui en aurait en besoin), la vaccination du VHB pour tous les UDI devra 
également atteindre une couverture totale. 
Mesures proposées: Voir priorité B, amélioration de la couverture de la distribution de 
seringues à travers des programmes spécialisés (NSP), des programmes de traitement 
du VIH et VHC, l’amélioration de la surveillance du VHC, les programmes de vaccina-
tion de l’hépatite B, la sensibilisation, l’implication des pairs et le support familial.  
Intérêt pour la santé publique: les maladies infectieuses font partie des principales 
maladies liées à la drogue et peuvent être influencées de manière facile et rentable par 
une distribution de seringue largement accessible à travers les programmes de se-
ringues spécialisés. Il a été prouvé que les TSO sont associés à 50 % de réduction des 
infections de VIH parmi les UDI (MacArthur et al. 2012). Le traitement du VIH et du 
VHC diminue les risques d’infection pour les autres et par conséquent sont des 
interventions rentables pour éviter les risques individuels et pour prévenir d’autres 
infections, qui pourraient conduire à un lourd fardeau sanitaire pour les utilisateurs de 
drogues ainsi que pour la société dans son ensemble.  
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III Kurzfassung (Deutsch) 
1  Einleitung 
Ziel dieses Projektes war es, die aktuelle Situation hinsichtlich der Umsetzung der 
Empfehlung des Rates der Europäischen Union vom 18. Juni 2003 zu Prävention und 
Reduktion von Gesundheitsschäden im Zusammenhang mit Drogenabhängigkeit 
darzustellen. Die Empfehlung des Rates nennt folgende Hauptziele: 
» Die Mitgliedstaaten sollten zur Gewährleistung eines hohen Gesundheitsschutzni-
veaus die Prävention von Drogenabhängigkeit und die Verringerung damit verbun-
dener Gefahren zum Ziel ihrer Gesundheitspolitik machen und dementsprechend 
umfassende Strategien ausarbeiten und umsetzen. 
» Die Mitgliedstaaten sollten zur Erreichung einer deutlichen Senkung der Inzidenz 
drogenbedingter Gesundheitsschäden (wie etwa HIV, Hepatitis B und C und Tuber-
kulose) sowie der Zahl drogenbedingter Todesfälle als integralen Bestandteil ihrer 
umfassenden Politiken zur Drogenbekämpfung und zur Drogenbehandlung ver-
schiedene Dienstleistungen und Einrichtungen vorsehen, die insbesondere auf die 
Risikominderung ausgerichtet sind - eingedenk des allgemeinen Ziels,den Dro-
genmissbrauch von vornherein zu verhindern. 
» Die Mitgliedstaaten sollten spezifische Aktivitäten zur Entwicklung geeigneter 
Evaluierungsverfahren, die die Effizienz und Wirksamkeit der Drogenprävention 
sowie die Reduzierung drogenbedingter Gesundheitsrisiken erhöhen, in Erwägung 
ziehen. 
Der vorliegende Bericht ist die zweite Bestandaufnahme zum Stand der Implementie-
rung der Ratsempfehlung und umfasst alle 27 EU Mitgliedsstaaten, das Beitrittsland 
Kroatien und die Kandidatenländer: ehemalige jugoslawische Republik Mazedonien, 
Island, Montenegro und die Türkei. Der Bericht enthält einen aktualisierten Überblick 
über die Implementierung der Ratsempfehlung mit Länder-Profilen, regionale und EU-
weite epidemiologische Trendanalysen und eine Beurteilung der Verfügbarkeit, des 
Zugangs und Deckungsgrads von Maßnahmen zur Schadensminimierung. Er bietet 
Länderüberblicke zu Schadensminimierungs-Strategien, Diensten und Einrichtungen 
(Länder-Profile). Darüber hinaus wurde die verfügbare wissenschaftliche Evidenz zu 
Maßnahmen zur Prävention und Verringerung von Gesundheitsschäden im Zusammen-
hang mit Drogenabhängigkeit analysiert. Anhand der bei der EBDD verfügbaren Daten 
aber auch anhand anderer relevanter Quellen wurden die epidemiologischen Hinter-
grunddaten und Entwicklungen zwischen den Jahren 2003 und 2010/2011 analysiert 
und die Entwicklungen in puncto Verfügbarkeit und Deckungsgrad von schadensmini-
mierenden Maßnahmen gemäß der Ratsempfehlung dargestellt. Hauptergebnis ist eine 
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Reihe von Schlussfolgerungen für eine neue Ratsempfehlung auf Basis der wissen-
schaftlichen Evidenz zu den Maßnahmen, bzw. deren Verfügbarkeit und Deckungsgrad.  
Die allgemeine Literaturauswertung aus dem Vorgängerbericht wurde mit aktuellen 
Übersichtsarbeiten aktualisiert. Ergebnisse rezenter Studien wurden einbezogen und 
relevante Websites wurden nach internationalen Leitlinien zu schadensminimierenden 
Maßnahmen durchsucht. Zu Bereichen, die nicht durch die allgemeine Literaturauswer-
tung abgedeckt waren, wurden vier systematische Literaturauswertungen durchgeführt 
(„Peer-Naloxon-Programme“, „Spritzentauschprogramme in Haftanstalten“, „Haftent-
lassungsmanagement“, „Maßnahmen zur Beeinflussung der Applikationsform“). Alle 
verfügbaren Daten der EBDD (alle „standard tables“ und „structured questionnaires“ die 
von der EBDD über das REITOX-Netzwerk gesammelt werden) wurden nach Informatio-
nen durchsucht, die hinsichtlich der Implementierung der Empfehlung des Rates 
relevant sind. Für die Analyse der epidemiologischen Trends wurden darüber hinaus 
auch Daten des „Statistical Bulletins“ der EBDD herangezogen. Die Zahlen beziehen 
hauptsächlich auf den Zeitraum von 2003 bis 2010/2011. 
Basierend auf den EBDD-Daten, den nationalen Berichten zur Drogensituation der Jahre 
2003 bis 2011 und den Länderübersichten der EBDD wurden Länder-Profile zu dro-
genbezogener Schadensminimierung erstellt. Diese wurden in der Folge als sogenann-
ter „gap-survey“ an die nationalen Knotenpunkte des REITOX Netzwerkes ausgesandt 
mit der Bitte gegebenenfalls Informationen hinzuzufügen oder die präsentierten 
Informationen zu ergänzen (Rücklauf: 26 von 32 Ländern). Um weitere Informationen 
bezüglich des Standes der Implementierung der Ratsempfehlung zu sammeln, wurden 
ein Online-Fragebogen für politische Entscheidungsträger und ein Online-Fragebogen 
zur Befragung von Feldorganisationen entwickelt. Die Europäische Kommission 
kontaktierte die ständigen Vertreter der einzelnen Länder mit der Bitte um die Nen-
nung einer für die Ratsempfehlung zuständigen Person, die den Fragebogen für die 
politischen Entscheidungsträger ausfüllen sollte (Rücklauf: 31 von 32 Ländern). Zur 
Befragung der Feldorganisationen wurden anhand einer systematischen Auswahlstra-
tegie insgesamt 123 Institutionen aus 32 Ländern identifiziert und kontaktiert (Rück-
lauf: 43 Institutionen aus 24 Ländern). 
Bei der Interpretation der Ergebnisse des vorliegenden Berichtes sind folgende Ein-
schränkungen zu berücksichtigen: Die Verfügbarkeit von Daten hat sich im Zeitraum 
von 2003 bis 2010 stark verbessert. Dank kontinuierlicher Bemühungen der EBDD in 
puncto Harmonisierung und Ausweitung der Datensammlung, ist eine beträchtliche 
Menge an vergleichbaren Daten zur Beschreibung der epidemiologischen Situation in 
Bezug auf die Drogenproblematik und schadensminimierende Maßnahmen vorhanden. 
Leider sind Zeitreihen-Daten nicht für alle Länder verfügbar; selbst grundlegende 
Daten zur Analyse von drogenbezogenem Schaden und zur Verfügbarkeit von scha-
densminimierenden Angeboten fehlen in manchen Ländern. Es ist weiters zu berück-
sichtigen, dass die Absolutzahlen (z. B. bei drogeninduzierten Todesfällen) auch von 
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der Qualität des jeweiligen Monitoring-Systems beeinflusst werden. Aus diesem Grund 
sollten länderspezifische Vergleiche nur mit äußerster Vorsicht angestellt bzw. für 
einzelne Länder gänzlich unterlassen werden. Eine weitere Einschränkung stellt die 
Tatsache dar, dass die Befragungsergebnisse der politischen Entscheidungsträger und 
der Feldorganisationen für ein ganzes Land stehen aber auf Aussagen von Einzelper-
sonen beruhen. Es ist zu berücksichtigen, dass es sich dabei um subjektive Experten-
meinungen handelt, weshalb sich die gesammelten Daten zwar dafür eignen einen 
Überblick über die Situation zu geben, nicht jedoch um direkte Ländervergleiche 
anzustellen.  
2 Evaluierung der Empfehlung des Rates zu 
Schadensminimierung 
Epidemiologische Situation: Bezüglich drogenassoziierter Infektionskrankheiten wurde 
eine signifikante Reduktion der HIV Infektionen unter Drogenkonsumierenden in den 
meisten Ländern erreicht, während Infektionsraten von Hepatitis C noch in vielen 
Ländern hoch sind. Rezente HIV-Ausbrüche in Griechenland und Rumänien zeigen, 
dass sich HIV Infektionsraten unter bestimmten Bedingungen schnell erhöhen, dazu 
zählt ein zu geringes Angebot an schadensminimierenden Maßnahmen. Hohe Raten an 
HCV Infektionen können als ein Indikator für das Risiko eines HIV-Ausbruchs gesehen 
werden. Es war in den meisten Ländern nicht möglich, die Anzahl der drogeninduzier-
ten Todesfälle (Todesfälle aufgrund von Überdosierungen) seit dem 2003 zu reduzie-
ren, obwohl sich die Anzahl der Personen in Substitutionsbehandlung erhöht hat. 
Einerseits sind Maßnahmen notwendig, um die Haltequoten in Substitutionsbehand-
lung zu verbessern und Unterbrechungen (z. B. durch Haft, Abstinenzbehandlungen 
ohne entsprechende Indikation) zu vermeiden. Andererseits sollten Interventionen zur 
Reduktion von Überdosierung, wie Konsumräume und Peer-Naloxon-Programme, in 
Betracht gezogen werden. Der Zeitpunkt der Haftentlassung (insbesondere bei fehlen-
der Nachversorgung) ist ein Risikofaktor für Überdosierungen, daher ist eine Kontinui-
tät der Versorgung (z. B. Fortführen der Substitutionsbehandlung im Gefängnis und bei 
Haftentlassung) essentiell. 
Wirksamkeit von Maßnahmen zur Schadensminimierung: Es liegt starke wissenschaftli-
che Evidenz für die Wirksamkeit der Substitutionsbehandlung, zur Senkung des 
Infektionsrisikos im Zusammenhang mit Drogenkonsum sowie zur Senkung der 
Mortalität vor. Unterbrechungen von Substitutionsbehandlungen sind ein Risikofaktor 
für drogeninduzierter Todesfälle. Herausforderungen für die Zukunft sind die Erhö-
hung des Deckungsgrades (z. B. Vermeidung von Wartelisten) und das Vermeiden von 
Behandlungsunterbrechungen. Dazu sind differenzierte Behandlungsangebote notwen-
dig, um die Bedürfnisse der verschiedenen Untergruppen von Opiatabhängigen zu 
erfüllen. Für Spritzentauschprogramme gibt es ebenfalls starke wissenschaftliche 
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Evidenz zur effektiven Reduktion des Infektionsrisikos (z. B. HIV, HCV, HBV). Heraus-
forderungen sind das notwendige Erhöhen des Deckungsgrades und der Umgang mit 
anderen Applikationsformen. Es gibt starke Evidenz für die Wirksamkeit von Scha-
densminderungsmaßnahmen (z. B. Substitutionsbehandlung und Spritzentausch) in 
Haftanstalten. Information, Aufklärung und Kommunikation sind wirksam, wenn das 
Setting geeignet ist und die Informationen in angemessener Form durch vertrauens-
würdige Personen zur Verfügung gestellt werden. Eine Möglichkeit, um das richtige 
Setting zu gewährleisten, ist die aufsuchende Sozialarbeit. Da Peers in vieler Hinsicht 
als vertrauenswürdige Personen angesehen werden, haben sich Peer-Programme als 
wirksam erwiesen. In den letzten zehn Jahren erhöhte sich die Evidenz für heroinge-
stützte Behandlung, Drogenkonsumräume und Peer-Naloxon-Programme als weitere 
Ansätze der Schadensminimierung signifikant. Auf Grundlage der verfügbaren Evidenz 
kann davon ausgegangen werden, dass diese Interventionen wirksam sind, sie sollten 
aber begleitend beobachtet und evaluiert werden. Die Impfung gegen Hepatitis B und 
die Behandlung von HIV, HBV und HCV sind wirksame Maßnahmen bei intravenös 
Konsumierenden. Die Behandlung von HCV ist auch ein besonders wirksames Instru-
ment der Infektionsprävention für andere. Drug Checking versteht sich als ein integra-
tives Service, das chemische Analysen immer mit Beratung vereint. Es gibt derzeit 
keine neuen Erkenntnisse über die Wirksamkeit von Drug Checking-Programmen. Neue 
Studien dazu sollten sich aber lohnen, da Drug Cheking-Programme auf der einen 
Seite eine Reaktion auf neue psychoaktive Substanzen am Markt sein könnten, und 
andererseits, weil in den letzten Jahren in Bezug auf Testung und Beratung eine 
Professionalisierung stattgefunden hat. In der wissenschaftlichen Literatur wird auf 
einen möglichen Nutzen von Maßnahmen hingewiesen, die den Wechsel von anderen 
Applikationsformen auf intravenösen Konsum verhindern bzw. auf den Wechsel von 
intravenösem Konsum auf andere Applikationsformen abzielen. Allerdings gibt es 
kaum Evidenz zu konkreten Projekten. 
Umsetzung von Maßnahmen zur Schadensminimierung und die Auswirkungen der 
Empfehlung des Rates: Die Situation betreffend Maßnahmen zur Schadensminimierung 
hat sich in den meisten Ländern deutlich verbessert. Der Deckungsgrad von Substituti-
onsbehandlung und Spritzentauschprogrammen hat sich merkbar erhöht, von einer 
ausreichenden Abdeckung ist man jedoch insbesondere in Bezug auf Spritzentausch in 
den meisten Ländern noch weit entfernt. Während Substitutionsbehandlungen mittler-
weile in vielen Haftanstalten angeboten werden, sind Spritzentauschprogramme nach 
wie vor sehr selten. Daher sind Haftanstalten immer noch eine Risikoumgebung für 
Infektionen mit HIV oder HCV und ein treibender Faktor für Infektionskrankheiten 
unter Drogenkonsumierenden. Aus diesem Grund sind Verbesserungen in Haftanstal-
ten dringend notwendig. Als weitere Maßnahmen zur Schadenminimierung werden 
heroingestützte Behandlung, Drug Checking, Peer-Naloxon-Programme und Drogen-
konsumräume in einigen wenigen Ländern umgesetzt. In Zeiten wirtschaftlicher Krisen 
sind die Finanzierung des Status quo und der Ausbau der Schadensminderung wichtige 
Themen in allen Ländern. In einigen EU 12 Staaten (z. B. Bulgarien und Rumänien) 
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wurden Schadensminderungsmaßnahmen zunächst durch den "Globaler Fonds zur 
Bekämpfung von AIDS, Tuberkulose und Malaria" finanziert, nun gibt es aber Probleme 
nationale Finanzierungen zu sichern.  
Der Einfluss und die Auswirkung der Empfehlung des Rates sind in allen EU-Ländern 
evident, insbesondere in jenen, die 2004 oder später (EU 12) beigetreten sind. Von 
Organisationen im Bereich der Schadensminimierung, wird um weitere EU-
Unterstützung gebeten. Ein klares Bekenntnis zu Schadensminimierung kann helfen, 
den Ausbau der Maßnahmen zu fördern. Diese EU-Empfehlung sollte insbesondere 
auch neue Maßnahmen wie Drogenkonsumräume und Peer-Naloxon-Programme (im 
Zusammenhang mit der Reduktion drogeninduzierter Todesfälle) und einen besonde-
ren Fokus auf Haftanstalten (Substitutionsbehandlung und Spritzentausch in Haft sowie 
eine Kontinuität der Behandlung) beinhalten. Darüber hinaus sollte die neue Empfeh-
lung im Jahr 2003 nicht inkludierte Bereiche wie Wohnen, soziale Reintegration und 
Beruf beinhalten, da diese wichtige Faktoren für die Stabilisierung sind. Allerdings 
müssen auch die bestehenden Angebote der Schadensminimierung wie Substitutions-
behandlung und Spritzentausch als zentrale Bausteine jeder drogenbezogenen Scha-
densminimierungs-Strategie gestärkt werden. 
3  Schlussfolgerungen und Vorschläge für 
weiteres Vorgehen  
Die folgenden konkreten Empfehlungen und Prioritäten basieren auf wissenschaftlicher 
Evidenz und der Analyse des Ist-Stands hinsichtlich Schadensminimierung. Die Emp-
fehlungen implizieren Aktivitäten auf unterschiedlichen Ebenen, das sind EU-Politik, 
nationale Politik der Mitgliedstaaten und praktische Implementierung. 
Die Empfehlung des Rates unterstützte den Ausbau schadensminimierender Maßnah-
men erfolgreich, dennoch ist die Versorgungslage in den meisten Bereichen noch nicht 
ausreichend. Dies macht eine weitere politische Stärkung von Schadensminimierung 
notwendig, die mit einer neuerlichen, überarbeiteten Empfehlung des Rates erreicht 
werden könnte.  
Priorität A: Verringerung drogeninduzierter Todesfälle 
Hintergrund: Es ist nicht gelungen die Zahl drogeninduzierter Todesfälle seit 2003 zu 
reduzieren. 
Ziel: Deutliche Reduktion der Zahl der drogeninduzierten Todesfälle in den nächsten 
zehn Jahren. 
Vorgeschlagene Maßnahmen: Verbesserung der Versorgungslage (für spezifische 
Zielgruppen von Opioidabhängigen, niederschwelliger Zugang zur Substitutionsbe-
handlung, Kostenübernahme der Substitutionsbehandlung durch die Sozialversiche-
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rung) und Durchführung der Substitutionsbehandlung (Vermeidung von Behandlungs-
unterbrechungen, Vermeidung von Wartelisten), Erleichterung der Inanspruchnahme 
von Notfalldiensten, Peer-Naloxon-Programme, Vernetzung von Einrichtungen (insbe-
sonders Haftentlassungsmanagement und Therapienachsorge), Drogenkonsumräume, 
aufsuchende Sozialarbeit, Peer-Programme und Unterstützung der Familien. 
Relevanz für Public Health: Tödliche Überdosierungen sind eine der häufigsten Todes-
ursachen bei jungen Erwachsenen, was Interventionen dringend notwendig macht. 
Insbesondere einfach zu realisierende und kosteneffektive Maßnahmen wie die erleich-
terte Inanspruchnahme von Notfalldiensten, sollten unverzüglich umgesetzt und auf 
europäischer Ebene unterstützt werden, um Leben zu retten.  
Priorität B: Verbesserung der Versorgungslage bzgl. Schadensmiminmierung in Haft 
Hintergrund: Schadensminimierung in Haftanstalten ist wesentlich seltener umgesetzt 
als außerhalb. Deswegen ist Haft eine Hochrisikosituation für intravenös Drogenkon-
sumierende, sich mit drogenassoziierten Infektionskrankheiten zu infizieren. Haftent-
lassung ohne entsprechende Nachsorge ist ein wesentlicher Risikofaktor für drogenin-
duzierte Todesfälle.  
Ziel: Schadensminimierung in Haft soll in den nächsten zehn Jahren als umfassendes 
Angebot im gleichen Ausmaß wie außerhalb der Haft sichergestellt werden.  
Vorgeschlagene Maßnahmen: Substitutionsbehandlung, Spritzentauschprogramme 
(Implementierung in allen Haftanstalten), Haftentlassungsmanagement, durchgehende 
Betreuung von Haftbeginn bis nach der Enthaftung (hinsichtlich der Kontinuität der 
Substitutionsbehandlung), Wohnversorgung für Haftentlassene, Gesundheitsuntersu-
chungen inklusive Prävention von Infektionskrankheiten. 
Relevanz für Public Health: Angebote der Schadensminimierung in Haft sind immer 
noch selten in Europa. Hohen Infektionsraten und eine erhöhte Mortalität nach Haft-
entlassungen sind die Folgen. Etwa 15 Prozent aller drogenbezogenen Todesfälle 
könnten allein durch adäquates Haftentlassungsmanagement verhindert werden 
(Frisher et al. 2012)3. Hohe Infektionsraten (z. B. HIV, Hepatitis) von Personen in Haft 
sind auch ein Risiko für die Gesamtbevölkerung. Die Weltgesundheitsorganisation sieht 
Gesundheit in Haft als essentiell: „Good prison health is good public health“ (WHO 
2007). Maßnahmen in diesem Bereich sind sehr erfolgsversprechend und können 
kosteneffektiv implementiert werden (z. B. Spritzentauschprogramme).  
Priorität C: Verringerung des Schadens durch drogenassoziierte Infektionskrankheiten  
Hintergrund: Die bereits existierenden Angebote zur Schadensminimierung waren 
ausreichend, um die HIV Prävalenz unter intravenös Drogenkonsumierenden in den 
                                                                                                                                         
3 
2005 starben 1.506 Drogengebrauchende in England an einer Überdosierung, Drogenmissbrauch oder 
Drogenabhängigkeit. Etwa 15 Prozent dieser Todesfälle geschahen nach einer Haftentlassung. Diese Todesfälle 
hätten möglicherweise durch ein adäquates und koordiniertes Haftentlassungsmanagement verhindert werden 
können (Department of Health 2007; Frisher et al. 2012). 
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meisten in diesem Bericht berücksichtigten Ländern deutlich zu senken. Aktuelle HIV-
Ausbrüche zeigen, dass sich diese Situation sehr schnell ändern kann, wenn Maßnah-
men zur Schadensminimierung nicht ausreichend sind. Die Hepatitis C Infektionsraten 
bewegen sich immer noch auf hohem Niveau, was – wenn keine ausreichenden Maß-
nahmen getroffen werden – zu enormen individuellen (z. B. Tod durch Folgekrankhei-
ten von Hepatitis C) und öffentlichen Kosten führen wird. 
Ziel: Deutliche Verringerung der Hepatitis C Prävalenz unter intravenös Drogenkonsu-
mierenden in den nächsten fünf Jahren, deutliche Verringerung der HIV Inzidenz in 
Ländern mit hohen oder steigenden Infektionsraten (Bulgarien, Estland, Griechenland, 
Lettland, Litauen, Portugal, Rumänien) in den nächsten fünf Jahren, die Behandlung 
(insbesondere die Hepatitis C Behandlung) von infizierten intravenös Drogenkonsumie-
renden soll in den nächsten fünf Jahren flächendeckend ausgebaut werden (Behand-
lung sollte für alle, die sie benötigen, möglich sein), und die Hepatitis B Impfung von 
intravenös Drogenkonsumierenden soll ebenfalls in den nächsten 5 Jahren flächende-
ckend ausgebaut werden. 
Vorgeschlagene Maßnahmen: Siehe Priorität B, Verbesserung der Versorgungslage 
hinsichtlich Spritzentausch, HIV und Hepatitis C Behandlungsprogramme, Verbesse-
rung der Hepatitis C Surveillance, Hepatitis B Impfprogramme, aufsuchende Sozialar-
beit, Peer-Programme und Unterstützung der Familien. 
Relevanz für Public Health: Infektionskrankheiten sind eine der schwerwiegenden 
Folgen von Drogensucht und können einfach und kosteneffektiv durch flächendecken-
de Spritzentauschprogramme verhindert werden. Es konnte nachgewiesen werden, 
dass Substitutionsbehandlung die HIV Infektionsrate von intravenös Drogenkonsumie-
renden um 50 Prozent senkt (MacArthur et al. 2012). Die Behandlung von HIV und 
Hepatitis C reduziert auch das Infektionsrisiko für andere Personen und ist daher eine 
kosteneffektive Intervention um Schaden zu vermeiden und um weitere Infektionen zu 
verhindern, die zu einer hohen Gesundheitsbelastung von Drogenabhängigen und der 
allgemeinen Bevölkerung führen würden. 
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IV Summary (Main report short version) 
1  Objectives and methods 
The purpose of the project was to produce a report on the current state of play of the 
2003 Council Recommendation (CR) of 18 June 2003 on the prevention and reduction 
of health-related harm associated with drug dependence, which mentions the follow-
ing main objectives: 
» Member States should, in order to provide for a high level of health protection, set 
as a public health objective the prevention of drug dependence and the reduction 
of related risks, and develop and implement comprehensive strategies accordingly. 
» Member States should, in order to reduce substantially the incidence of drug-
related health damage (such as HIV, hepatitis B and C and tuberculosis) and the 
number of drug-related deaths, make available, as an integral part of their overall 
drug prevention and treatment policies, a range of different services and facilities, 
particularly aiming at risk reduction; to this end, bearing in mind the general ob-
jective, in the first place, to prevent drug abuse. 
» Member States should consider measures, in order to develop appropriate evalua-
tion to increase the effectiveness and efficiency of drug prevention and the reduc-
tion of drug-related health risks. 
This report is an extended update of a previous report (Trimbos 2006) and covers all 
27 EU countries, the acceding country Croatia and the candidate countries: The former 
Yugoslav Republic of Macedonia, Iceland, Montenegro and Turkey. The report provides 
an overview on recent developments in epidemiology and on the availability and 
coverage of harm reduction measures in those countries. It further discusses the 
evidence of the effectiveness of harm reduction interventions implemented to prevent 
drug-related infectious diseases and drug-induced deaths. 
The general literature review on harm reduction measures presented in the previous 
report has been updated using recent comprehensive reviews like the synthesis of 
literature concerning the prevention of infectious diseases conducted by the European 
Centre for Diseases Prevention and Control (ECDC) and the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) (ECDC and EMCDDA 2011a; ECDC and 
EMCDDA 2011b), the EMCDDA insights on new heroin assisted treatment (EMCDDA 
2012b) and the systematic review on the effectiveness of opioid substitution treatment 
in prison settings (Hedrich et al. 2011). Significant recent studies, not covered by the 
above-mentioned reviews, have been added and the relevant websites have been 
searched for international guidelines. For areas not covered by recent reviews, four 
systematic literature reviews have been carried out (“peer naloxone programmes”, 
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“needle exchange programmes in prison”, “prison release management” and “measures 
to influence the route of administration”). 
As a first step of analysis of data available at the EMCDDA, all standard tables and 
structured questionnaires collected by the EMCDDA, via the REITOX network, were 
scanned for information relevant for the description of the CR-implementation. In co-
operation with the EMCDDA, a data extraction tool was developed and for each country 
the data were extracted in EXCEL-format. For the analysis of epidemiological trends, 
data presented in the EMCDDA Statistical Bulletin have been used, additionally. Data 
mainly refer to the time period 2003 to 2010 and have been updated for 2011 for 
countries with significant recent developments (HIV-outbreak in Greece and Romania). 
Based on the analysis of the information available at the EMCDDA, the national reports 
on the drug situation from 2003 to 2011 and the EMCDDA country overviews for each 
country, country profiles focusing on drug-related harm (reduction) were elaborated. 
They were sent out to the REITOX Focal Points to carry out a gap-survey in the course 
of which they were asked to add information, if necessary, and to comment on the 
information presented.  
Based on the previous report (Trimbos 2006) and on the results of the discussion 
process with the Executive Agency for Health and Consumers (EAHC), EMCDDA, 
European Commission (EC) and leading experts from Austrian harm reduction organi-
sations, an online-survey for policy makers and a consultation of stakeholders were 
designed. The EC contacted the permanent representatives of each country asking for 
the nomination of one responsible person for the Council Recommendation. This 
person was in charge of coordinating the answers to the policy maker survey. Based on 
a systematic selection strategy, a total of 123 institutions from 32 countries were 
contacted during the stakeholder survey. Table 1.1 gives an overview concerning data 
availability and responses to the surveys.  
Table 1.1: 
Data availability and responses to the surveys 
Data sources/survey Availability/responses  
EMCDDA statistical tables and 
structured questionnaires 
29 countries; not available for the former Yugoslav Republic of Macedonia, 
Iceland, Montenegro 
EMCDDA country overviews 31 countries; not available for Iceland 
National reports 29 countries; not available for the former Yugoslav Republic of Macedonia, 
Iceland, Montenegro 
Gap-survey 26 countries; not possible for the former Yugoslav Republic of Macedonia, 
Iceland, Montenegro, Turkey (no REITOX FP), no answers from Bulgaria and 
Romania 
Policy maker survey 31 countries; no answer from Slovakia 
Stakeholder survey 24 countries; no response from Cyprus, Lithuania, Sweden, Poland, the 
former Yugoslav Republic of Macedonia, Iceland, Montenegro and Turkey  
graphic representation: GÖ FP  
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For the interpretation of this report’s results the following limitations have to be taken 
into account: Data availability made a very good progress in the time-span from 2003 
to 2010. Thanks to the continuous efforts of the EMCDDA for the harmonisation and 
expansion of the data collection, a lot of comparable data are available to describe the 
epidemiology of the drug situation and harm reduction measures. Unfortunately, data 
for time-series are not available for all countries; even basic data to analyse drug-
related harm and availability of measures of harm reduction are missing in some 
countries. It has to be taken into account that absolute numbers (e. g. number of 
drug-induced deaths) are influenced by the quality of the respective monitoring 
system too. Therefore country-specific comparisons have to be made with caution and 
should be completely avoided for some countries. Another limitation of the present 
work is that the view of policy makers and stakeholders is based on the answers of 
single persons (answering often for a big country). This makes their statements 
subjective expert opinions. Therefore the data gathered are appropriate to give a 
general impression but not for direct country comparisons.  
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2 Epidemiological situation 
Epidemiological data on harm related to drug use were analysed (mainly based on 
EMCDDA data collections). Due to the efforts of the EMCDDA to standardise the data 
collection process and to improve data collection, a great number of good quality data 
are available; partly in long time series. However, work is still under progress and 
especially comparisons between countries should always be made carefully.  
Problem drug use (PDU): Problem drug use is defined as “injecting drug use or long-
duration/regular use of opioids, cocaine and/or amphetamines”. Recently the scope 
has been broadened to "high risk drug use", which includes former problem drug use, 
but includes high risk and frequent cannabis use, high risk use of new drugs in 
addition and is open to other substances which may emerge in the future. 
The EMCDDA estimates that there were about 1,4 million of problem opioid users 
(mainly heroin, but also other opioids like fentanyl or buprenorphine) in the EU in 
2010. The overall situation concerning prevalence of problem opioid use seems to be 
stable between 2004 and 2010. Cocaine plays an important role in problem drug use 
in the Netherlands, Italy, Spain and in the UK. Together these four countries account 
for around 85 % of all reported cocaine clients entering treatment. Amphetamines play 
an important role in Poland, Finland and Sweden, and methamphetamines in the Czech 
Republic and Slovakia (EMCDDA 2012d). Treatment data show a broad range of rate of 
injecting among opioid users (e. g. Belgium, Denmark, Spain, France, Netherlands and 
Portugal: below 25 %; Bulgaria, Czech Republic, Estonia, Latvia, Romania, Slovakia, 
Finland and Croatia: over 70 %). Due to the lack of data it is hard to make a statement 
about trends in injecting but there are indications of a decrease of injecting; at least 
for opioid injecting (EMCDDA 2012d). Looking at 2010 data, just 36 percent of clients 
entering treatment due to opioids state that they chose injecting as route of admini-
stration (EMCDDA 2012c). But there are also countries which show an increasing trend 
of injecting (e. g. Czech Republic). Within Europe and even more globally, new drugs 
and new patterns of drug use are increasingly attracting political, media and public 
attention (EMCDDA 2012). While in most of the countries the “legal highs” phenome-
non is regarded as a matter of recreational use, in some countries or regions sub-
stances like mephedrone are also injected by those who have previously injected other 
substances like opioids (e. g. Hungary, Romania). This shift, which might be an effect 
of heroin shortages in the respective regions, seems to have contributed to HIV-
outbreak in Romania (see below). Whether these new patterns of use will lead to a 
permanent change of the drug situation and therefore become relevant for harm 
reduction remains unclear at the moment. 
Drug related infectious diseases (DRID): In the European Union the number of new 
human immunodeficiency virus (HIV) infections among injecting drug users is rather 
low compared to the United States and other European countries. In the year 2010, the 
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average rate of newly diagnosed HIV cases among injecting drug users (IDUs) was 2,54 
per million (1.192 cases) (EMCDDA 2012a). Comparisons between countries are 
difficult due to differences in the study methodology and coverage. The rates of newly 
diagnosed HIV infections among injecting drug users vary significantly between 
countries. Very high rates are reported for the Baltic States (Estonia, Latvia and Lithua-
nia) with up to 46,3 cases per million inhabitants and very low rates (less than one new 
infection per million inhabitants) in the Czech Republic, Cyprus, Hungary, Malta, 
Netherlands and Croatia.  
Twelve countries (Austria, Belgium, Estonia, France, Germany, Ireland, Italy, Latvia, 
Netherland, Poland, Portugal, Spain) report a significant decrease in the number of HIV 
infections via IDU from 2003/2004 to 2009/2010. Only four countries (Bulgaria, 
Greece, Lithuania and Romania) report a significant increase. 
Local HIV-outbreaks have been observed in Greece and Romania. Until 2010 (2005 -
2010) in Greece, 9 to 16 cases of newly diagnosed drug injectors with HIV were 
reported per annum. This rate increased to 256 cases in 2011 and 314 cases in 2012 
(January till August). In Romania, the numbers of newly diagnosed drug injectors with 
HIV increased from 0–14 per year until 2010 (2005-2010) to 129 cases in 2011 and 
102 cases in 2012 (January till June).  
Hepatitis C virus (HCV) infection is highly prevalent among IDUs in most EU countries. 
Since high prevalence is found among young and new injectors it can be assumed that 
the transmission rate is very high. Due to the lack of data an overall picture concerning 
trends is not available.  
From 2005 to 2010 declining HCV prevalences in injecting drug users have been 
observed at national or regional level in six countries while five others showed an 
increase (Austria, Bulgaria, Cyprus, Greece and Romania).  
For hepatitis B virus (HBV) the situation concerning the availability of data is worse 
than for HCV. However, an analysis based on data from some countries and on registry 
data shows that 6 % of all HBV cases and 12 % of the notified acute cases are due to 
IDU (EMCDDA 2012a). This leads to the conclusion that IDUs still are a high risk group 
for HBV infection.  
Drug-induced deaths /overdoses: Fatalities due to overdoses (drug-induced deaths) 
including illegal drugs belong to the main causes of mortality among young people in 
Europe (EMCDDA 2012a). Country comparison in Europe should be made with caution, 
since there are still some differences between countries in the capacity to ascertain the 
drug-induced death cases. Another major limitation is the remaining differences in 
coding, recording and extracting cases. Most national reporting systems have been 
stable over time, which allows, in the majority of countries, an analysis of the trend 
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over time. Nonetheless, caution is needed here as well, as some countries have 
changed over time (e.g. upgrade of monitoring system).  
In 2010, the average EU mortality rate of drug-induced deaths is estimated to be about 
20 deaths per million inhabitants aged 15-64 years. Around 7.000 drug-induced 
deaths (overdoses) occurred in the EU Member States in 2010. Estonia reports more 
than 110 drug-induced deaths per million inhabitants aged 15-64 years followed by 
Ireland and Denmark. Drug-induced deaths in the EU are mainly caused by opioids (in 
particular heroin). 11 % of the drug-induced deaths in Europe are reported among 
people aged under 25 years, 32 % from 25 to 35 years and 57 % aged 35 years or older 
(EMCDDA 2012c). By far, most of the drug-induced deaths are male (80 %), and the 
majority of cases are related to the use of several drugs – in most cases opioids in 
combination with other drugs (EMCDDA 2012c).  
The number of reported drug-induced deaths in the EU slightly increased in the 2004–
09 period from about 6.450 in 2004 to about 7.300 in 2009/2010 (EMCDDA 2012c; 
EMCDDA 2012d). 
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3 Effectiveness of interventions 
Starting from the evidence collected in the previous report (Trimbos 2006), the present 
review gives an overview of recent scientific evidence on the prevention of infectious 
diseases among drug users, the prevention of drug-induced deaths and harm reduc-
tion in prison settings (details see chapter 10). The previous report was based on 
reviews and studies which followed the “classical approach” of evidence based on 
randomised controlled trials (RCT) and controlled studies. Since this approach is not 
adequate for many aspects of harm reduction, it was extended using the Interactive 
Domain Model (IDM) developed in the field of health promotion. This approach defines 
“Best practices in health promotion are those sets of processes and actions that are 
consistent with health promotion values, theories, evidence, and understanding of the 
environment, and that are most likely to achieve health promotion goals in a given 
situation” (Kahan/Goodstadt 2001, 47) and was transposed to the field of harm 
reduction (details see chapter 10.1). 
Prevention of drug-related infectious diseases (DRID): Concerning the prevention of 
risk behaviour (e. g. needle sharing) related to DRID (e. g. HIV, hepatitis), opioid 
substitution treatment (OST) and syringe provision through specialised programmes 
(needle exchange programmes - NSP) have proven their effectiveness in a range of 
high quality studies. This factor leads to the conclusion that these two interventions 
should be the central part of any strategy to reduce prevalence of DRIDs. Recent 
literature points out the necessity of a high coverage of both interventions to reduce 
hepatitis C infection rate. In addition, heroin assisted treatment has shown effective-
ness as second line intervention. Information, education and communication are 
effective when the setting is appropriate and messages are provided in an adequate 
form by trustable persons. One possibility to assure the right setting is outreach work. 
Since peers are the most trustable persons in many aspects peer involvement which 
has proven to be effective is a good strategy. The possible benefit of measures to 
avoid shifting from other routes of administration to injecting drug use (IDU) and to 
foster shifting from IDU to other routes of administration is pointed out in scientific 
literature. However, there is hardly any evidence on concrete projects. Thus, action is 
needed in this area. A good starting point is existing measures targeting mainly IDUs 
which might be used for promoting other routes of administration (e. g. syringe 
provision through specialised programmes where in addition foil and counselling 
concerning heroin chasing are offered – see annex 2). Vaccination for hepatitis B, 
treatment of HIV, HBV and HCV in IDUs are effective measures. The treatment for HCV 
is a particularly effective instrument of infection prevention for others, too. 
Prevention of drug-induced deaths: Based on consistent evidence from one meta-
analysis and multiple robust studies in supplementary reviews, there is sufficient 
review-level evidence to support the effectiveness of opioid substitution treatment 
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(OST) in reducing opioid-induced death. The first weeks after starting OST and the 
time immediately after the termination of OST are phases of increased mortality. Prison 
and treatment release management are important to avoid interruptions in OST (see 
annex 2). The quality of primary studies concerning peer naloxone programmes is low 
to medium and the size of the study groups is usually small. Based on the results from 
the evaluation studies, on the recommendations from experts and on the analysis of 
the objections against naloxone, the authors come to the conclusion that naloxone is a 
safe drug to use. In combination with emergency training, naloxone distribution pro-
grammes to peers should be expanded in Europe (see annex 2). A comprehensive ove-
view concerning studies on drug consumption rooms shows that if the coverage and 
the capacity are sufficient and opening hours are appropriate, drug consumption 
rooms can attribute to reducing drug-induced deaths at city level. A systematic review 
of eight randomised control trials comes to the conclusion that heroin plus methadone 
prescription, for maintenance treatment in adult chronic opioid users who failed 
previous methadone treatment attempts, is effective in increasing treatment retention 
and probably in reducing the risk of death. Drug Checking is considered an integrated 
service that always combines chemical analysis with advice or counselling. Although 
there is no new evidence on the effectiveness of Drug Checking programmes, it might 
be worth to conduct new studies; on the one hand, because Drug Checking/coun-
selling might be a reaction to the emerging of new psychoactive substances on the 
markets, on the other hand, because professionalisation took place concerning testing 
and counselling methods during the last few years.  
Harm reduction in prison: There is evidence that harm reduction measures, which 
proved their effectiveness outside prison, are also effective inside prison. The broad 
range of benefits from opioid substitution treatment (OST) in prison (among others: 
reduction of needle-sharing and injecting drug use) has been observed to be similar to 
the benefits outside prison. Concerning mortality, the situation is less clear due to the 
lack of adequate studies (Hedrich et al. 2012). The fact that the first weeks after star-
ting OST and the time immediately after the termination of OST are phases of in-
creased mortality, has to be considered especially in the prison setting. Adequate 
possibilities to continue OST in prison and after prison release (throughcare) are 
essential. Almost all studies on needle exchange programmes (NSP) in prison show a 
dramatic decrease in needle sharing and no or very low seroconversion rates concern-
ing HIV, HCV and HBV. Although the study designs are not the best (no control group) 
– which may lie in the nature of the topic (ethical or ideological constraints to serve as 
a comparison prison with no NSP) – the firm conclusion can be drawn that NSP in 
prison is an effective method to reduce risk behaviour concerning infections with HIV, 
HBV and HCV. Although, the number of countries that have implemented needle and 
syringe exchange in prison is limited, these programmes have been established 
successfully in different settings and diverse environments. The concern regarding 
possible negative consequences of NSP in prison has been proven to be unfounded 
(see annex 2).  
IV / Summary (Main report short version)  29 
4 Implementation of CR 1 
The EU drug strategy aims at making “a contribution to the attainment of a high level 
of health protection, well-being and social cohesion by complementing the Member 
States´ action in preventing and reducing drug use, dependence and drug-related 
harm to health and society” and at “ensuring a high level of security for the general 
public” (Council of the European Union 2004, 5). For more than one decade harm 
reduction has been an integral part of the EU drug action plans giving priority to 
preventing transmission of infectious diseases and to reducing drug-induced deaths 
among IDUs (Rhodes/Hedrich 2010). The Lisbon Treaty article 168 on high level 
protection of human health strengthens the harm reduction approach as well as the 
Communication from the Commission to the European Parliament, the Council, the 
European Economic and Social Committee and the Committee of the Regions of 26 
October 2009 - Combating HIV/AIDS in the European Union and neighbouring coun-
tries, 2009-2013. 
One general problem concerning funding is that in some EU 12 states (countries which 
joined the EU in 2004 or later) harm reduction projects were initially financed by the 
Fund to Fight AIDS, Tuberculosis, and Malaria. There are currently problems to ensure 
national funding. This problem was expressed by policy makers and stakeholders. 
All EU Member States, Croatia, Montenegro and the former Yugoslav Republic of 
Macedonia have adopted (public health) policy objectives that aim to prevent and 
reduce health-related harm associated with drug dependence. In Turkey and Iceland 
policies regarding some key elements of harm reduction do not exist yet. In Turkey 
there is no policy for the provision of appropriate access to injection materials. Fur-
thermore the provision of drug-free treatment as well as appropriate opioid substitu-
tion treatment (OST) in accordance with the individual needs of the drug abuser is not 
provided. For the latter, a respective policy is waiting for approval; OST has been 
available in Turkey since 2010. In Iceland an official policy for the provision of appro-
priate access to injection materials does not exist either but in practice, these services 
are available to some extent.  
Regarding the influence of the Council Recommendation 1 (CR 1) on these policies, 
more than half of the investigated countries confirm at least a medium impact. The 
rate of the impact of the CR is higher in the EU 12 than in the EU 15 (countries which 
joined the EU before 2004). 
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5 Implementation of CR 2 
The policies defined in CR 2 are implemented in almost all countries investigated; 
exceptions are: Iceland concerning all policies, Croatia for CR 2.2 (information), CR 2.4 
(peer involvement), CR 2.5 (networking); Slovakia for CR 2.4 (peer involvement), CR 2.5 
(networking); Hungary for CR 2.4 (peer involvement), Greece for CR 2.5 (networking); 
Latvia for CR 2.5 (networking); Turkey for CR 2.6 (drug treatment), CR 2.10 (prevent 
DRID), CR 2.12 (integration of services) and Bulgaria for CR 2.12 (integration of 
services) The full wording of all CRs can be found in section 15.  
Figure 5.1: 
Coverage of harm reduction measures, estimated by stakeholders and policy makers 
 
HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, OST=opioid substitution 
treatment, STD=sexually transmitted diseases, TBC=tuberculosis 
Remark: data refer to Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovakia, 
Slovenia, Spain, United Kingdom; The full wording of all CRs can be found in section 15. 
Coverage: 1=not available, 2=rare, 3=limited, 4=extensive, 5=full coverage 
Source: GÖ FP, stakeholder survey, policy maker survey; graphic representation: GÖ FP 
The stakeholders’ estimation of the coverage of harm reduction measures related to 
CR 2 is lower than the estimation of policy makers. Since data from stakeholders are 
available for 24 countries only, direct comparisons between stakeholders and policy 
makers is only possible for these countries. Although, the estimated coverage differs, 
the patterns of estimations of policy makers and stakeholders are quite similar (see 
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e. g. measures with lowest coverage Figure 5.1). Major differences can be observed for 
harm reduction in prison. The coverage of harm reduction in prison is stated to be 
“rare” by stakeholders whereas policy maker perceive it as “limited”. 
Table 5.1 gives an overview concerning the implementation of the CR 2, the coverage 
of measures related to CR 2 estimated by policy makers and stakeholders as well as 
the change of coverage and the impact of the CR perceived from policy makers. 
Table 5.1: 
Implementation of CR 2 – policy makers’ and stakeholders’ estimation 
CR 
Policy exists 
number of 
countries; 
(policy maker) 
Intervention 
Estimated coverage of intervention 
Impact of CR 
medium or 
stronger  
(policy maker) 
Full or 
extensive 
(policy maker) 
Full or 
extensive 
(stakeholder) 
Coverage 
increase since 
2003 
(policy maker) 
2.1 31 of 32 Information and counselling 26 of 31 (84%) 56% 27 of 31 (87%) 17 of 29 (57%) 
2.2 31 of 32 Information for families and communities 12 of 31 (39%) 19% 20 of 30 (67%) 12 of 28 (43%) 
2.3 29 of 31 Outreach work 17 of 31 (55%) 42% 24 of 31 (77%) 16 of 26 (62%) 
2.4 27 of 31 Peer involvement in ORW 10 of 30 (33%) 19% 20 of 30 (67%) 12 of 26 (62%) 
2.5 26 of 31 
Networking and 
cooperation between 
agencies involved in ORW 
15 of 30 (50%) 33% 20 of 30 (67%) 12 of 28 (43%) 
2.6 30 of 31 
Drug free treatment 21 of 31 (68%) 60% 20 of 31 (67%) 
14 of 26 (54%) 
OST 26 of 31 (84%) 74% 28 of 31 (90%) 
Psychosocial care and 
rehabilitation supporting 
OST 
22 of 31 (71%) 50% 21 of 30 (70%) 
No data Heroin assisted treatment No data 7% No data No data 
2.7 29 of 30 
Measures to prevent 
diversion of substitution 
substances 
25 of 29 (86%) No data 19 of 28 (68%) 12 of 27 (44%) 
2.8 30 of 31 Harm reduction in prison 10 of 29 (34%) 2% 22 of 30 (73%) 13 of 25 (52%) 
2.9 30 of 31 
HBV vaccination 15 of 30 (50%) 30% 15 of 30 (50%) 
15 of 25 (60%) 
HIV screening 25 of 31 (81%) 42% 
19 of 27 (70%) 
HBV/HCV screening 18 of 31 (58%) 40% 
TBC screening 15 of 30 (50%) 18% 
STD screening 16 of 29 (55%) 34% 
HIV/AIDS treatment 25 of 28 (89%) 58% 
HCV treatment 17 of 28 (61%) 26% 
TBC treatment 24 of 26 (92%) 42% 
STD treatment 21 of 24 (88%) 42% 
2.10 
29 of 31 
Condom distribution 19 of 28 (68%) No data 21 of 27 (78%) 14 of 25 (56%) 
Distribution of injection 
material 20 of 31 (65%) see below 27 of 31 (87%) 17 of 29 (59%) 
Needle and syringe 
exchange see above 64% see above see above 
Paraphernalia distribution 
for IDUs see above 50% see above see above 
No data Drug consumption rooms No data 5% No data No data 
Continued next page 
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Table 5.1, continued 
CR 
Policy exists 
number of 
countries; 
(policy maker) 
Intervention 
Estimated coverage of intervention 
Impact of CR 
medium or 
stronger  
(policy maker) 
Full or 
extensive 
(policy maker) 
Full or 
extensive 
(stakeholder) 
Coverage 
increase since 
2003 
(policy maker) 
2.11 
30 of 31 
Emergency services 
adequately prepared to 
deal with overdoses 
26 of 29 (90%) 48% 15 of 28 (54%) 11 of 25 (44%) 
Naloxone in ambulances see above 51%   
Training of emergency 
staff to deal with 
overdoses 
No data 27%   
No data Peer naloxone pro-grammes No data 2% No data No data 
2.12 28 of 31 
Integration between health 
services, social care and 
specialised risk reduction 
17 of 31 (55%) No data 22 of 28 (79%) 14 of 25 (56%) 
2.13 30 of 31 Professional training on harm reduction 21 of 31 (68%) No data 26 of 29 (90%) 11 of 23 (48%) 
new No data Night shelters No data 24% No data No data 
new No data Assisted living No data 16% No data No data 
new No data Housing first No data 10% No data No data 
new No data Drug Checking No data 7% No data No data 
Remarks: The respective information is not available for all countries. For the policy maker survey the 
availability of data is shown for each indicator (e. g. in column 2 30 of 31 means that for 31 of the 32 countries 
covered with the survey, data are available and that in 30 of the 31 countries the respective policy exists). 
Since Slovakia did not take part in the policy maker survey, data concerning implementation of policies from the 
Trimbos report (Trimbos 2006) have been used. The stakeholder survey covers 24 countries; details for 
coverage of the surveys see section 1 
Rates over 80 percent are marked in green, rates below 50 percent are highlighted in red. 
The full wording of all CRs can be found in section 15. 
Source: GÖ FP, stakeholder survey, policy maker survey; graphic representation: GÖ FP 
The coverage of OST and information/counselling is estimated to be extensive or full 
in over 70 percent of the countries by both policy makers and stakeholders. Concern-
ing NSPs, the estimations are quite lower (two thirds of the countries). Although proven 
to be effective (see section 3), very low coverage is reported for harm reduction in 
prison and peer involvement, especially peer involvement within outreach work. 
Involvement of communities and families is also estimated to be low. In the field of 
screening and treating drug-related infectious diseases, a need for improvement exists 
in more than half of the countries according to the opinions of the stakeholders. 
Although 90 percent of the policymakers state full or extensive coverage for emer-
gency services to be well prepared to deal with overdoses, only half of the stake-
holders express this opinion. In addition, the coverage of training of emergency staff 
to be able to deal with overdoses is estimated to be ‘low’ by the stakeholders. For 
some measures like drug consumption rooms, heroin assisted treatment and peer 
naloxone programmes the coverage is estimated to be ‘very low’ by the stakeholders. 
For almost all areas of harm reduction, except HBV vaccination and emergency ser-
vices, being adequately prepared to deal with overdoses, policy makers see an increase 
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of coverage since 2003 in over two thirds of the countries. The biggest increase is 
seen in information and counselling, OST, distribution of injection materials and 
professional training on harm reduction (see Table 5.1). At least a medium impact of 
the Council Recommendation on the implementation of harm reduction measures is 
detected by about half of the policy makers. The impact was rated strongest for 
outreach work and peer involvement in outreach work (see Table 5.1). 
Whereas, most of the harm reduction measures according to CR 2 are available in 
almost all of the countries, some measures are available in just a few ones (see Table 
5.2). 
Table 5.2: 
Harm reduction measures available in just a few countries 
Harm reduction measure Availability  
Drug consumption room (1) Germany, Luxembourg, Netherlands, Spain, Denmark 
Peer naloxone programme (2) Italy, Germany, Spain, Lithuania, United Kingdom (England, Wales, Scotland), 
Bulgaria, Denmark, Portugal 
Heroin assisted treatment (3) Belgium, Denmark, Germany, Netherlands, Spain, UK 
NSP in prison (4) Germany, Spain, Luxembourg, Portugal, Romania 
Pill testing (5) Austria, Belgium, France, Netherlands, Portugal, Spain 
Remark: Data from NFPs have been amended by other information. The data partly refer to (pilot-) projects 
which are very small and which might be closed again. There may well be other, local, un-official initiatives in 
some countries. 
Source: (1) IDPC – Drug consumption rooms evidence and practice + country profile Denmark – see annex 1; (2) 
Special review on peer naloxone programmes – see annex 2; (3) EMCDDA Statistical Bulletin 2012, Table HSR-1; 
(4) Special review on NSP in prison – see annex 2; (5) TEDI 2011; graphic representation: GÖ FP 
Table 5.3 puts the two most important measures, OST and NSP, in relation to epidemi-
ological data and trends. Country comparison in Europe should be made with caution 
(see chapter 11). However in order to analyse the reported coverage and drug-related 
harm, the trends for HIV and drug-induced deaths were modelled. This analysis is 
limited by possible changes in the monitoring systems in some countries.  
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Table 5.3: 
Trends in DRD, HIV, NSP, OST (Significant differences 2003/2004 and 2009/2010 data) 
Country DRD 
trend 
(1) 
DRD 
rate 
(2) 
HIV 
trend 
(3) 
HIV rate
(4) 
NSP 
trend 
(5) 
IDU % 
 
(6) 
OST 
trend 
(7) 
POU %
OST 
(8) 
Austria  3,0  0,3 n.a. 35  58 
Belgium n.a. 1,4  0,1  21  n.a. 
Bulgaria  0,7  0,7  82  n.a. 
Cyprus  1,9 n.a. 0,0  64 n.a. 45 
Czech Rep.  0,7  0,0  79  54 
Denmark  5,5  0,1 n.a. 16  n.a. 
Estonia  11,1  4,6  87  n.a. 
Finland  4,7  0,2  75  43 
France  0,8  0,1  23  n.a. 
Germany  2,3  0,1 n.a. 36  49 
Greece  2,1  2,2  38  28 
Hungary  0,2 n.a. 0,0  69  33 
Ireland  6,5  0,5 n.a. 32  42 
Italy  0,9  0,3 n.a. 53  47 
Latvia  0,5  3,8  94  2 
Lithuania  2,2  3,1  n.a. n.a 17 
Luxembourg  3,5 n.a. 0,2  68  66 
Malta  2,1 n.a. 0,0  61  64 
Netherlands  0,8  0,0 n.a. 7  57 
Poland  0,7  0,1  66  8 
Portugal n.a. 0,7  1,1  15  n.a. 
Romania  0,2  0,5  91  n.a. 
Slovakia  0,5 n.a. 0,0  78  12 
Slovenia  1,8 n.a. 0,0 n.a. 52 n.a n.a. 
Spain  1,4  0,5  16  n.a. 
Sweden  4,1  0,3  59 n.a n.a. 
United Kingdom  5,4  0,2 n.a. 34 n.a n.a. 
Croatia  2,5  0,0  n.a.  n.a. 
The former 
Yugoslav Republic 
of Macedonia  
n.a. n.a. n.a. n.a. n.a. 73 n.a. n.a. 
Iceland n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Montenegro n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Turkey  0,3 n.a. n.a. n.a. n.a. n.a n.a. 
Remarks: n.a.=no data available (1) Significant change of number of drug-induced death 2003-2010 
[=significant increase, =no change, =significant decrease]; (2) Number of drug-induced death per 100.000 
inhabitants aged 15 to 64. Country comparison should be made with caution, since there are still some dif-
ferences between countries in the capacity to ascertain the drug-induced death cases. For example Ireland has 
a thorough and extensive monitoring system for drug-induced deaths which might be one reason for the high 
rate (see chapter 13). (3) Significant change of HIV infections (AIDS) newly diagnosed IDUs 2003-2010 – for 
Greece and Romania 2003-2011 [see (1) +  =no change and HIV rates (4) < 0,2]; (4) Number of HIV-infections 
(AIDS) via injecting drug use newly diagnosed in 2010 per 100.000 population – for Greece and Romania 2011 
[rates > 1]; Country comparison should be made with caution, since there are still some differences between 
countries in the monitoring systems. (5) Significant change of number of needles/syringes distributed through 
specialised programmes 2003-2010 [see (1)]; (6) % of IDU as main route of administration of opioids among 
clients starting outpatient treatment [rates below 30, rates 30 to 60, rates > 60]; (7) significant change of num-
bers of clients in opioid substitution treatment 2003-2010 [see (1)]; (8) Rate of problem opioid users in opioid 
substitution treatment [rates below 30, rates 30 to 50, rates > 50] - for calculation of trends see chapter 13 
Source: (1) EMCDDA Statistical Bulletin 2012, Table DRD-2, (2) EMCDDA Statistical Bulletin 2012, Table DRD-7, 
(3) ECDC/WHO, 2011 data collection, (4) EMCDDA Statistical Bulletin 2012, Table INF-104; (5) EMCDDA 
Statistical Bulletin 2012, Table HSR-3; (6) EMCDDA Statistical Bulletin 2012, Table TDI-17 part II; (7) EMCDDA 
Statistical Bulletin 2012, Table HSR-3; (8) EMCDDA Statistical Bulletin 2012, Figure HSR-1;  
graphic representation: GÖ FP 
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An analysis of the estimated coverage/availability of harm reduction measures4 
according to trends in drug-induced deaths shows, that countries that have experi-
enced a significant decrease in drug-induced deaths (Denmark, Spain, Italy) report the 
broadest coverage/availability of harm reduction measures in the EU. The pattern is 
less consistent comparing stable and increasing trends to the coverage/availability of 
harm reduction measures. But countries with an increase in the numbers of drug-
induced deaths (Bulgaria, Estonia, Ireland, France, Lithuania, Poland, Romania, Finland, 
Sweden, UK and Turkey) from 2003/2004 to 2009/2010 tend to have a slightly lower 
coverage/availability than those with stable trends (Czech Republic, Germany, Greece, 
Cyprus, Latvia, Luxembourg, Hungary, Malta, Netherlands, Austria, Slovenia, Slovakia, 
Croatia). Looking at the differences in the coverage, in particular “integration of 
services” (CR 2.12), the availability of “drug treatment” (CR 2.6) and “harm reduction in 
prison” (CR 2.8) indicate the largest gaps. A direct causal association between a high 
coverage of harm reduction measures in these fields and a decrease in the number of 
drug-induced deaths cannot be deducted; however, it gives a clear hint for the direc-
tion of further research and analysis (details see chapter 13).  
Countries with increasing drug-induced deaths rates should analyse their coverage 
concerning “integration of services”, the availability of “drug treatment” and “harm 
reduction in prison”. 
The coverage/availability of harm reduction measures in the EU was also analysed 
according to increasing, decreasing or stable trends of newly diagnosed HIV infections 
with IDU as way of infection. The picture is less clear than the one for drug-induced 
deaths trends. Countries with a significant increase of newly diagnosed HIV (Bulgaria, 
Lithuania, Greece, Romania) report lower coverage/availability of most harm reduction 
measures than countries with stable or decreasing rates. Again, “integration of ser-
vices” (CR 2.12) shows the greatest differences, with the highest coverage reported in 
countries showing a stable trend. It is important to note that harm reduction measures 
associated with infectious diseases - in particular (e. g. screening) in Council Recom-
mendation 2.9 - show higher coverage for countries with stable or decreasing trends 
than for countries with HIV increase; however, differences are rather slim.  
Concerning the impact of the CR on implementation of harm reduction, a clear pattern 
can be observed (see Figure 5.2). The impact of the Council Recommendation on the 
coverage/availability of harm reduction measures was higher in the EU 12 than in the 
EU 15. It is important to keep in mind, that the EU 15 report a higher coverage of harm 
reduction measures and have a higher “starting point”, for example for syringe provi-
sion through specialised programmes and OST. The improvement of the coverage in 
                                                                                                                                         
4 
Based upon policy maker survey 
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the last few years (see Table 5.1) was probably influenced by the Council Recommen-
dation in particular in the EU 12. The highest impact of the Council Recommendation 
was measured on the coverage of “condom distribution” in the candidate and acceding 
countries and in “counselling” and “distribution of injection material” in the EU 12. The 
impact of the Council Recommendation in the EU 15 was on average “little”; for 
instance almost no impact on the prevention of diversion of substitution medications 
to the black market and availability of naloxone in emergency services was reported.  
Figure 5.2: 
Impact of the Council Recommendation on the coverage of harm reduction measures in 
the EU and candidate countries 
 
Remark: data refer to: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, the former Yugoslav Republic of 
Macedonia, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, 
Croatia, Island, Montenegro, Turkey;  
Impact: 1=no impact, 5=very strong impact 
The full wording of all CRs can be found in section 15. 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Based on Table 5.3, the results from the statistical modelling using the policy maker 
survey (see chapter 13) and epidemiological data countries with specific needs can be 
defined. 
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CR 2.2 (information)
CR 2.3 (outreach)
CR 2.4 (peer involvement)
CR 2.5 (networking)
CR 2.6 (drug  treatment)
CR 2.7 (avoid diversion)
CR 2.8 (harm reduction in 
prison)
CR  2.9 (infectious diseases)
CR 2.10 (condom distribution)
CR 2.10 (injection material)
CR 2.11 (emergeny services)
CR 2.12 (integration of services)
CR 2.13 (qualification 
professionals)
CR 3 (evaluation)
EU 15 EU 12 candidate/acceding countries
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Countries with increasing drug-induced deaths rates should set priorities regarding 
the prevention of drug-induced deaths: e. g. improving the coverage of opioid substi-
tution treatment (OST), peer naloxone programmes, prison release management, drug 
consumption rooms; Countries with very low drug-induced deaths rates should 
discuss if the rates reflect the real situation or are due to underreporting – especially 
Hungary, Romania, and Turkey.  
Countries with increasing or high HIV rates should set priorities regarding the preven-
tion of drug-related infectious diseases: e. g. improving the coverage of OST, syringe 
provision through specialised programmes (in prison) - especially Bulgaria, Estonia, 
Greece, Latvia, Lithuania, Portugal and Romania. In Bulgaria, Lithuania and Romania the 
numbers of HIV infections via injecting drug use and the numbers of drug-induced 
deaths have increased significantly, indicating urgent needs for interventions. 
Asked for harm reduction measures, whose implementation/expansion would show 
the biggest effect in the reduction of prevalence of drug-related infectious diseases 
among injecting drug users in the respective country/region, civil society organisations 
(stakeholder survey) quoted needle and syringe exchange and harm reduction meas-
ures in prison most often followed by paraphernalia distribution for injecting drug 
users and safer injection training. Asked for measures, whose implementa-
tion/expansion would have the biggest effect in the reduction of drug-induced deaths 
(overdoses) in the respective country/region, first aid training for drug users and 
naloxone “take-home” programmes were quoted most often followed by information 
and counselling services to drug users focusing on harm reduction and prison release 
management (details see section 12.14 and annex 3).  
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6 Implementation of CR 3 
Council Recommendation 3 focuses on scientific evidence, monitoring and evaluation. 
Questions concerning CR 3 were not included in the stakeholder survey. All referred 
data originate from the policy maker survey.  
Table 6.1 gives an overview of the existence of the respective policies in the countries 
investigated. Most common is the policy according CR 3.5 (organising standardised 
data-collection and information dissemination according to the EMCDDA recommen-
dations through the REITOX national focal points) that exists in 30 countries but not in 
Iceland (Romania no information). Least common are policies according CR 3.3 (devel-
oping and implementing adequate evaluation protocols for all drug prevention and risk 
reduction programmes) and CR 3.8 (integrating innovative methods that enable all 
actors and stakeholders to be involved in evaluation, in order to increase acceptance of 
evaluation) that exist in only 21 of 31 countries (Romania no information). 
Differences can be observed in the estimated level of implementation of the various 
sub-recommendations by the policy makers. CR 3.5 (standardised data collection 
according to the EMCDDA recommendations) is estimated to be implemented to a 
large extent by 26 of 31 countries, which is the best ranking. Using scientific evidence 
of effectiveness as a main basis to select the appropriate intervention, CR 3.1 is 
estimated to be implemented to a large extent by 18 countries (2nd highest rating 
concerning implementation). Only five countries estimate a high rate of implementa-
tion for the involvement of actor and stakeholders in evaluation (CR 3.8). For all sub 
recommendations of CR 3, more than half of policy makers estimate an increase or a 
strong increase in the level implementation since 2005. 
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Table 6.1: 
Recommendation 3 – overview of existence 
CR 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 total 
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Austria 1   1   0 NT 0 NT 1   0 OT 1 0 NT 0 NP 4 
Belgium 1   1 1 1   1   1 1 1 DIV 1   1   1   9 
Bulgaria 0    0 PA 0 OT 1 1 1 1 0 PA 0    0 PA 1 1 3 
Croatia 1    1    1    0    1    1    0    0    1    6 
Cyprus 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Czech Republic 1   1 1 1 1 1 1 1   1   1   1 1 1   9 
Denmark 1   1   1   1   1   1   1   1   1   9 
Estonia 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Finland 1   1   1 1 1   1   1   1   1   1   9 
France 1   1     OT 0 OT 1   1       0 OT 1   5 
The former Yugoslav Republic  of 
Macedonia 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Germany 1 1 1   1 1 1 1 1 1 1   1   1   1 1 9 
Greece 1   1   1   1   1   1   1   1   1   9 
Hungary 0 NT 0 NT 0 NT 0 NT 1   0 NT 0 NT 0 NT 1   2 
Ireland 1   1   1   1   1   1   1   1   8 
Iceland 1   1   0 OT     0 OT 0 OT 0 OT 0 OT 0 OT 2 
Italy 1   1 NT 1 NT 1   1   1 NT 1 1 1 1 1   9 
Latvia 0 NT 1 1 0 NT 1 1 1 1 1 1 0 NT 0 NT 1 1 5 
Lithuania 1 1 1   1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Luxembourg 1   1   1 OT 1   1   1   1   1   1 1 9 
Malta 1   1   0 PA 0 OT 1   1   0 OT 1 1 1   6 
Montenegro 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Netherlands 1   0 NT 0 OT 0 NT 1   1   1   0 OT 1   5 
Poland 1   1   1   1   1   1   1   1   1   9 
Portugal 1   1   1   1   1   1   1   1   1   9 
Romania 
Slovakia 1 1 0 PA 0 PA 0 PA 1 1 1 NP 0 NP 0 NP 1 1 4 
Slovenia 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Spain 1   1   1   1   1   1   1   1   1   9 
Sweden 1   1   1   1   1   1   1   1   1   9 
Turkey 1 1 1    0 OT 0 OT 1 1 1 1 1 1 5 
UK 1   1   1 1 1 1 1   1   1 1 1 1 1   9 
Total  28  27  21  22  30  27  22  21  28    
Remarks: 0=no; 1=yes; blank=no information 
Reasons why not based on Council Recommendation: OT=other reason | NP=not a priority | NT=not task of national 
government | PA=pending for approval | NA=not available | DIV=diverging answers. 
The full wording of all CRs can be found in section 15. 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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7 Conclusions and recommendations 
This report provides an overview of the availability and coverage of harm reduction 
measures in the EU, Croatia, the former Yugoslav Republic of Macedonia, Iceland, 
Montenegro and Turkey and discusses the evidence of their effectiveness. A special 
focus was put on the impact of the Council Recommendations and on developing 
recommendations for improvements in the field of harm reduction. The following 
conclusions and recommendations are based on the literature review, the analysis of 
the current situation and the recommendations of the stakeholders for future interven-
tions. First, general conclusion on the effectiveness of the interventions are presented 
and discussed. In a second step, concrete recommendations have been elaborated, 
addressing the EU level, the national level and the harm reduction sites.  
Strong scientific evidence exists for the effectiveness of opioid substitution treatment 
(OST) to reduce the infection risk in connection with drug-related infectious diseases 
as well as mortality. Interruptions of OST are a risk factor for drug-induced deaths. 
Challenges for the future are to clarify how coverage can be increased further (e. g. 
avoid waiting lists), how interruptions can be avoided and how OST concerning sub-
stances and regimes can be diversified to meet the needs of different subgroups of 
opioid addicts. For syringe provision through specialised programmes there is strong 
scientific evidence concerning the reduction of infection risk, too. Challenges are the 
improvement of coverage and dealing with other routes of administration. On one 
hand it has to be clarified if and how needle exchange programmes (NSPs) can be used 
to promote other ways of administration than IDU. On the other hand, there are signs 
that injecting as route of administration is decreasing and delivering of safer use 
materials and information for other routes of administration gets more relevance. In 
the last decade evidence on heroin assisted treatment as a second line intervention, 
drug consumption rooms and peer naloxone programmes have increased significantly. 
Based on this evidence it can be assumed that these interventions are effective, but 
they should be further monitored and evaluated. There is strong evidence concerning 
the effectiveness of harm reduction in prison. 
To summarise the epidemiologic situation concerning drug-related harm it can be 
stated that a significant reduction of HIV infections among IDUs in most countries was 
achieved, but infection rates of hepatitis C are still high in many countries. Recent HIV-
outbreaks in Greece and Romania show that HIV infection rates can increase rapidly 
under specific conditions including low coverage of harm reduction measures. High 
rates of HCV infection can be seen as an indicator for the risk of a HIV-outbreak. It was 
not possible to reduce drug-induced deaths since 2003 in most countries, although 
the coverage of OST increased. On one hand measures to improve retention rates in 
OST and to avoid interruptions (e. g. prison, attempts to become drug free with no 
adequate indication) are necessary. On the other hand interventions focusing on 
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overdose risk like drug consumption rooms and peer naloxone programmes should be 
considered. Prison release is a risk factor for drug-induced deaths and therefore 
adequate throughcare including prison release management and continuation of OST 
in prison and over the period of release is crucial. 
The situation concerning harm reduction measures improved a lot in most countries. 
The Coverage of OST and NSP considerably increased but especially NSP is still far 
away from full coverage in all countries. While OST is now available in many prisons, 
NSP is not. Therefore, prisons are still a high risk environment for infections with HIV 
or HCV and a driving factor for infectious diseases among injecting drug users (IDUs). 
Therefore, improvements in the prison setting are very urgent. Heroin assisted treat-
ment as a second line intervention, Drug Checking, peer naloxone programmes and 
drug consumption rooms are implemented in a few countries, only. In times of eco-
nomic crises, the financing of the status quo and the expansion of harm reduction is 
an important issue in all countries. In some EU 12 states (e. g. Bulgaria and Romania) 
harm reduction projects were initially funded by the “Global Fund to Fight AIDS, 
Tuberculosis, and Malaria”. There are now problems to ensure national funding. 
The role of the Council Recommendation on harm reduction can be judged as impor-
tant especially in the countries joining the EU in 2004 or later (EU 12). From organisa-
tions involved in harm reduction, further support from EU level is requested. A clear 
new statement on harm reduction can help to foster expansion of harm reduction 
measures. These EU-recommendations should include in particular also new measures 
like drug consumption rooms and peer naloxone programmes related to the reduction 
of drug-induced death and give a special focus to prisons (OST, NSP and adequate 
throughcare). In addition, the new recommendations should cover new areas like 
housing, social re-integration and occupation because these are the main factors for 
stabilisation (or de-stabilisation if lacking). However, existing harm reduction meas-
ures such as OSP and NSP as the backbone of any harm reduction strategy need to be 
strengthened. 
Data availability made a very good progress in the time-span from 2003 to 2010. 
Thanks to the continuous efforts of the EMCDDA for harmonisation and expansion of 
data collection, a lot of comparable data are available to describe the epidemiology of 
the drug situation and harm reduction measures. Unfortunately, data for time-series 
are not available for all countries; even basic data to analyse drug-related harm and 
availability of measures of harm reduction are missing in some countries. It has to be 
taken into account that absolute numbers (e. g. number of drug-induced deaths) are 
also influenced by the quality of the respective monitoring system. Therefore country-
specific comparisons have to be made with caution and should be totally avoided for 
some countries. The implementation of adequate evaluation protocols for all drug 
prevention and risk reduction programmes as well as the involvement of all actors and 
stakeholders in evaluation could be improved.  
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Based on the literature review and the analysis of the situation concerning harm 
reduction, the following concrete recommendations have been elaborated (see also 
chapter 14): These recommendations implicate activities on different levels: EU-policy-
level, national-policy-level and the level of practical implementation in the field. 
Political strengthening of harm reduction: Harm reduction is still politically not undis-
puted. While in many countries harm reduction measures became well implemented in 
the last decade, in some countries steps backwards can be observed or are feared. 
Moral barriers and the prioritisation of abstinence orientated services by some decision 
makers remain major obstacles for harm reduction services (stakeholder survey). Many 
stakeholders express concerns regarding the financing of harm reduction measures in 
the future due to the financial crisis. But there are also objections by uninformed or 
despondent decision makers. The harm reduction approach should further be 
strengthened in follow-up policy work at EU level. 
Syringe provision through specialised programmes: Syringe exchange for injecting 
drug users (IDUs) is an integral part of drug policies in all EU Member States and 
candidate countries, with the exception of Turkey. But nearly all countries where 
respective data are available miss the WHO, UNODC, UNAIDS criteria of 200 syringes 
per IDU per year for good coverage concerning HIV prevention. This is a major obstacle 
taking into account that the levels required for the prevention of hepatitis C (HCV) are 
likely to be much higher. Activities to improve the coverage of the availability of sterile 
needles and syringes especially in rural areas are needed. Especially countries with an 
increase of HCV prevalence (Austria, Bulgaria, Cyprus, Greece and Romania) or of newly 
diagnosed HIV or high HIV rates among IDUs (Bulgaria, Estonia, Latvia, Lithuania, 
Greece, Portugal, Romania) are called upon to take some actions. 
Opioid substitution treatment (OST) improvement of coverage and organisation: The 
coverage of OST has increased significantly since 2003. However, coverage is not 
regarded as full or extensive in all countries, and waiting lists for OST are common. 
Other challenges for practice and research are the diversification of OST according to 
substances used, routes of administration and regimes (e. g. OST via drug treatment 
centres versus OST via general practitioners) to meet the needs of different groups of 
clients. The main purpose should be to avoid interruptions which are a risk factor, 
especially concerning drug-induced deaths. In this connection, clear indications for the 
change from OST to drug-free treatment are needed because failed attempts to 
become drug free might increase the risk of drug-induced deaths. Another factor in 
avoiding interruptions is that parallel consumption of other drugs should not be a 
reason to suspend someone from OST. Only Spain, Italy and Denmark experienced a 
significant decrease in drug-induced deaths during the last decade. Thus, in almost all 
countries improvements in this field seem to be necessary. In addition heroin assisted 
treatment should be expanded as a second line intervention. 
Harm reduction in prison: While OST is now available in many prisons, syringe provi-
sion through specialised programmes (NSP) is not. The coverage of harm reduction in 
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prison is estimated to be very low in general. Therefore, prisons are still a high risk 
environment for infection with HIV or HCV and a driving factor for infectious diseases 
among IDUs. There is a high risk of fatal overdoses (drug-induced deaths) after prison 
release which points out the importance of adequate prison release management 
(throughcare). The conclusion is that a lot has to be done in this area. The implemen-
tation of NSP which is possible and effective (see Spain for example), the improvement 
of OST coverage and adequate throughcare including prison release management 
(assuring continuation of OST in prison and after prison release) are necessary. To 
speed up the full implementation of harm reduction measures in prison, this issue 
should be especially highlighted in follow-up policy work at EU level.  
Naloxone “take-home” programmes: Asked which implementation/expansion of harm 
reduction measures would have the biggest effect on reducing the numbers of drug-
induced deaths (overdoses) in the respective country/region, first aid training for drug 
users and naloxone “take-home” programmes were quoted most often by civil society 
organisations. Based on the results from the evaluation studies, the recommendations 
from experts and the analysis of the objections against naloxone, it can be concluded 
that naloxone is a safe drug to use and peer naloxone programmes - in combination 
with emergency training - should be expanded in Europe to decrease the number of 
drug-induced deaths.  
Facilitate the use of emergency-services: The use of emergency services is an impor-
tant aspect in preventing drug-induced deaths. However, the use of emergency 
services and its impact on harm reduction is hardly studied. One major aspect is the 
(perceived) risks of police arrests associated with calling emergency services or the 
fear of violating conditions of probation. As a possible measure in this field, for 
example in Luxembourg, a law exempts drug users who call for assistance in case 
another user is in need of medical help, from prison sentences and from fines in 
certain circumstances. In general, witnesses meeting these conditions are not prose-
cuted. As an accompanying measure, an information flyer has been elaborated jointly 
with field agencies and the Ministry of Health and broadly distributed. The flyer 
contains useful information on safer injection and advice in case of overdose events 
(NFP-Luxembourg 2011). More research is needed to identify and overcome obstacles 
(e. g. legal implications) when calling ambulance services during an overdose in 
Europe. Furthermore it is important that expenses for the hospital stay as well as for 
the rescue effort are paid by the health insurance and not by the patient. 
Drug consumption rooms: It was not possible to reduce the number of drug-induced 
deaths in most of the countries from 2003 to 2009 (see section 11.3). Additional 
measures focusing on preventing drug-induced deaths are necessary. According to the 
stakeholders, the implementation of drug consumption rooms would be the second 
most effective measure to reduce drug-induced deaths after peer naloxone pro-
grammes. Based on evidence from recent literature on the effectiveness to reduce 
mortality and on the absence of negative consequences of consumption rooms, this 
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measure can be recommended. Implementation should be accompanied by adequate 
monitoring and evaluation to strengthen the scientific base. 
Counselling, outreach and peer involvement: Counselling and outreach are mainly part 
of other interventions and proved to be effective when the setting is appropriate and 
messages are provided by trustable persons. Especially peer delivered counselling 
including outreach fulfils these criteria (see section 10.2.3). The coverage of outreach 
is estimated to be at least extensive in roughly half of the countries and peer involve-
ment in just one third of the countries (see section 12.6). The coverage of outreach 
and peer involvement in counselling should be improved. 
Access to HCV treatment: Only 31 % of the countries in the stakeholder survey rate the 
coverage of medical treatment of HCV for injecting drug users as full or extensive. 
Many stakeholders state that nowadays, increasing the coverage of HCV screening and 
treatment is a great challenge. Scientific studies show that an integrated approach 
using needle exchange as well as HCV treatment is needed to reduce the prevalence of 
HCV, especially in high prevalence countries. The expansion of the coverage of HCV 
screening and treatment should be improved. 
HBV vaccination: HBV vaccination is effective for IDUs and especially important if there 
is already a HCV infection, as this leads to additional complications (see section 
10.2.6). Taking into account the high rates of HCV infections among IDUs in most 
countries (see section 11.2.2) the low coverage of HBV vaccination (only 7 countries 
report full coverage; see section 12.7) is very critical. Measures to improve the HBV 
vaccination coverage are necessary. 
Housing: Housing was not covered by the Council Recommendation but is a relevant 
issue for improving the quality of life and stabilisation. Housing seems to be a field of 
harm reduction where still a lot of improvement is necessary, as all measures (night 
shelters, assisted living, “housing first” approach) are described to have a rather low 
coverage (stakeholder survey). For night shelters, which is the measure with the 
highest coverage only 24 % report full or extensive coverage. The problem of housing 
should be considered in follow-up policy work. 
Integration of services: The integration of services between health, social care and risk 
reduction is reported to be fully or extensively covered in most countries. However, 
countries that have experienced significant increases in drug-induced deaths report 
limited or less coverage. Integration of services such as hospital release management 
(integrating health and social care) and treatment release management should be 
considered a priority to reduce the number of drug-induced deaths. Throughcare and 
prison release management are also very important issues (see above). 
Research and Evaluation: The following priority areas, where measures for improve-
ment and targeted research related to harm reduction are necessary, have been 
identified: 
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» Improvement of the coverage of estimates for prevalence of problem drug use, 
especially injecting drug use 
» The mortality rates directly related to overdoses (drug-induced deaths) differ to a 
large extent between countries. Research is needed to get insight if these differ-
ences are real (important information for policy evaluation) or due to different 
quality of data collection systems 
» More standardised data and longitudinal research to follow the development of 
HCV epidemics are needed 
» The proportion of injecting as route of administration of opioids differs a lot 
between countries. Research is needed to get insight into the reasons behind this 
and based on the results measures to shift away from injection or to avoid shifting 
to injection from other routes of administration should be developed – if possible 
» Implementation of adequate evaluation protocols for all drug prevention and risk 
reduction programmes that involve all actors and stakeholders in evaluation is 
needed 
These recommendations implicate activities on different levels: EU-policy-level, 
national-policy-level and the level of practical implementation in the field. 
Priorities and proposed activities on EU level:  
The Council Recommendation (CR) helped foster harm reduction in the EU, but the 
coverage is still far from sufficient in most areas. This calls for political strengthening 
of harm reduction which can be achieved by a new or revised CR. Based on the analysis 
of the situation and scientific evidence the following priorities shall be addressed:  
Priority A: reduction of drug-induced deaths 
Reasoning: It was not possible to reduce the number of drug-induced deaths since 
2003. 
Target: Significant reduction of the number of drug-induced deaths in the next ten 
years. 
Proposed measures: Improvement of the coverage (for specific subgroups of opioid 
addicts, low threshold access to OST, comprehensive health insurance covering OST) 
and organisation of opioid substitution treatment (avoid interruptions, avoid waiting 
lists), facilitate the use of emergency services, peer naloxone programmes, integration 
of services (especially prison and treatment release management), drug consumption 
rooms, outreach, peer involvement and family support. 
Relevance for public health: Drug-induced deaths remain one of the major causes of 
death among young adults which calls for immediate action. In particular, easy to 
adopt and cost-effective measures such as facilitating the use of emergency services 
should be addressed and supported on European level in order to save young lives.  
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Priority B: improvement of harm reduction in prison 
Reasoning: The coverage of harm reduction measures in prison lies far behind the 
coverage outside prison. Therefore prison is a high risk environment for injecting drug 
users (IDUs) to get infected with drug-related infectious diseases. Prison release 
without adequate throughcare is one main risk factor for drug-induced deaths. 
Target: Harm reduction measures in prison should be assured as a comprehensive 
response, equivalent to the community in the next ten years.  
Proposed measures: Opioid substitution treatment (OST), syringe provision through 
specialised programmes (introduction in all prisons), release management, through-
care into and out from prison (regarding OST continuity), housing for released prison-
ers, health assessments including infection prevention.  
Relevance for public health: Harm reduction in prison is still very rare or limited in 
Europe leading to high infections rates and increased mortality after prison release. 
Around 15 percent of all drug related deaths could be avoided with adequate prison 
release management only (Frisher et al. 2012)5. High infection rates (e. g. HIV, hepati-
tis) of the prisons’ population threaten health of general population too. Good prison 
health is good public health (WHO 2007). Action in this field promises instant results 
and can be implemented cost-effectively (e. g. syringe provision through specialised 
programmes).  
Priority C: reduction of harm caused by drug-related infections 
Reasoning: Existing harm reduction measures have been sufficient to decrease HIV 
prevalence in injecting drug users (IDUs) significantly in most countries covered with 
this research. Recent HIV outbreaks show that this situation can change very fast when 
harm reduction is not appropriate. Hepatitis C (HCV) rates are still on a high level and 
will lead – if the reaction is not adequate – to enormous individual (e. g. death due to 
consequences of HCV) and public costs. 
Target: Significant reduction of HCV prevalence among IDUs in the next five years, 
significant reduction of HIV incidence in countries with high rates or increasing trends 
(Bulgaria, Estonia, Latvia, Lithuania, Greece, Portugal, Romania) in the next five years, 
treatment (especially HCV treatment) of infected IDUs shall reach full coverage in the 
next five years (treatment should be available for anyone in need of it), HBV vaccination 
of IDUs shall reach full coverage in the next five years. 
                                                                                                                                         
5 
In 2005, 1.506 drug users died in England from ‘overdose’ or poisoning, drug abuse or drug dependence. 
Around 15% of these deaths occur in people after release from prison. Those fatalities might be avoided with 
adequate and coordinated prison release management (Department of Health 2007; Frisher et al. 2012). 
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Proposed measures: See priority B, improvement of the coverage of syringe provision 
through specialised programmes (NSP), HIV and HCV treatment programmes, im-
provement of HCV surveillance, hepatitis B vaccination programmes, outreach, peer 
involvement and family support. 
Relevance for public health: Infection diseases are one of the major drug-related 
diseases and can be easily and cost-effectively influenced by widely available syringe 
provision through specialised programmes. It has been proven that OST is associated 
with a 50 percent reduction of HIV infection among IDUs (MacArthur et al. 2012). HIV 
and HCV treatment decrease the risk of infections for others and are therefore cost-
effective interventions to avoid individual harm and prevent further infections, which 
could lead to a substantial health burden for drug users and the society as whole.  
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8 Introduction 
The European Union is committed to achieving a high level of health protection for its 
citizens. Under Article 168 of the Lisbon Treaty, the EU action shall be directed towards 
improving public health, preventing physical and mental illness and diseases, and 
obviating sources of danger to physical and mental health. In relation to the drug 
prevention, the Union shall complement the Member States’ action in reducing drug-
related health damage, including information and prevention.  
Accordingly, the EU is taking initiatives to reduce health inequalities in and between EU 
Member States and regions, and to build capacity for development and implementation 
of effective public health policies with a particular focus on the Health in All Policies 
approach. 
Living a life free from addictions and their related harmful effects on health is an 
important element in a comprehensive public health strategy that promotes good 
health for all EU citizens.  
The Council Recommendation of 18 June 2003 on the prevention and reduction of 
health-related harm associated with drug dependence formulates the following main 
objectives: 
» Member States should, in order to provide for a high level of health protection, set 
as a public health objective the prevention of drug dependence and the reduction 
of related risks, and develop and implement comprehensive strategies accordingly. 
» Member States should, in order to reduce substantially the incidence of drug-
related health damage (such as HIV, hepatitis B and C and tuberculosis) and the 
number of drug-related deaths, make available, as an integral part of their overall 
drug prevention and treatment policies, a range of different services and facilities, 
particularly aiming at risk reduction; to this end, bearing in mind the general ob-
jective, in the first place, to prevent drug abuse. 
» Member States should consider measures, in order to develop appropriate evalua-
tion to increase the effectiveness and efficiency of drug prevention and the reduc-
tion of drug-related health risks. 
» Member States should report to the Commission on the implementation of this 
Recommendation within two years of its adoption and subsequently on request by 
the Commission with a view to contributing to the follow-up of this recommenda-
tion at Community level and acting as appropriate in the context of the European 
Union Action Plan on Drugs. 
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For main objectives 2 and 3, a list of concrete sub-targets is formulated (for details 
see section 15). 
Following the adoption of the 2005-2012 EU Drugs Strategy and its corresponding EU 
Drugs Action Plan for 2008-2013, the European Commission submitted in 2006 a first 
report on the implementation of the Recommendation, accompanied by a detailed 
background document (Trimbos 2006). This report is an extended follow up. 
8.1 Project objectives 
The purpose of the project was to produce a (progress) report on the current state of 
play of the 2003 Council Recommendation. The aforementioned report from the year 
2006 served as a baseline (Trimbos 2006). The recent report focuses on: 
» Recent developments in epidemiology in the field of drug-related harm: epidemi-
ological key indicators like drug-related infectious diseases, drug-induced deaths 
as well as drug consumption patterns and new challenges (e. g. rise of consump-
tion of new substances, local outbreak of HIV epidemics) 
» Supply of harm reduction measures in Member States and candidate/acceding 
countries and recent developments: the expert opinion of relevant stakeholders 
and policy makers working in the field of harm reduction 
» Statistical analysis of changes in the epidemiological situation and the supply of 
harm reduction, using modelling methods to get insight in the complex interaction 
of both, where possible 
» Effectiveness of harm reduction interventions to prevent drug-related infectious 
diseases and drug-induced deaths based on a systematic literature review with 
special focus on questions which are relevant for further recommendations by the 
Commission 
» Conclusions and Recommendations based on the evidence  
The report covers all 27 EU countries, the acceding country Croatia and the candidate 
countries the former Yugoslav Republic of Macedonia, Iceland, Montenegro and 
Turkey. 
In addition to this main report, an extensive annex including country profiles on harm 
reduction in all EU Member States and candidate/acceding countries (annex 1), a 
literature review on selected topics (“measures to influence route of administration”, 
“peer naloxone programmes”, “needle exchange programmes in prison” and “prison 
release management”; annex 2) and an in-depth analysis of the stakeholder survey 
(annex 3) is provided. For some overview tables see annex 4 and the questionnaires 
used for the policy maker survey and the stakeholder survey see annex 5. 
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9  Methods 
9.1 Analysis of data available at the EMCDDA  
In a first step all standard tables and structured questionnaires which are collected 
from EMCDDA via the REITOX network were scanned for information relevant for the 
description of the implementation of the Council Recommendation (CR). A data 
extraction tool was elaborated in co-operation with EMCDDA and the data were 
extracted in EXCEL-format for each country. Based on this extraction the data are 
presented in the country profiles (see annex 1). In addition for the analysis of epidemi-
ological trends the data presented in the EMCDDA Statistical Bulletin have been used. 
Data mainly refer to the time period 2003 to 2010 and have partly been updated to 
2011 for countries with important recent developments (HIV-outbreak in Greece and 
Romania). 
9.2 Gap-survey 
Based on the analysis of information available at EMCDDA (National Reports, Standard 
Questionnaire (SQ) 23, 27, 28 and 29, European Legal database, Best Practice Portal, 
Standard Table (ST) 10; Statistical Bulletin, Best practice portal) for each country, a 
country profile was elaborated, covering epidemiologic situation concerning drug-
induced death and drug related infectious diseases and information on the coverage 
and implementation of services related to the Council Recommendation.  
The country profiles were sent out to the REITOX network focal points as a gap-survey 
in the course of which REITOX Focal points should add information where necessary 
and also make comments on the information presented (epidemiological data, data 
already extracted from ST, SQs, national reports, etc.). Concerning epidemiological 
data, it was asked whether time series can be interpreted as a trend or if they are 
influenced by e. g. changes in data collection. Several rounds of reminders had to be 
sent out to get the gap-survey filled in. Croatia and all EU Member States with the 
exception of Bulgaria and Romania contributed to the gap-survey.  
9.3 Policy maker survey 
Based on the Trimbos report and the results of the discussion process with EAHC, 
EMCDDA and EC, the questionnaire was designed. The questionnaire was programmed 
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using the GlobalPark software. This software is a dynamic tool that allows to provide 
items according to previous questions and helps to avoid irrelevant questions (ques-
tionnaire see annex 5). 
The EC contacted the permanent representatives of each country (also the candidate 
countries) asking for the nomination of one responsible person for the Council Rec-
ommendation. This person should coordinate the answers to the survey. The secretary 
from DG SANCO sent the country specific link, the password (both were provided by 
GÖG to DG SANCO for each country) and the filled questionnaire from 2005 (Trimbos 
2006) to this person. GÖG sent an overview of the response rate regularly. Based on 
this the secretary of DG SANCO sent out several reminders. Data collection started on 
April 27th 2012 the deadline that was originally planned for end of May was expanded 
several times, finally all countries except Slovakia filled the questionnaire; the last one 
was finalised on November 23rd 2012. 
9.4 Consultation of stakeholders 
Based on the previous report (Trimbos 2006) and the results of the discussion process 
with EAHC, EMCDDA and EC, and after the consultation of leading experts from 
Austrian harm reduction organisations, the questionnaire was designed. The question-
naire was programmed using the GlobalPark software (see 9.3) and pre-tested by a 
field organisation (questionnaire see annex 5).  
A selection strategy that consisted of two phases of consultation was elaborated. The 
first phase covered organisations organised in international and national networks 
(e. g. EuroHRN, civil society forum on drugs) and was conducted from March 2012 to 
end of June 2012. The second phase (“snowballing”) covered organisations that where 
recommended by respondents in phase one and was conducted from July 2012 to 
November 2012. The deadline provided was expanded for several times. Overall, five 
reminding emails were sent out; moreover, stakeholders and members of national 
focal points were asked for their support at four expert meetings in Lisbon. In the final 
phase of data collection, GÖG contacted institutions from countries that had not 
responded till then individually. Overall, 123 institutions from 32 countries were 
contacted, 43 civil society organisations from 24 countries completed the question-
naire (response rate: 35 %). As for some Member States, more than one civil society 
organisation completed the questionnaire data were weighted in the analysis (details 
see annex 3).  
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9.5 Review of literature 
This literature review is an update of the review done by Trimbos (Trimbos 2006) for 
the previous report in the year 2005. The time span for the systematic literature search 
in that report was 1990 to 2005. Since then a synthesis of relevant literature on most 
important aspects of prevention of infectious diseases covering the years 2000 to mid-
2011 was done by ECDC and EMCDDA in 2011 (technical background documents of 
the ECDC and EMCDDA guidance “Prevention and control of infectious diseases among 
people who inject drugs (ECDC and EMCDDA 2011a; ECDC and EMCDDA 2011b). These 
documents are used for the update in this area. For the area not covered by the ECDC 
and EMCDDA guidance and the respective background documents recent reviews like 
the EMCDDA harm reduction monograph (EMCDDA 2010a), the EMCDDA insights on 
new heroin assisted treatment (EMCDDA 2012b) and the systematic review on the 
effectiveness of opioid substitution treatment in prison settings (Hedrich et al. 2011) 
have been used. For area not covered by recent reviews special literature reviews have 
been carried out (see below). In addition the relevant websites have been searched for 
international guidelines. 
For the previous report Medline, PsycInfo, Embase and Toxline were screened with 
database-specific strings of key terms to identify and select relevant studies. The key 
terms used focussed on several indicators for effectiveness, (users of) illicit drugs and 
harm reduction. The indices of several journals and websites in this domain for more 
recent publications were checked further. Reference lists in selected publications were 
screened on relevant additional publications and some experts were contacted. 
Predominantly, English publications were selected. In many of the review studies 
however, publications in other languages were included. More recent publications were 
added based on tips from experts and screening websites of scientific databases and 
websites, for instance from the Cochrane Library, the World Health Organisation or 
governmental organisations (Trimbos 2006). 
The Technical Report “Evidence for the effectiveness of interventions to prevent 
infections among people who inject drugs” mentioned above is mainly based on the 
“review of reviews” method. Reviews are considered high-level evidence because they 
summarise and collate findings from primary literature. Based on a list of search terms 
the following electronic databases were searched: 
» The Cochrane Library 
» EMBASE 
» MEDLINE 
» CINAHL 
» PsycINFO 
» IBSS 
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Based on the discussion on effectiveness in chapter 10.1 theoretical modelling studies 
have been used in addition. 
For the special literature reviews a systematic literature research was performed in 
Medline, Eric, Psycinfo, Embase and Cochrance with predefined keywords. The selec-
tion of abstracts and full-text versions was performed according to predefined selec-
tion criteria. To determine the quality of the studies, internal validity (risk for biases) 
and external validity (application of study-results for persons beyond the study-
populations) were both evaluated with predefined criteria. Contents of primary and 
secondary studies were displayed in table format. An additional hand-search was 
conducted and guidelines and general remarks were included and discussed following 
theory-based validity (details see annex 2). 
9.6 Limitations 
For the interpretation of the results of this report, the following limitations have to be 
taken into account: Data availability made a very good progress in the time-span from 
2003 to 2010. Thanks to the continuous efforts of the EMCDDA for harmonisation and 
expansion of data collection, a lot of comparable data are available to describe the 
epidemiology of the drug situation and harm reduction measures. Unfortunately, data 
for time-series are not available for all countries; even basic data to analyse drug-
related harm and availability of measures of harm reduction are missing in some 
countries. It has to be taken into account that absolute numbers (e. g. number of 
drug-induced deaths) are influenced by the quality of the respective monitoring 
system too. Therefore country-specific comparisons have to be made with caution and 
should be avoided for some countries at all. Another limitation of the present work is 
that the view of policy makers and stakeholders is based on the answers of single 
persons (answering often for a big country). This makes their statements subjective 
expert opinions. Therefore the data gathered are appropriate to give a general impres-
sion but not for direct country comparisons.  
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10 Effectiveness of interventions 
This chapter presents evidence on the effectiveness of harm reduction measures on 
the prevention and treatment of drug-related infectious diseases among drug users, 
the prevention of drug-induced deaths and harm reduction in prison settings. In a first 
step, the evaluation criteria of evidence are discussed. To assess the effectiveness of 
harm reduction measures an update of the review done by Trimbos for the previous 
report in the year 2005 was conducted. Since there is an actual synthesis of relevant 
literature on the most important aspects of prevention of infectious diseases covering 
the years 2000 to mid-2011 done by ECDC and EMCDDA dating to 2011 (technical 
background documents of the ECDC and EMCDDA guidance “Prevention and control of 
infectious diseases among people who inject drugs (ECDC and EMCDDA 2011a; ECDC 
and EMCDDA 2011b) these documents are mainly used for updates in this area. For the 
selected research areas “measures to influence route of administration”, “peer 
naloxone programmes”, “needle exchange programmes in prison” and “prison release 
management” special PICO-questions have been designed and systematic literature 
reviews have been conducted. The detailed results are included in annex 2 and short 
versions can be found in the respective sections of this chapter. 
10.1 Evaluation criteria and different levels of evidence 
The previous report as well as the technical reports on evidence for the effectiveness of 
interventions to prevent infections among people who inject drugs (ECDC and EMCDDA 
2011a; ECDC and EMCDDA 2011b) are more or less based on the “classical approach” 
of evidence which sticks to the paradigm that randomised controlled trials (RCTs) are 
the gold standard to evaluate effectiveness of interventions. A lot of literature can be 
found where the need of extending this approach is adressed. (Uhl 2010) stated: 
“Whenever the effects of interventions lie in the far future, whenever it is hard to 
measure effects objectively, whenever competing influences cannot be adequately 
controlled experimentally or statistically, and whenever the available sample sizes in 
practical applications are too small to expect any statistically significant results, we 
have to accept research strategies that are miles away from the ideal approach for 
investigating causal relationships, i.e. randomized, controlled trials (RCTs).” (Uhl 2010, 
26). Also, the previous report states that there is an ongoing debate about the best 
methodology to be used in determining effectiveness of interventions in public health.  
Especially in the field of harm reduction, it is very hard to follow a strict RCT approach. 
Since most interventions are low threshold activities the setting per se is a contradic-
tion to the need of controlled conditions as well as the strict distinction into control 
and experimental groups. Ethical reasons contradict RCTs in this field as well. Since 
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harm reduction measures often aim to avoid life threatening damages it would be 
ethically very problematic to build a control-group with no intervention. It can be 
stated that many harm reduction measures - caused by their nature - will never reach 
the status of evidence based on the classical RCT-paradigm. However, this does not 
mean that they are not effective. 
But the critical debate of the RCT-paradigm leaves open the question on how to decide 
on the effectiveness of interventions. The previous report states that in a strict scien-
tific sense, alternative designs are not optimal to prove effectiveness. Thus, the 
methodological debate on the study design, suitable to produce evidence of effective-
ness in public health, currently remains unsolved (Trimbos 2006). 
On the other hand it can be postulated that many harm reduction activities have theory 
based validity. For example, the risk of being infected with HIV using the injection 
equipment of another person becomes inexistent when a new sterile syringe is used. 
There is no need to evaluate this. The same occurs for drug consumption, without 
medical supervision it is dangerous due to many reasons, but these risks are reduced 
in medical supervised consumption rooms. There is just one argument against this 
“theory based validity” approach: when the availability of harm reduction measures has 
the consequence that the problematic behaviour is increasing (e. g. if there are needle 
exchange programmes more people inject more often) negative effects could occur. 
One possible approach to reverse the burden of proof could be to stick to measures 
with theory based validity, as long as no proof of negative effects or failure is found. 
Studies which deal with theory based validity in a scientific sense are mathematical 
modelling studies which build mathematical models on plausible assumptions to 
predict effects on a theoretical base. If available, studies of this kind are used in the 
discussion on theory based validity in this report. 
The Interactive Domain Model (IDM) offers a good possibility to broaden the scope of 
view, developed in the field of health promotion which defines: “Best practices in 
health promotion are those sets of processes and actions that are consistent with 
health promotion values, theories, evidence, and understanding of the environment, 
and that are most likely to achieve health promotion goals in a given situation.” 
(Kahan/Goodstadt 2001, 47). 
Another aspect which has to be considered in the discussion of effectiveness is that 
the investigation of single interventions does not fit to reality where interventions 
always happen in specific contexts and interact with other interventions. Harm reduc-
tion measures can be considered as “complex interventions” (Petticrew 2011) For 
example, it can be assumed that counselling on safer injection does not make much 
sense when there is a lack of possibilities to get sterile injection equipment. Another 
example for interactions of interventions is that it has been recently proved that high 
coverage of needle exchange programmes, in combination with adequately dosed 
opioid substitution treatment, is statistically significantly associated with reduced 
transmission of hepatitis C (Turner et al. 2011).  
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10.1.1 Levels of evidence in the Trimbos report 
The previous report followed the conservative methodological rules of experiment, as 
applied in medical and psychological research, at the time as it was written in line with 
well-known scientific networks such as the Cochrane Collaboration and the Campbell 
Collaboration. The methodological scope was expanded a little by including studies 
deviating from the RCT design (e. g. time-series or prospective cohort studies, pref-
erably combined with a multivariate analysis, including factors that may also influence 
the outcomes). Finally, the results of some systematic reviews that used an adapted 
methodology for grading evidence were also included. This was done because the 
methodology used, added value to the well-known methods for grading scientific 
evidence that were used in the literature review (Trimbos 2006).  
In the previous report, a rough grading procedure was used, i. e. without systemati-
cally specifying quantity and quality of the studies. 
Effective interventions: When a systematic review or a meta-analysis of at least three 
RCTs was available, with equally directed significant outcomes or three separately 
published RCTs with outcomes that were alike and significant, the evidence is consid-
ered “sufficient”. Thus, the intervention is considered effective. 
Probably effective interventions: An amount of two RCTs or one RCT combined with at 
least two studies of lesser quality (i. e. well-done time-series or prospective cohort 
studies) was considered to give valuable indications for effectiveness. In these cases 
the intervention is probably effective.  
Possibly effective interventions: In case of a doubt, i. e. only one RCT (with or without 
one study of lesser quality) or merely one or two studies that are all of lesser quality 
but with positive findings, the evidence is in fact still insufficient.  
No evidence: For some interventions no studies were found or studies showed no 
consistent positive findings (Trimbos 2006). 
10.1.2 Levels of evidence in the report “Effectiveness 
of interventions to prevent infections among 
people who inject drugs” 
The Technical Report “Evidence for the effectiveness of interventions to prevent 
infections among people who inject drugs” (ECDC and EMCDDA 2011b) used the 
following evidence criteria: The reviews selected were critically appraised using a 
checklist and it was distinguished between “core reviews” (the whole or only a part of 
the review is judged to be of high quality) and “supplementary reviews”. Four levels of 
evidence were defined: 
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Sufficient review-level evidence to either support or discount the effectiveness of an 
intervention 
» Clear and consistent statement from one or more core reviews based on multiple 
robust studies, or 
» consistent evidence across multiple robust studies within one or more core 
reviews, in the absence of a clear and consistent statement in the review(s); 
Tentative review-level evidence to either support or discount the effectiveness of an 
intervention 
» A tentative statement from one or more core reviews based on consistent evidence 
from a small number of robust studies or multiple weaker studies, or 
» consistent evidence from a small number of robust studies or multiple weaker 
studies within one or more core reviews, in the absence of a clear and consistent 
statement in the review(s), or 
» conflicting evidence from one or more core reviews, with the stronger evidence 
weighted towards one side (either supporting or discounting effectiveness) and a 
plausible reason for the conflict, or 
» consistent evidence from multiple robust studies within one or more supplemen-
tary reviews, in the absence of a core review; 
Insufficient review-level evidence to either support or discount the effectiveness of an 
intervention 
» A statement of insufficient evidence from a core review, or 
» insufficient evidence to either support or discount the effectiveness of an interven-
tion (either because there is too little evidence or the evidence is too weak), in the 
absence of a clear and consistent statement of evidence from (a) core review(s), or 
» anything less than consistent evidence from multiple robust studies within one or 
more supplementary reviews; 
No review-level evidence  
» No core or supplementary reviews of the topic identified, possibly due to a lack of 
primary studies; 
10.1.3 Level of evidence used for the present report 
The present review tries to give an overview about recent scientific work starting from 
the evidence collected in the previous report. It is based on reviews which followed the 
“classical approach” of evidence (see above) but in addition some comments on “theory 
based validity” are made. Interventions are classified as effective even when effectivity 
was not proven by RCT (e. g no RCT has been done, RCT-design is inappropriate) and 
a lot of studies including control groups, epidemiological studies, pre-post-design 
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studies or statistical modelling based on plausible assumptions and theoretical 
considerations come to the conclusion that effectivity can be assumed. One important 
factor in this respect is the absence of negative consequences in the scientific evidence 
of some measures which often are used as counter-arguments (e. g. consumption 
rooms increase drug consumption). 
10.2 Prevention and treatment of drug-related infec-
tious diseases (DRID) among drug users 
Drug-related infectious diseases (DRID) can cause serious health problems among 
drug users that may lead to chronic complications and possibly death. Injecting drug 
use increases the risk of hepatitis C infection considerably. Together with unsafe 
sexual behaviours, injecting drug use increases the risks of HIV and hepatitis B infec-
tions. Drug-related infectious diseases exert a high financial and social burden on 
society (Trimbos 2006).  
Prevention of injecting drug use or risky injecting drug use (e. g. needle sharing) could 
be one of the most effective strategies to reduce drug-related infectious diseases 
(DRID). However, these diseases are not solely related to injecting drug use but also to 
unsafe sexual contacts and unsafe life style in general (Trimbos 2006). To describe the 
effectiveness of measures for the prevention of DRID the following outcome measures 
are used: 
» Reduction of transmission of DRID 
» Reduction of injecting (risk behaviour) among people who inject drugs 
10.2.1 Needle and syringe exchange 
Sharing injecting equipment is a main risk factor for the transmission of drug-related 
infectious diseases. In general, the incidence of these diseases among injecting drug 
users is highest compared to non-injecting drug users. Needle and syringe exchange 
programmes are meant to reduce the spread of infectious diseases among injecting 
drug users (Trimbos 2006).  
The goal of needle and syringe provision is to reduce the sharing and reuse of nee-
dles/syringes and the transmission of blood-borne viruses among IDUs by increasing 
access to sterile needles/syringes and removing potentially contaminated ones from 
circulation. Needle and syringe exchange can be done in different settings: in low 
threshold facilities which offer a range of support to drug users, in accident and 
emergency departments, genito-urinary medicine clinics, or primary care settings. 
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Alternative means of providing needles/syringes are pharmacies, vending machines, 
and outreach (ECDC and EMCDDA 2011b). 
The theory based validity of this kind of approach is based on the rationale that the 
risk of being infected with blood borne diseases like HIV or hepatitis C using a sterile 
syringe is zero, while there is a considerable risk for being infected when injecting with 
a syringe already used by an infected person. 
The previous report came to the conclusion that needle and syringe exchange pro-
grammes are easily applicable effective and possibly also cost effective in reducing risk 
behaviours and the transmission of infectious diseases (Trimbos 2006). 
The review of reviews “Effectiveness of interventions to prevent infections among 
people who inject drugs” supports the results of the previous report and comes to the 
conclusion that there is sufficient review-level evidence to support the effectiveness of 
needle and syringe exchange programmes in reducing self-reported risk behaviour 
and tentative review-level evidence to support the effectiveness of needle and syringe 
exchange programmes in reducing HIV transmission among IDUs (ECDC and EMCDDA 
2011b). For the reduction of HCV transmission there is not sufficient evidence to come 
to a final conclusion at the moment. In general epidemiological data show that in most 
EU countries it was possible to reduce HIV prevalence to a large extent, but in many 
countries the rate of hepatitis C prevalence is still high. One possible interpretation of 
this situation might be that the harm reduction measures provided have been suffi-
cient for the reduction of HIV infections but not for the prevention of HCV infections. 
One interesting robust study dealing with this problem came to the conclusion that 
high coverage of needle exchange programmes in combination with adequately dosed 
opioid substitution treatment is statistically significantly associated with the reduced 
transmission of hepatitis C (Turner et al. 2011). 
10.2.2 Opioid substitution treatment (OST) of opiate 
dependence for preventing DRID 
Drug treatment encompasses a range of strategies to manage injecting drug use, 
including pharmacological maintenance treatment or opioid substitution treatment 
(OST), pharmacological detoxification treatment, pharmacotherapy combined with 
psychosocial approaches such as counselling or contingency management and resi-
dential rehabilitation. The strongest strategy in relation to the impact of OST in opioid-
dependent injecting drug users (IDUs) is the evidence regarding the effectiveness of 
drug treatment in preventing DRID-associated harm. At present, there are compara-
tively few studies regarding the effectiveness of drug treatment for stimulant or 
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cocaine-dependent persons, although evidence suggests that this is a growing prob-
lem in some parts of Europe (ECDC and EMCDDA 2011a). 
Pharmacotherapy for opioid dependence involves the use of agonist and antagonist 
agents. Opioid agonist treatments, such as methadone and the partial agonist bupre-
norphine, can be used either for detoxification or longer-term maintenance treatment. 
Methadone maintenance treatment (MMT) and buprenorphine maintenance treatment 
are the most commonly prescribed forms of OST and these treatments prevent with-
drawal symptoms, reduce cravings associated with opioid use, and reduce the effects 
of illicit opiates. Such therapy is most effective when it is continuous and is providing  
adequate doses (ECDC and EMCDDA 2011a). 
OST can be provided in conjunction with psychosocial treatments such as individual 
counselling, family or couple therapy; cognitive behavioural therapy, motivational 
interviewing or contingency management, which involves the provision of rewards for 
individuals that remain abstinent from drugs or who meet specific objectives of 
treatment (ECDC and EMCDDA 2011a). 
Theory based validity of this kind of approach is based on the rationale that the risk of 
being infected with blood-borne diseases like HIV or hepatitis C is lower when the 
frequency of injection is decreased or injecting drug use is stopped at all.  
OST is one of the best studied interventions in the drug field. The previous report 
came to the conclusion that OST is effective in reducing injecting drug use. According 
to the report “Effectiveness of interventions to prevent infections among people who 
inject drugs” there is sufficient review level evidence to support the effectiveness of 
OST in reducing the frequency of injection, the sharing of injecting equipment and the 
injecting risk behaviour. Concerning the reduction of HIV seroconversion there is also 
sufficient review level evidence, especially for those in continuous treatment. To 
reduce HCV incidence, a recent meta-analysis of UK studies taken together with 
primary studies show tentative review level evidence although consistent evidence 
from multiple longitudinal studies within supplementary reviews shows weak or absent 
association between OST and the reduction of HCV incidence. Since opioid addiction is 
a chronic disease and people in OST relapse to intravenous drug use in many cases, it 
is interesting to look at the combination of needle and syringe exchange programmes 
and OST. Evidence from one meta-analysis and two cohort studies indicates that the 
participation in full harm reduction programmes involving opioid substitution treat-
ment and high coverage of needle and syringe exchange programmes are associated 
with reductions in HIV and HCV incidence and reduced injecting risk behaviour (ECDC 
and EMCDDA 2011a) – see also section 10.2.1). 
OST is well implemented in many EU countries but an in-depth view shows that there 
are huge differences how OST is provided. In different countries different substances 
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are used (see also section 12.4). Even on regional level there are differences in the 
substances prescribed. Another difference can be detected when OST is included in 
routine medical supply by general practitioners or offered in specialised drug treat-
ment centres only. OST and drug treatment in general should be targeted to the 
individual needs of the client. It is a challenge of future research to build an evidence 
base for which kind of clients in which phase of the drug-related illness which sub-
stances and which regime of OST is most appropriate. Another important question is 
which other measures, besides medication, should be included in OST. For example 
there is tentative review level evidence of a beneficial impact of any psychosocial 
treatment provided alongside OST with respect to compliance, completion of treatment 
and abstinence at follow up (ECDC and EMCDDA 2011a). Due to different reasons a 
long time OST and abstinence orientated treatment have been seen as some kind of 
“hostile” approaches. Fortunately, this has changed to a large extent. But research for 
the combination of both approaches is still very scarce; e. g. concerning indications 
which approach is most effective in which situation (Busch et al. 2007). 
10.2.3 Information, education and communication 
(IEC) 
Many types of information, education and communication (IEC) are being used in 
preventing injecting drug use. IEC-messages may be spread via leaflets, booklets, 
audio-visual media or advocacy. IEC may be part of other interventions, e. g. mass 
media campaigns, outreach and other harm reduction interventions, treatment, HIV-
testing and counselling, or harm reduction counselling (Trimbos 2006).  
Theory based validity of this kind of approach is based on the rationale that, first of all, 
you need knowledge about risks to avoid them. But there is a lot of evidence that 
knowledge alone is not sufficient to change behaviour in many cases. 
Few high-quality studies can currently be found in the international literature on IEC, 
and the evidence of effectiveness of IEC is weak. IEC may at best be short-term 
effective in raising awareness and in more specific variants in changing knowledge and 
understanding, not in changing behaviour. These interventions are widely used as part 
of more extensive prevention or treatment packages. In general it is assumed that 
these interventions are more effective when combined with other prevention strategies 
(Trimbos 2006). 
The review of reviews supports the findings of the previous report. But the report 
found tentative review level evidence to support the effectiveness of outreach, which 
includes IEC in reducing risk behaviour among IDUs (ECDC and EMCDDA 2011b). This 
statement is based on three reviews. One of these reviews provides a clear statement 
VI / Main report - long version  63 
on the effectiveness of peer-delivered IEC. Other factors of IEC which are associated 
with reduction of HIV risk behaviour are: interventions delivered later in the course of 
treatment, separate sessions for men and women, the use of didactic lectures, the 
provision of training in self-control and coping skills, and the conduct of peer group 
counselling and discussion (ECDC and EMCDDA 2011b). This leads to the conclusion 
that IEC is effective when the setting is appropriate and the messages are provided in 
an adequate form by trustable persons.  
10.2.4 Community-outreach programmes 
Community-based outreach programmes are considered another component of 
preventing drug-related infectious diseases among risk groups i. e. those exposing 
sexual risk behaviour or injecting drug use. These outreach programmes aim to create 
access to hidden populations in their daily environment for targeted action against 
high-risk behaviours. Outreach activities are matched to the individual needs of 
members of the target group. Activities include increasing risk awareness, demon-
strating skills to avoid or reduce risks, behavioural counselling, distributing injecting 
equipment (see 2.1.3), or providing referral to regular treatment (Trimbos 2006).  
The Theory based validity of this approach is based on the rationale that you have to 
get into contact first when you want to give information or other kind of support. For 
many reasons hidden or marginalised populations will not come to you so you have to 
reach them in their environment. 
These programmes serve to access (partly) hidden populations of drug users in their 
natural surroundings and enable them to reduce drug-related risk-behaviours. Desired 
outcomes are an increase in programme coverage, programme participation, and a 
reduction of both risk behaviour and infection rates (Trimbos 2006).  
The previous reports states that the results of more than 40 published studies, includ-
ing multi-country, multi-site studies and meta-analyses (sufficient evidence), reveal 
that community outreach programmes are effective on several outcomes. Injecting 
drug users (IDUs) reached by these programmes and who are offered access to harm 
reduction services, report reducing their risk behaviour and lowering their exposure to 
HIV. IDUs referred by outreach workers to available, accessible and acceptable services 
(e. g. voluntary testing, counselling, and drug dependence treatment) increasingly use 
these services and reduce their injecting drug use. In general, drug users who partici-
pated in a community-based outreach intervention were also slightly more likely to 
reduce their sexual risk behaviour, compared to those who followed another (unspeci-
fied) intervention strategy. In studies focussing on sex behaviours, there were indica-
tions that treatment compliance increased and drug use reduced considerably when 
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the intervention-group was compared to a group that had no intervention at all. Most 
findings were consistently reported in different places, under different circumstances 
and at different times during HIV epidemics. Besides being effective on several out-
comes, outreach programmes are relatively inexpensive interventions for preventing 
HIV and other drug-related infections among IDUs. Empirical studies of outreach 
programmes that also include preventing HIV infections (seroincidence) are rare and of 
minor quality, but the outcomes suggest that outreach work may substantially reduce 
HIV infections among injecting drug users (Trimbos 2006).  
The review of reviews examined IEC together with outreach work as IEC is often 
provided via outreach. The report found tentative review level evidence to support the 
effectiveness of outreach, which includes IEC in reducing risk behaviour among IDUs. 
The conclusion of the previous report about the usefulness of outreach to bring IDUs 
(especially hard to reach groups) in contact with other services (e. g. treatment pro-
grammes, needle exchange) is strongly supported (ECDC and EMCDDA 2011b).  
10.2.5 Measures to avoid shifting from other routes 
of administration to IDU and to foster shifting 
from IDU to other routes of administration 
Epidemiological data show that there are huge differences in the route of administra-
tion of opioids between countries (see section 11.1.2). For example, in the Nether-
lands, for just seven percent of the clients in outpatient treatment, injection was the 
main route of administration of opioids while in Estonia 87 percent used that form of 
administration. In general, it seems that the proportion of opioid users who inject the 
drug is decreasing (see section 11.1.2). 
Looking at the literature since almost 20 years several authors strike out the necessity 
of interventions to influence route of administration – e. g. (Des Jarlais et al. 1992) 
(Vlahov et al. 2004) and recently (Malekinejad/Vazirian 2012). Despite this fact litera-
ture on interventions and evaluation of interventions is scarce.  
One intervention, where some evidence is available, is the distribution of foils for 
chasing heroin instead of injecting at syringe provision through specialised pro-
grammes (NSP). A study was conducted in the North-West of England where foil packs 
where provided at NSP. Out of 320 attendees, 54 % took the foil packs when they 
became available. Over the period of the evaluation, NSP transactions increased by 
32,5 % from 1.672 to 2.216. Additionally, 32 new clients (non-injecting heroin users) 
started attending the service to obtain the foil packs. This group would otherwise not 
have been in contact with the treatment service. More detailed data from one site are 
reported for 48 recent injectors who took foil within the NSP where the piloting first 
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started. Prior to the introduction of the foil packs, 46 % of this sub-group reported 
chasing heroin in the previous four weeks. At follow up, 85 % reported using the foil to 
chase heroin on occasions when they would otherwise have injected (Pizzey/Hunt 
2008). For more details see annex 2. 
10.2.6 Vaccination for hepatitis A and B and TB 
Series of vaccination are effective in preventing hepatitis B infections which may 
ultimately end in serious liver diseases (cirrhosis or cancer). The use of vaccination is 
several decades old and has proven to be effective for protection against clinical 
hepatitis B infection and chronic carriage of this disease for those who responded to 
complete hepatitis B primary vaccination series (three vaccinations). Follow-up studies 
showed that from ten to fifteen years after completed vaccination, no infections 
occurred and the development of a chronic infection was very rare (Trimbos 2006).  
Due to unstable life conditions of drug users it might be difficult to ensure that the 
client gets all three doses of hepatitis B vaccination. One possibility to improve vacci-
nation completion rates is contingency management or choosing a stable setting for 
vaccination (e. g. prison). When the completion of vaccination is not reached, a first 
dose only provides partial immunity (ECDC and EMCDDA 2011d). Vaccination for 
hepatitis A and B is also successful in the specific target population of IDUs (Baral et al. 
2007). Since some IDUs are hard to reach for vaccination through traditional means, a 
link to other drug-related support (e. g. NSP, treatment, testing) makes sense. IDUs 
should be defined as a target group for hepatitis A and B vaccination, especially taking 
into account the high prevalence of hepatitis C (ECDC and EMCDDA 2011d). 
Vaccination against TB is usually recommended for infants living in areas where TB is 
highly endemic and for infants and children at particular risk of TB exposure in low 
incidence areas only (ECDC and EMCDDA 2011d). 
10.2.7 Treatment of HIV/ AIDS, hepatitis B and C 
and of tuberculosis 
Recent studies have demonstrated clear benefits of antiviral treatment against HIV, 
HBV and HCV among persons using drugs and there is strong evidence for the benefits 
of TB treatment on individual and population-level (ECDC and EMCDDA 2011d). The 
theory based validity of this approach is that drug use per se is no contraindication for 
medical treatment of infectious diseases. Some studies show higher rates of premature 
treatment discontinuation (for HCV treatment) which points out to the importance of 
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an adequate setting and need for measures to ensure compliance. Multiple studies 
have confirmed that those who are HIV positive or HIV and HCV co-infected and 
receive opioid substitution treatment are more likely to adhere to the treatment 
regimen of their infection(s) (ECDC and EMCDDA 2011d).  
Treatment of HIV/AIDS, hepatitis B and C and of tuberculosis among IDUs can also 
been seen as prevention of transmission of these diseases because a lower (HIV) or 
terminated (HCV) virus load decreases the risk of transmission. Modelling studies show 
that HCV antiviral treatment of IDUs at achievable rate may be an effective primary 
prevention tool for substantially reducing the prevalence of HCV infection (Martin et al. 
2011).  
10.2.8 Remarks from general guidelines 
The recent ECDC and EMCDDA Guidance for prevention and control of infectious 
diseases among people who inject drugs recommend the following key interventions 
components: 
Injection equipment: Provision of, and legal access to, clean drug injection equipment, 
including sufficient supply of sterile needles and syringes free of charge, as part of a 
combined multi-component approach, implemented through harm-reduction, coun-
selling and treatment programmes (see section 10.2.1). 
Vaccination: Hepatitis A and B, tetanus, influenza vaccines, and, in particular for HIV-
positive individuals, pneumococcal vaccine (see section 10.2.6). 
Drug dependence treatment: Opioid substitution treatment and other effective forms 
of drug dependence treatment (see section 10.2.2). 
Testing: Voluntary and confidential testing with informed consent for HIV, HCV (HBV 
for unvaccinated) and other infections including TB should be routinely offered and 
linked to referral to treatment. 
Infectious disease treatment: Antiviral treatment based on clinical indications for those 
who are HIV, HBV or HCV infected; anti-tuberculosis treatment for active TB cases; TB 
prophylactic therapy should be considered for latent TB cases. Treatment for other 
infectious diseases should be offered as clinically indicated. 
Health promotion: Health promotion focused on safer injecting behaviour; sexual 
health, including condom use; and disease prevention, testing and treatment. 
Targeted delivery of services: Services should be combined, organised and delivered 
according to user needs and local conditions; this includes the provision of services 
through outreach and fixed site settings offering drug treatment, harm reduction, 
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counselling and testing, and referrals to general primary health and specialist medical 
services. 
In addition to this The “Global Fund to fight AIDS, Tuberculosis and Malaria” considers 
drug injecting as major driver of the HIV epidemic and therefore provides recommen-
dations on harm reduction for people who use drugs (The Global Fund to Fight AIDS 
2011). It is based on the WHO and UNAIDS “comprehensive package”: 
» Needle and syringe programmes 
» Opioid substitution therapy and other drug dependence treatment 
» HIV testing and counselling 
» Antiretroviral therapy 
» Prevention and treatment of sexually transmitted infections 
» Condom distribution programmes for people who inject drugs and their sexual 
partners 
» Targeted information, education and communication for people which inject drugs 
and their sexual partners 
» Vaccination, diagnosis and treatment of viral hepatitis 
» Prevention, diagnosis and treatment of tuberculosis 
In addition to these recommendations the “Global Fund to fight against AIDS, TB and 
Malaria” also recommends a range of complementary interventions that should be 
considered: Community involvement and user-oriented services (involve drug-users in 
planning, delivery and evaluation of HIV response programmes); Community system 
strengthening (include the community, its resources and capacity building in setting 
up harm reduction measures); gender-sensitive programmes, prisons and pre-trial 
detention (continuity of antiretroviral therapy, NSP and OST in prison); drug detention 
centres (close drug detention centres and identify and include more effective and 
human rights-based alternatives); ensuring supportive environments and human rights 
(advocacy for harm reduction); fatal overdose prevention (e. g. naloxone); monitoring 
and evaluation.  
10.2.9 Conclusions 
Concerning the prevention of risk behaviour (e. g. needle sharing) related to DRID (e. 
g. HIV, hepatitis), opioid substitution treatment (OST) and syringe provision through 
specialised programmes (needle exchange programmes - NSP) have proven their 
effectiveness in a range of high quality studies. This factor leads to the conclusion that 
these two interventions should be the central part of any strategy to reduce prevalence 
of DRIDs. Recent literature points out the necessity of high coverage of both interven-
tions to reduce hepatitis C infection rate. Information, education and communication 
are effective when the setting is appropriate and messages are provided in an ade-
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quate form by trustable persons. One possibility to assure the right setting is outreach 
work. Since peers are the most trustable persons in many aspects, peer involvement 
which has proven to be effective is a good strategy. The possible benefit of measures 
to avoid shifting from other routes of administration to injecting drug use (IDU) and to 
foster shifting from IDU to other routes of administration is pointed out in scientific 
literature. However, there is hardly any evidence on concrete projects. Thus, action is 
needed in this area. A good starting point are existing measures targeting mainly IDUs 
which might be used for promoting other routes of administration (e. g. syringe 
provision through specialised programmes where in addition foil and counselling 
concerning heroin chasing are offered – see annex 2). Vaccination for hepatitis B, 
treatment of HIV, HBV and HCV in IDUs are effective measures. Especially the treatment 
for HCV is an effective instrument of infection prevention for others, too. 
10.3 Prevention of drug-induced deaths 
10.3.1 Opioid substitution treatment for preventing 
drug-induced deaths 
The previous report concludes that several studies show a relationship between 
maintenance treatment of opiate users and a reduction of drug-induced death. Most 
studies address methadone programmes. Though there are hardly any randomised 
controlled trials on this subject, some studies show that maintenance treatment is still 
a promising alternative in reducing drug-induced deaths (Trimbos 2006). 
Theory based validity concerning the relationship between opioid substitution treat-
ment (OST) and reduction of mortality is the fact that the risk of overdose is much 
lower when opioids with unknown concentration consumed in unsecure and often 
stressful conditions are substituted by opioids with known concentration under 
medical supervision accompanied with a general stabilisation of the client. 
Beneath a meta-analysis of one RCT and five cohort studies identified in the previous 
report done by Caplehorn which showed that the risk of dying from overdose is just 
one quarter for opioid addicts in substitution, compared to those of former substitu-
tion clients, opioid addicts on waiting lists for substitution treatment or IDUs visiting a 
clinic due to psychiatric or general health problems another meta-analysis of eleven 
RCTs found no significant relation between reduced mortality and substitution treat-
ment (Mattick et al. 2009). One reason for the missing evidence found in RCTs might 
be short observation periods (Busch et al. 2007). A recent study shows that the risk of 
drug-induced death at the beginning of the substitution treatment and in the period 
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after termination, is higher but in general is reduced when the duration of substitution 
treatment exceeds one year (Cornish et al. 2010).  
In addition a lot of cohort studies e. g. (Fugelstad et al. 1998; Risser et al. 2001; 
Scherbaum et al. 2002) show a significant reduction of mortality for patients in OST. 
For example a high-quality Spanish cohort study among more than 5.000 opioid 
dependent persons strongly supports a causal relationship between not attending low 
threshold methadone programmes and death rate. All heroin dependents seeking 
treatment in Barcelona between 1992 and 1997 were (on average) assessed every nine 
months until the end of 1999. The death rate among this population was some twenty 
percent (N=1.005). Thirty-five percent of those who died in this period died from 
overdose, 38 % from AIDS and 27 % from other factors. Approximately half of this 
population participated in methadone programmes. Methadone most probably con-
tributed to a reduction in mortality rates or HIV infections. The total death rate reduced 
from 5,9 per 100 person years in 1992 to 1,6 in 1999. The most important factor 
associated with mortality was “not participating in a methadone programme” (Brugal et 
al. 2005; Trimbos 2006).  
The review on scientific studies in the EMCDDA harm reduction monograph comes to 
the conclusion that based on consistent evidence from one meta-analysis and multiple 
robust studies in supplementary reviews, there is sufficient review-level evidence to 
support the effectiveness of OST in reducing opioid-induced death (Kimber et al. 2010) 
10.3.2 Preventing opiate-induced death with peer 
naloxone programmes 
Naloxone is a non-selective opioid-antagonist which can be administered intravenous, 
intramuscular or subcutaneous (Baca/Grant 2005). Naloxone is readily transported 
across the blood-brain barrier and quickly reverses the opioid effects (e. g. respiratory 
depression). As naloxone rapidly (but temporarily) inhibits the effects of opioids it can 
induce severe withdrawal syndromes such as vomiting. It is important to note that 
naloxone has a short half-life of about 60 to 90 minutes whereas most opioids have 
longer half-lives (Advisory Council on the Misuse of Drugs 2012; Darke/Hall 1997). 
Therefore it is vital to monitor the patient after administering naloxone as the symp-
toms of the overdose may return. There is no recent evidence for life-threatening side 
effects such as cardiac arrests and therefore it is considered a drug which can be used 
more or less safely. 
The previous report concludes (based on a narrative review of Baca and Grant 
(Baca/Grant 2005)) that naloxone programmes are effective for the prevention of 
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drug-induced deaths, but additional measures such as training in rescue breathing 
should be taken (Trimbos 2006). 
In a systematic literature review and by hand-search for the present report (details see 
annex 2), 13 studies were identified on “take-home” naloxone programmes to actively 
injecting opioid users and peer based. All but one of these studies lack control groups 
and the main outcomes are narrative prescriptions from opioid users and their experi-
ence with naloxone. All of the studies conclude that naloxone is a safe drug to use and 
that negative consequences (e. g. severe withdrawal symptoms) are rare. All studies 
focus on peer training and peer distribution of naloxone. Most peer training pro-
grammes include didactic and interactive components (e. g. practicing with a resusci-
tation dummy), opioid symptom recognition and response training (administration of 
naloxone, rescue breathing, etc.) and contacting emergency medical service. Most 
persons were recruited at needle exchange sites. The measured outcomes are usually 
self-reported use of naloxone at peer-overdose. The duration of the training varies 
significantly: 10 to 30 minutes in New York (Piper et al. 2008) 25 minutes in Pittsburgh 
(Bennett et al. 2011) and eight hours in New York (Seal et al. 2005).  
The quality of the primary studies is low to medium and the size of the study groups is 
usually small. One of the main problems is the lack of control groups and changes in 
drug-induced deaths or behaviour could be influenced by other factors (e. g. heroin 
availability). In particular at the follow-up there is a bias, of those who return at the 
drug services sites and most studies report a very low follow-up rate. It is therefore 
unclear what happened to all the other trained persons and how they experienced or 
used naloxone.  
Theory-based validity and results: The discussion and recommendations on naloxone-
use often takes place at a theoretical level. One of the main objections against 
naloxone distribution is the fear that the availability of naloxone as a “safety net” 
would encourage more risky patterns of drug use. One study looking at this risk found, 
that injecting drug users would not use more heroin when naloxone is available. One 
small scale study showed a decrease of heroin use after an intensive overdose preven-
tion training including naloxone distribution (Seal et al. 2005). The provided training 
associated with naloxone prescription could increase self-efficacy and awareness and 
therefore reduce risky patterns (Advisory Council on the Misuse of Drugs 2012). There 
is not enough evidence to prove that “take-home” naloxone will increase riskier use, 
the same was shown by Dettmer (Dettmer et al. 2001). Among the main arguments for 
the distribution of naloxone among drug users is the fact that naloxone has no 
pharmacological effects in the absence of opioids and therefore imposes no risk for 
non-opioid users such as children of heroin users (Baca/Grant 2005; Darke/Hall 1997) 
and that naloxone has no abuse potentials (Darke/Hall 1997). It is not possible to 
overdose on naloxone (Darke/Hall 1997; Drug Policy Alliance). Therefore from a 
medical perspective the “current opinion is that naloxone is a safe drug to use” (van 
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Dorp et al. 2007, 90). Research on drug overdoses suggest that bystanders are present 
during most cases of overdoses (Advisory Council on the Misuse of Drugs 2012; 
Darke/Hall 1997; Strang et al. 1999) and peers are willing to administer naloxone if 
necessary (Bennett/Holloway 2012; Strang 1999). Many overdoses occur at home, 
where naloxone can be stored (Darke/Hall 1997) and overdoses do not occur instanta-
neously, but over a course of one to three hours giving a lot of opportunity for inter-
ventions such a naloxone administration (Sherman et al. 2008).  
None of the identified discussions and recommendations concludes that naloxone is 
unsafe. The general conclusion is that the potential benefits of naloxone programmes 
outweigh the potential risks (Bazazi et al. 2010; Kim et al. 2009).  
Based on the results from the evaluation studies, the recommendations from experts 
and the analysis of the objections against naloxone, the authors come to the conclu-
sion that naloxone is a safe drug to use and that naloxone distribution programmes, in 
combination with emergency training, should be expanded in Europe (see 14.5 for 
more details see annex 2). 
10.3.3 Drug consumption rooms 
Drug consumption rooms are professionally supervised healthcare facilities where drug 
users can use drugs in safer and more hygienic conditions (Hedrich et al. 2010). The 
previous report came to the conclusion that drug consumption rooms may reduce 
needle sharing and drug-induced deaths but more studies are needed to draw firm 
conclusions (Trimbos 2006). 
Theory based validity of consumption rooms is that medically supervised drug con-
sumption in a safe and hygienic environment is less risky than consuming in the street 
or in private housing. In addition it can be a first contact to the drug-help system. 
In the meantime a comprehensive overview concerning studies on consumption rooms 
is available (Hedrich et al. 2010). Based on evidence concerning emergencies which 
happened in drug consumption rooms, modelling studies and ecologically based time 
series analyses, it comes to the conclusion that where the coverage and capacity are 
sufficient and opening hours are appropriate, drug consumption rooms may attribute 
to reducing drug-induced deaths at city level. 
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10.3.4 Medical heroin (co)prescription 
Medical heroin (co)prescription is exclusively meant for a subgroup of chronic, treat-
ment resistant or treatment refractory patients that did not fare well with other treat-
ment options during their drug taking career. Frequently mentioned aims of medical 
heroin (co)prescription for this group are improving the physical and psychosocial 
health situation of opiate dependent persons, a reduction in drug-related criminality, 
an increase in several beneficial effects on society i. e. a reduction of public nuisance 
and lower costs of addiction in general (Trimbos 2006). 
The theory based validity of this approach is that if heroin is prescribed there is no 
necessity to consume street heroin with unknown concentration and contaminations 
and to engage in criminal activities. This decreases the risk of overdoses. 
In 2012 an “EMCDDA insights”-publication compiled the available evidence (EMCDDA 
2012b) and in 2011 a Cochrane Library review entitled “Heroin maintenance for 
chronic heroin dependents” was published (Ferri et al. 2011). The review comes to the 
conclusion that heroin plus methadone prescription, for maintenance treatments of 
adult chronic opioid users who failed previous methadone treatment attempts, is 
effective in a systematic review of eight randomised control trials (N=2.007) remaining 
in treatment until the end of the study (RR 1,44, 95 % CI 1,19 to1,75) and probably 
reducing the risk of death (RR 0,65, 95 % CI 0,25 to 1,69). The lack of significance 
concerning the effect on the reduction of mortality (just a tendency was observed) 
might be due, on one hand, to the short duration of some of the studies and on the 
other hand, to the fact that heroin treatment was tested against other forms of opioid 
substitution treatment (e. g. methadone maintenance) which also have an protective 
effect concerning mortality (see section 10.3.1). Looking at the increased retention 
rate, heroin assisted treatments can be considered as an important supplement of OST 
for hard to reach patients who repeatedly fail other forms of treatment and who are 
able and willing to accept the strict regulations of most heroin prescription pro-
grammes (second line treatment).  
Most heroin prescription programmes are based on injecting heroin. Further research 
should also take into account other routes of administration of heroin [such as: 
smoking (van den Brink et al. 2003), sniffing (Mitchell et al. 2006) or oral (Frick et al. 
2010)] - one hand, due to changing route of administration patterns (see section 
11.1.2) and on the other hand because these programmes might also be used as 
measures to foster shifting away from injection. For opioid addicts who stick to 
injection in addition substitution injection of other substances than heroin (e. g. 
hydromorphone) should be investigated. 
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10.3.5 Preventing drug-induced death with informa-
tion, education and communication 
Research on the effectiveness of information, education and communication (IEC) for 
injecting drug users was already evaluated in section 10.2.3. The conclusion was that 
IEC is effective if the setting is appropriate and the messages are provided in an 
adequate form by trustable persons.  
10.3.6 Preventing drug-induced death with promotion 
of other routes of administration than IDU 
See section 10.2.5 
10.3.7 Pill Testing / Drug Checking programmes 
There is still only one evaluation study on effectiveness of pill testing interventions 
dating back to 2002 (Benshop et al. 2002) which was already described in the previous 
report. This study brought some evidence that: 
» Health warnings about dangerous substances are received with greater trust and 
acceptance when delivered in the context of pill-testing programmes 
» Pill-testing programmes result in better-informed drug users and increasingly 
health-conscious behaviour 
» Pill-testing programmes do not stimulate the use of ecstasy and most likely will 
not extend the circle of ecstasy users 
» Pill testing programmes lead potential ecstasy users to postpone or abstain from 
an initial use of the drug 
The previous report (Trimbos 2006) states that pill testing programmes have several 
disadvantages like:  
» Testing methods are not standardised 
» Limited information by simple tests like colour tests  
» Pill testing is only one factor influencing drug use in recreational settings and 
probably not the most important one  
Theory based validity of drug-checking interventions is that the consumption of a 
tested substance is safer than the consumption of a mixture of unknown compounds. 
Furthermore on-site interventions give access to a group of persons that cannot be 
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reached by “traditional” drug care institutions (especially when combined with the 
confidence-building measure of drug-checking).  
Although no new studies are available, except for a smaller evaluation from Switzer-
land (Bücheli et al. 2010) and (Quinteros–Hungerbühler et al. 2011) which shows that 
“party drug users” are not a homogenous group, some important developments can be 
reported in this field:  
Due to the fact that the projects do not only focus on ecstasy tablets any more but also 
on other substances like cocaine and new psychoactive substances (e. g. so called 
“research chemicals”) the term “Drug Checking” is now more common. Drug Checking 
programmes are currently available in more European countries than in 2006 namely in 
Austria, Belgium, France, the Netherlands, Portugal, Spain and Switzerland. Drug 
Checking is seen as an integrated service that always combines the chemical analysis 
with advice or counselling (TEDI 2011). In their self-perception (VWS 2012) Drug 
Checking programmes often define themselves as information and counselling pro-
grammes that also provide drug-checking (in this order of importance).  
Simple colour reaction tests and the use of pill-lists are not common anymore; the 
programmes use at least thin layer chromatography but many use also laboratory 
analysis, which helps not only with identifying more substances but also gives a better 
input for early warning and monitoring systems. In many programmes peers are 
involved, partially high standards for professional counsellors like advanced education 
in motivational interviewing are reported. Drug Checking programmes regard them-
selves being cost effective as they reach drug users at an early stage which gives the 
possibility of early interventions. Moreover, the analyses can provide beneficial results 
to general public health (TEDI 2011). Through the use of modern social media Drug 
Checking projects are able to gain a broader but nevertheless targeted public than 
some ten years ago. 
In the course of the EU-financed project Nightlife Empowerment & Well-being Imple-
mentation Project (NEWIP) all European Drug-Checking programmes work together in 
the TEDI (Trans European Drug Information) workgroup on a common database and 
focus on: 
» Standardising the various processes related to Drug Checking 
»  Making recommendations to help improve first-line project field interventions 
»  Monitoring the evolution of new substances and new trends throughout Europe 
(http://www.safernightlife.org) 
Although there is no new evidence on the effectiveness of Drug Checking programmes, 
it might be worth to conduct new studies – on one hand especially because of the 
challenge to react to the emerging of new psychoactive substances on the markets (see 
also 11.4.2.). On the other hand one can assume that the fact that Drug Checking 
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programmes are financed by some countries now for 15 or more years indicates that 
good experiences with this kind of intervention exist. 
10.3.8 Pre-release counselling – prison and 
drug free treatment 
The first weeks after prison release are an extremely critical period regarding fatal 
overdoses for drug users. A meta-analysis of studies concerning drug-induced deaths 
soon after prison release shows that six out of ten deaths in the first twelve weeks 
after prison release are drug-induced. A three-to eightfold increased risk was found 
comparing weeks 1 and 2 with weeks 3 to 12 (Merrall et al. 2010). Beside the de-
creased tolerance after a period of relative abstinence, the concurrent use of multiple 
drugs, the lack of pre-release counselling, post-release follow-up and failure to 
identify those at risk are reasons for the overdoses (WHO 2010).  
Various possible measures are described in the literature to prevent fatalities due to 
overdoses like throughcare (continuity of treatment before, during and after prison), 
opioid substitution treatment (including start of OST before release), Naltrexone 
treatment, naloxone “take-home” programmes, pre-release counselling on overdose 
risks (including risk assessments, overdose prevention training and/or training in first 
aid and overdose management), optimising referral to aftercare services and into 
community treatment. A term like “prison release management” for a bundle of 
measures does not exist in literature yet, hence a short overview on evidence concern-
ing the single measures is provided here. 
Throughcare means the uninterrupted professional healthcare throughout the criminal 
justice system and the subsequent amalgamation with community interventions. 
Regarding theory based validity it makes sense to provide healthcare from the very 
beginning of imprisonment until reintegration in society (“throughcare”). Many various 
factors may contribute to the effectiveness of throughcare; so it is impossible to 
investigate it as a whole, nevertheless the possibility of continuity of care and treat-
ment stability is one of the key recommendations of WHO (2010) concerning the 
prevention of drug-related mortality. 
OST in prison was investigated in a systematic review by Hedrich et al. (2011) and 
concludes that evidence concerning the influence on post release fatalities is (still?) 
weak and states that the lack of research in this field is somewhat surprising. The 
results of Kinlock et al. (2009) and McKenzie et al. (2012) indicate at least that OST, in 
combination with counselling and active referral, might be more effective than coun-
selling only.  
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Opioid substitution treatment with the opioid antagonist Naltrexone seems to be 
problematic due to its poor acceptance by the patients (Coviello et al. 2010; Trimbos 
2006). 
Evidence on naloxone “take-home” programmes is described in chapter 10.3.2 and 
annex 2, Wakeman et al. (2009) conclude, that a pre-release overdose prevention 
education programme including naloxone prescription would likely prevent many 
overdose deaths among (former) prisoners. 
Studies on the effectiveness of pre-release counselling and different ways of referral to 
community based treatment are scarcely to find, as in studies these measures are 
often combined with other measures like OST and/or the content of counselling and 
the circumstances of referral are not described in detail (e. g. (Kinlock et al. 2009; Lee 
et al. 2012; Magura et al. 2009). Reliable data about the availability of pre-release 
measures are scarce (EMCDDA 2012h). Good models of practice in pre-release coun-
selling on overdose risks or overdose prevention training were identified in Belgium 
(Flemish prisons) and Portugal (EMCDDA 2012h). 
Binswanger et al. (2012; 2011) describe in a qualitative study the transitional chal-
lenges for released inmates and barriers like access to housing, job and physical and 
mental healthcare, and problematic conditions of parole. Further cognitive and emo-
tional responses during the transitional period are discussed. For the future it might be 
useful to conduct both: more studies on the problems and challenges of released 
prisoners and studies on the effectiveness of various interventions. More details see 
annex 2. 
Finally it has to be indicated that there is also an elevated risk of overdose related to 
mortality among drug users after discharge from (abstinence orientated) inpatient 
treatment (Ravndal/Amundsen 2010). Also in this case the low drug tolerance is the 
main explanation. The conclusion of the authors fits well into the following presented 
bundle of measures: 
“Preventive strategies must be planned and carried out in treatment and community 
settings alike, and in continuous cooperation between active users of heroin, clients in 
treatment, the families of heroin users, and healthcare and social service authorities. 
Only broad cooperation between all involved parties can help ensure that fewer heroin 
users, old and young alike, die from accidental or planned overdoses.” 
(Ravndal/Amundsen 2010, 68) 
VI / Main report - long version  77 
10.3.9 Remarks from general guidelines 
There are no international guidelines directly addressing the prevention of drug-
induced deaths. There is a guideline for the psychosocially assisted pharmacological 
treatment of opioid dependence (WHO 2009); other measures are not topic of interna-
tional guidelines. Concerning prison see 10.4.3. 
10.3.10 Conclusions 
Based on consistent evidence from one meta-analysis and multiple robust studies in 
supplementary reviews, there is sufficient review-level evidence to support the effec-
tiveness of opioid substitution treatment (OST) in reducing opioid overdose death. The 
first weeks after starting OST and the time directly following  the termination of OST 
are phases of increased mortality. Prison and treatment release management are 
important to avoid interruptions in OST (see annex 2). The quality of primary studies 
concerning peer naloxone programmes is low to medium and the size of the study 
groups is usually small. Based on the results from the evaluation studies, on the 
recommendations from experts and on the analysis of the objections against naloxone, 
the authors come to the conclusion that naloxone is a safe drug to use. In combination 
with emergency training, naloxone distribution programmes to peers should be 
expanded in Europe (see annex 2). A comprehensive overview concerning studies on 
drug consumption rooms shows that if the coverage and capacity are sufficient and 
opening hours are appropriate, drug consumption rooms can contribute to reducing 
drug-induced deaths at city level. A systematic review of eight randomised control 
trials comes to the conclusion that heroin plus methadone prescription for mainte-
nance treatments of adult chronic opioid users who failed previous methadone treat-
ment attempts is effective in increasing treatment retention and probably in reducing 
the risk of death. Drug Checking is considered as an integrated service that always 
combines chemical analysis with advice or counselling. Although, there is no new 
evidence on the effectiveness of Drug Checking programmes, it might be worth, on the 
one hand, to conduct new studies; because Drug Checking/counselling might be a 
reaction to the emerging of new psychoactive substances on the markets, and on the 
other hand because professionalisation took place concerning testing and counselling 
methods during the last few years.  
10.4 Harm reduction in prison 
Between 2001 and 2010 the prison population in the 27 EU Member States increased 
from 582.000 to 635.000. Offences related to use, possession or supply of illicit drugs 
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are one main reasons for imprisonment (10 % and 25 % of all sentenced prisoners). For 
the interpretation of these numbers it has to be taken into account that on one hand, 
not all of these prisoners necessarily have experience or problems with drug use. On 
the other hand, not all prisoners with problem drug use have been imprisoned for a 
drug law offence (e. g. imprisonment for other leading offences like burglary, shoplift-
ing, etc.) (EMCDDA 2012h). Estimations suggest that about 50 percent of prisoners in 
the EU have a history of drug use and a high proportion of them have one with prob-
lem drug use (WHO 2007). Concerning injecting drug use (IDU), there is evidence that 
on one side, in prison, some IDUs reduce the frequency of injection but on the other 
side it has also been described that, due to the low availability of heroin in prison, 
some drug users switch to injecting from other routes of administration (e. g. smok-
ing) (EMCDDA 2010b; Peña-Orellana et al. 2011). The scarcity of injecting equipment 
fosters sharing networks more intensively than outside prison. Additionally, inade-
quate cleaning practices of the equipment used for injecting and the rent of needles 
and syringes in exchange for the drugs are promoted (Long et al. 2004). In addition, 
some prisoners start (IDU-) drug use in prison. A recent study in 31 German prisons 
(14.537 inmates) shows that 22 % of all prisoners are IDUs (Schulte et al. 2009). It is 
not surprising that various studies have shown that prison is a risk factor for HIV, HBV 
and HCV infections (Judd et al. 2005; Lines et al. 2006; Stark et al. 2006). Due to these 
facts it is consequent to introduce in the prison setting harm reduction measures that 
have proven to be effective outside prison. According to the theory based validity the 
main question is: Are there any reasons why harm reduction measures with proven 
effectivity outside prison do not function inside prison?  
10.4.1 Opioid substitution treatment in prison 
A recent review on opioid substitution treatment (OST) in prison comes to the conclu-
sion that the effects are similar as outside prison. Based on five studies, OST was 
associated with reduced heroin injecting and self-reported needle sharing. Concerning 
mortality the situation is less clear due to a lack of adequate studies (Hedrich et al. 
2012). The fact that the first weeks after starting OST and the time directly following 
the termination of OST are phases of increased mortality has to be especially consid-
ered in the prison setting. Adequate possibilities to continue OST in and after prison-
release (throughcare) are essential (see also 10.3.8 and annex 2). 
10.4.2 Needle exchange programmes (NSP) 
Almost all studies on NSP in prison show a dramatic decrease in needle sharing and no 
or very low seroconversion rates concerning HIV, HCV and HBV. Although the study 
designs are not the best (no comparison) – which may lie in the nature of the topic 
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(ethical or ideological constraints to serve as a comparison prison with no NSP) – the 
firm conclusion can be drawn that NSP in prison is an effective method to reduce risk 
behaviour concerning infection with HIV, HBV and HCV.  
The fear that the syringes distributed will be used as weapons or lead to staff injuries 
when they are carrying out their routine duties (e. g. cell searches) has to be rejected. 
No such event has been reported in the literature on NSP in prison reviewed. On the 
contrary NSP can be seen as a prevention measure of the latter when the NSP includes 
the possibility to store the syringe safely and there is no reason to hide it because 
hiding of syringes is one of the reasons for needle stick injuries of prison staff 
(Larney/Dolan 2008). 
Since no increase of (injecting) drug use after the implementation of NSP has been 
found in the evaluations, the fear on fostering drug use via NSP has to be rejected, too. 
There is only one qualitative study which dates back to 1998 which found out, that 
some prisoners who had stopped using drugs, started drug use in prison again and 
others changed from other routes of administration to IDU. In the study it was sug-
gested that the presence of anonymous syringe dispensing machines might serve as 
temptation Gross (1998) cited from (Lines et al. 2005). For single cases, a change of 
the route of administration to IDU was also reported by (Stark et al. 2006). These 
concerns have been intensively discussed in scientific literature. On one hand, these 
phenomena have been observed in two studies for single cases only and there is no 
quantitative study reporting an increase of (injecting) drug use after the implementa-
tion of NSP in prison. On the other hand, relapse to drug use and change of other 
routes of administration to IDU happen in prison without NSP, too (Long et al. 2004; 
Stark et al. 2006) . 
The hypothetical argument that prison needle exchange would undermine abstinence-
based messages and programmes by condoning drug use can be objected. In most 
cases, NSP is part of a wider range of interventions and – like outside prison – NSP 
sometimes constitutes the first health-related contact with IDUs. After the introduction 
of NSP an increase of treatment referrals has been observed in some prisons. NSP in 
prison has successfully cohabited in prisons with other drug addiction prevention and 
treatment programmes (Stöver et al. 2008). 
Contradictory to the statement against full coverage of NSP in prison that the success-
ful implementation of prison needle exchange programmes in one prison does not 
mean that it will be possible to implement NSP in other prisons (since existing pro-
grammes are based on specific and unique institutional environments evidence) the 
fact is that in different countries, in different settings, NSP has been implemented 
successfully. The best possible example for offering NSP in prison is Spain, where NSP 
is implemented nationwide in 41 prisons with good coverage (for more details see 
annex 2). 
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10.4.3 Remarks from general guidelines 
There is a consensus in European policy that prisoners should have the same health 
support as the general population e. g. the Dublin declaration on HIV/AIDS in prisons 
in Europe and Central Asia (WHO 2007). Article 1 of the Dublin declaration on HIV/AIDS 
in prisons in Europe and Central Asia states: “Prisoners have a right to protect them-
selves against HIV infection. Prisoners living with HIV/AIDS have a right to protect 
themselves from re-infection and/or co-infection with hepatitis C and/or TB. There-
fore, States have a responsibility to: Ensure that HIV prevention measures available in 
the outside community are also available in prisons. This includes providing prisoners 
with free access to HIV prevention and harm-reduction measures including, but not 
limited to, sterile syringes and injecting paraphernalia […]. (Lines et al. 2004) 
The WHO guide to the essentials in prison health (WHO 2007) addresses (among 
others) communicable diseases, HIV infection, tuberculosis control, drug use and 
substitution treatment in prison. 
Measures to prevent the transmission of infectious diseases among drug users include: 
» Communicating face to face: counselling, personal assistance, assistance from and 
integration of outside AIDS-help agencies and safer-use training for drug users 
» Providing leaflets 
» Implementing vaccination programmes against hepatitis A and B and tuberculosis 
» Making condoms available 
» Making bleach or other decontaminants available 
» Making sterile injecting equipment available 
Prison drug policy should allow for: 
» Screening, counselling and treatment on a voluntary basis 
» Keeping a distance from the drug-using subculture, since drug users who are 
motivated to undergo a treatment programme have to be able to do so in an envi-
ronment that allows them to keep their distance from the drug scene in prison, a 
protected environment, which is difficult to reach for many prisons due to over-
crowding 
» Throughcare and aftercare, which are essential elements of efforts to reduce 
relapse and re-offence 
» Providing the diversity of measures that are offered outside prisons: social ser-
vices, drug-care units, drug counselling and treatment services (including harm 
reduction) 
» Discouraging drug import and traffic within the prison system 
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Recently, the UNODC policy brief “HIV prevention, treatment and care in prisons and 
other closed settings: a comprehensive package of interventions” (UNODC 2012) lists 
15 key interventions: 
» Information, education and communication 
» HIV testing and counselling 
» Treatment, care and support 
» Prevention, diagnosis and treatment of tuberculosis 
» Prevention of mother-to-child transmission of HIV 
» Condom programmes 
» Prevention and treatment of sexually transmitted infections 
» Prevention of sexual violence 
» Drug dependence treatment 
» Needle and syringe programmes 
» Vaccination, diagnosis and treatment of viral hepatitis 
» Post-exposure prophylaxis 
» Prevention of transmission through medical or dental services 
» Prevention of transmission through tattooing, piercing and other forms of skin 
penetration 
» Protecting staff from occupational hazards 
10.4.4 Conclusions 
There is evidence that harm reduction measures, which proved their effectiveness 
outside prison, are also effective inside prison. The broad range of benefits from 
opioid substitution treatment (OST) in prison (among others: reduction of needle-
sharing and injecting drug use) has been observed to be similar to the benefits outside 
prison. Concerning mortality, the situation is less clear due to the lack of adequate 
studies (Hedrich et al. 2012). The fact, that the first weeks after starting OST and the 
time directly following the termination of OST are phases of increased mortality has to 
be considered especially in the prison setting. Adequate possibilities to continue OST 
in prison and after prison release (throughcare) are essential. Almost all studies on 
needle exchange programmes (NSP) in prison show a dramatic decrease in needle 
sharing and no or very low seroconversion rates concerning HIV, HCV and HBV. 
Although the study designs are not the best (no control group) – which may lie in the 
nature of the topic (ethical or ideological constraints to serve as a comparison prison 
with no NSP) – the firm conclusion can be drawn that NSP in prison is an effective 
method to reduce risk behaviour concerning infections with HIV, HBV and HCV. 
Although, the number of countries that have implemented needle and syringe ex-
change in prison is limited, these programmes have been established successfully in 
different settings and diverse environments. The concern regarding possible negative 
consequences of NSP in prison has been proven to be unfounded (see annex 2). 
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11 Epidemiological situation concerning 
drug-related harm in the EU and 
candidate/acceding countries 
This chapter provides an overview of the epidemiological situation in relation to drug-
related harm in the EU. Most of the analysis is based on EMCDDA standard tables and 
publications in the Statistical Bulletin. Data on the prevalence of drug use and routes of 
administration as well as drug-related harm such as drug-related infectious diseases 
(DRID) and drug-induced deaths are presented. Due to the efforts of EMCDDA to 
standardise the data collection process and to improve data collection, a lot of good 
quality data partly in long time series are available. But work is still under progress and 
especially comparisons between countries should always be made with care. Therefore 
data quality issues are also addressed in the following analysis.  
11.1 Problem drug use (PDU)  
Problem drug use is defined by the EMCDDA as “injecting drug use or long duration or 
regular use of opioids, cocaine or amphetamines”. Problem drug users are mostly 
polydrug users, and prevalence figures are much higher in urban areas and among 
marginalised groups. Given the relatively low prevalence and the hidden nature of 
problem drug use, statistical extrapolations are required to obtain prevalence esti-
mates from the available data sources - mainly drug treatment data and law enforce-
ment data (EMCDDA 2012a). Currently, EMCDDA is working on ways to adapt the 
indicator to new challenges in problem drug use like monitoring: higher share of 
problem stimulant use, new, previously unseen groups of problem users and intensive, 
long-term and dependent use of other drugs, e. g. cannabis6. Recently, the scope has 
been broadened to "high risk drug use", which includes former problem drug use, but 
includes high risk and frequent cannabis use, high risk use of new drugs in addition 
and is open to other substances which may emerge in the future). 
                                                                                                                                         
6 
Currently, EMCDDA is working on ways to adapt the indicator to new challenges in problem drug use monitor-
ing: higher share of problem stimulant use, new, previously unseen groups of problem users and intensive, 
long-term and dependent use of other drugs, e.g. cannabis. 
http://www.emcdda.europa.eu/themes/key-indicators/pdu (3.1.2013) 
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11.1.1 Regional differences in PDU and substance use 
Injecting drug use and the use of opioids form the greater part of problem drug use in 
Europe although, in a few countries, users of amphetamines or cocaine form an 
important part (EMCDDA 2012a). 
Figure 11.1: 
Primary drugs opioids, stimulants and cocaine in the EU and candidate countries 
(clients starting outpatient treatment 2010 or most recent year) 
Remark: For this overview, only treatment demands for the primary drugs mentioned in the definition of PDU 
(opioids, stimulants and cocaine) are used (clients starting treatment due to opioids, stimulants or cocaine = 
100 %). Predominant means that the respective drug is mentioned most frequently. 
Source: EMCDDA Statistical Bulletin 2012, Table TDI-19 part II – GÖ FP own calculations;  
graphic representation: GÖ FP 
One possibility to give a comprehensive overview about regional differences is to look 
at the primary drug of treatment demands. For this overview, only treatment demands 
for the primary drugs mentioned in the definition of PDU (opioids, stimulants and 
cocaine) are used (clients starting treatment due to opioids, stimulants or cocaine = 
100 %). Figure 11.1 shows that in all but four countries (where this information is 
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available) opioids predominate. The exceptions are Spain and the Netherlands where 
cocaine predominates and the Czech Republic and Hungary where stimulants pre-
dominate. In Poland, Slovakia and Sweden opioids play a dominant role but stimulants 
are also of relevance. In Italy beside opioids cocaine is also relevant. In Belgium opioids 
dominate but also cocaine and stimulants are relevant. It has to be taken into account 
that this description is based on treatment data only and different access to treatment 
for different drugs might have an influence on the picture presented. Another factor is, 
that in many countries (a part of) opioid substitution treatment (OST) is not included in 
outpatient treatment data which might lead to the underestimation of the relevance of 
opioids in PDU.  
Apart from treatment data, in the frame-work of the key indicator prevalence of 
problem drug use indirect estimation methods give an impression about the overall 
situation of problem drug use. Unfortunately good quality estimates are not available 
for all countries (long term time series of). 
The EMCDDA estimates that there were about 1,4 million of problem opioid users in 
the EU and Norway in 2010. The overall situation concerning prevalence of problem 
opioid use seems to be stable between 2004 and 2010. Besides heroin in some 
countries other opioids like fentanyl or buprenorphine are relevant (EMCDDA 2012d). It 
has to be noted that problem opioid use happens in most cases in the framework of 
polydrug use which means that together with opioids other illegal substances (e. g. 
cocaine, cannabis) or legal substances (e. g. alcohol) are consumed in a problematic 
way. Cocaine plays an important role in problem drug use in the Netherlands, Italy, 
Spain and in the UK. Together these four countries account for around 85 % of all 
reported cocaine clients entering treatment. Trend data on estimates of problem 
cocaine use are available only for Italy, and show a gradual increase between 2005 and 
2010. Crack cocaine use has been a cause of concern in Europe for some years. 
Despite worrying reports usually based on local studies, analysis of EU-wide treatment 
entry data indicates that the crack problem remains limited to the United Kingdom and 
to a lesser extent the Netherlands. Amphetamines play an important role in Poland, 
Finland and Sweden, and methamphetamines in the Czech Republic and Slovakia 
(EMCDDA 2012d). 
11.1.2 Route of administration 
Data on route of administration of opioids are collected by EMCDDA in the framework 
of the Treatment Demand Indicator (TDI) and partly through the Problem Drug Use 
Indicator (PDU).  
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Table 11.1: 
Route of administration of clients entering treatment by primary drug, 2010 or most 
recent year available – All opioid outpatient clients by country and usual route of 
administration (%) 
  
Route of administration of opioids 
Country 
 
Inject Smoke/inhale Eat/drink11 Sniff Others 
Austria   34,7 6,5 17,9 40,8 0,0 
Belgium 1 20,6 63,7 12,8 2,7 0,2 
Bulgaria   81,8 4,6 0,9 7,4 5,2 
Cyprus   64,1 29,9 3,2 2,8 0,0 
Czech Republic   79,3 7,4 8,9 4,2 0,1 
Denmark   15,6 19,5 58,8 6,1 0,0 
Estonia 2 86,5 11,4 1,3 0,8 0,0 
Finland   74,7 0,5 16,7 8,1 0,0 
France   22,8 14,1 9,3 52,9 0,9 
Germany   35,8 17,0 39,7 6,6 1,0 
Greece   38,0 10,5 0,9 50,5 0,0 
Hungary   69,3 15,2 11,7 3,9 0,0 
Ireland   32,0 60,9 7,0 0,1 0,0 
Italy 3 53,3 35,3 1,9 8,7 0,8 
Latvia 4 93,5 0,3 5,5 0,7 0,0 
Lithuania   : : : : : 
Luxembourg   68,4 30,5 0,0 0,0 1,1 
Malta 5 61,2 30,9 0,4 5,8 1,7 
Netherlands 6 7,0 77,3 13,4 2,4 0,0 
Poland 7 66,2 29,2 4,2 0,4 0,0 
Portugal 8 14,5 84,1 0,9 0,4 0,1 
Romania   91,4 6,9 1,0 0,8 0,0 
Slovakia   78,0 12,4 3,5 6,0 0,0 
Slovenia   51,9 35,0 2,5 10,6 0,0 
Spain 9 16,4 71,1 5,1 6,0 1,4 
Sweden   58,5 11,3 27,6 2,3 0,3 
UK 10 33,5 54,9 10,0 0,9 0,7 
Croatia   73,4 5,2 1,5 19,9 0,0 
Notes:  
1 - In Belgium if the exact primary drug is not known, the generic category is recorded. In 2010 there were 198 
opiates, 7 cocaine, 7 stimulants, 2 hypnotics and sedatives and 1 hallucinogens clients with the exact primary  
drug unknown. Of which 24 and 5 were new clients for respectively opiates and stimulants. 2 - Data are from 
outpatient, inpatient treatment centres and prisons (aggregated data). 3 - In 2010 around 29 % of all clients 
and 30 % of new clients were registered as not known / missing for the primary drug category. Caution should 
be made when comparing data over time. 4 - In 2010 Latvia submitted a new dataset with a more precise TDI 
EMCDDA definition. Caution should be made when comparing data with previous years. 5 - Data refer to 
outpatient and inpatient treatment centres, low-threshold services and prisons (aggregated data). 6 - Data are 
from outpatient, inpatient treatment centres and low-threshold services (aggregated data). 7 - Data are from 
2009. Double counting is not eliminated in data from outpatient centres. Caution should be made when 
interpreting the data. Heroin includes both heroin and so called "kompot" (heroin gained from the poppy 
straws). 8 - In 2010 came into implementation a new national information system implying methodological 
changes particularly in the registration criteria. 9 - Data are from 2009. Data are from outpatient treatment 
centres and some treatment units in prison (aggregated data). 10 - Data are from 1st of April 2009 to 31st of 
March 2010. 11 – data on eat/drink as route of administration has to be interpreted very cautiously because 
sometimes clients name substances prescribed for substitution treatment as their primary drug (e g. if a client, 
being 10 years in stable substitution treatment with no use of any other opioids in this time-span, starts a new 
outpatient treatment episode). 
Source: EMCDDA Statistical Bulletin 2012 – TDI-17/2  
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The data from TDI refer to the period before starting treatment (30 days before the 
beginning of treatment) and concern two types of patterns of drug use: the route of 
administration of the primary drug and the current/ever injection behaviour for any 
drug. This may result in quite different pictures and provide additional information on 
risk behaviours. Methodological limitations may originate from data validity problems 
in the phase of recording the client´s information and the lack of information on past 
drug use behaviours (TDI reports if a person has been an injector but the type of drug 
remains unknown). The new TDI-protocol 3.0 is tackling with these problems. 
A look at the data leads to the following conclusions:  
» The three main routes of illegal administration of opioids in Europe are injection, 
smoking/inhaling (“chasing the dragon”) and sniffing/snorting. 
» There are significant differences in the proportion of injecting, smoking and 
sniffing of opioids. 
Due to the lack of data it is hard to present injecting trends but there are some 
indications of a decrease of injecting; at least for opioid injecting (EMCDDA 2012d). 
Looking at 2010 data just 36 percent of clients entering treatment due to opioids, 
state that their route of administration was injecting (EMCDDA 2012c). But there are 
also countries with an increasing trend of injecting (e. g. Czech Republic). 
11.2 Infectious diseases 
Infectious diseases are among the main negative health consequences associated with 
drug abuse in particular among injecting drug users. The EMCDDA monitors the main 
infectious diseases associated with drug use; in particular HIV, hepatitis B and hepatitis 
C infections among injecting drug users.  
11.2.1 HIV 
The rate of new HIV infections among injecting drug users is rather low in the Euro-
pean Union compared to the US and other European countries. The average rate of 
newly diagnosed cases with HIV among injecting drug users in 2010 was 2,54 per 
million (1.192 cases) (EMCDDA 2012a). Comparisons between countries are difficult 
due to differences in study methodology and coverage. Newly diagnosed HIV infections 
among injecting drug users vary significantly between the countries. Very high rates 
are reported in the Baltic States (Estonia, Latvia and Lithuania) with up to 46,3 cases 
per million population and very low rates of less than one new infection per million 
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population in Austria, Czech Republic, Cyprus, Hungary, Malta, Netherlands, Poland, 
Slovakia, Slovenia and Croatia (ECDC 2012). 
Figure 11.2: 
Significant changes of HIV infections via IDU 2003-2010 in the EU 
 
Source: Table 13.1; graphic representation: GÖ FP 
Twelve countries report a significant decrease in the number of newly diagnosed HIV 
infection among injecting drug users from 2003/2004 to 2009/2010. Only four 
countries (Bulgaria, Greece, Lithuania and Romania) report a significant increase in the 
number of newly diagnosed HIV. For Greece and Romania 2011 data were included 
because in both countries in 2011 there were local outbreaks of HIV transmission 
(ECDC 2010) -see section 11.4.1.  
Looking at Figure 11.2 it can be concluded that in most EU-countries a significant 
reduction of HIV infection via IDU has been reached. Although it is difficult to prove a 
direct link to harm reduction on this global level it can be assumed that this reduction 
has occurred partly due to the introduction and expansion of harm reduction meas-
ures. This conclusion is supported by an analysis of trends in newly diagnosed HIV 
cases among IDUs in the WHO European region which showed big differences in trends  
- increasing trends in eastern countries outside EU with low coverage of (harm reduc-
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tion) interventions versus decreasing trends in the EU-region with a higher coverage of 
interventions (EMCDDA 2012d). More details concerning trends see section 13. 
11.2.2 Hepatitis C and B 
Hepatitis C (HCV) infection is highly prevalent among IDUs in most EU countries (see 
Figure 11.3). Since high prevalence is found among young and new injectors (ECDC 
and EMCDDA 2011c) it can be assumed that the transmission rate is very high. Con-
cerning trends due to lack of data an overall picture is not available. Between 2005 and 
2010 declining HCV prevalence in injecting drug users at national or regional level 
have been observed in six countries while five others observed an increase (Austria, 
Bulgaria, Cyprus, Greece and Romania). Italy reported a decline at national level 
between 2005 and 2009 with increases in three of 21 regions (EMCDDA 2012a). It is 
important to note that it seems that there are huge regional differences in infection 
rates between countries as well as inside countries. 
Figure 11.3: 
Prevalence of HCV antibodies among injecting drug users 
Remarks: Data for the years 2009 and 2010. Black squares are samples with national coverage; blue triangles 
are samples with sub-national (local or regional) coverage. Differences between countries have to be 
interpreted with caution owing to differences in types of settings and study methods; national sampling 
strategies vary. Countries are presented in order of increasing prevalence, based on the average of national data 
or, if not available, of sub-national data.  
Source: EMCDDA Annual Report 2012, page 82 
For hepatitis B the situation concerning availability of data is worse than for HCV. But 
data from some countries showing that 6 % of all HBV cases and 12 % of the notified 
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acute cases are due to IDU (EMCDDA 2012a) lead to the conclusion that IDU still are a 
high risk group for HBV infection. Given the high HCV prevalence this fact is very 
alarming because there is increased risk of health damage when a person infected with 
HCV gets co-infected with HBV on one hand and on the other hand HBV infections 
could be avoided via HBV vaccination (see 10.2.6). 
11.3 Drug-induced deaths 
One of the key epidemiological indicators developed by the EMCDDA to monitor the 
situation is ‘drug-related death (DRD) and mortality among drug users’. The first 
component of the indicator focuses on drug-induced deaths called as well ‘overdoses’ 
or ‘poisonings’. The term ‘drug-induced death’ has been introduced in a general form 
in the EMCDDA 2008 Annual report. It is more specific of deaths included in the 
EMCDDA definition than the broader term ‘drug related deaths’. The second compo-
nent focuses on mortality - of all causes – among drug users, studied through mortal-
ity cohort studies (EMCDDA 2012a; EMCDDA 2012g). The EMCDDA case definition of 
drug-induced deaths includes the ‘deaths happening shortly after consumption of one 
or more illicit psychoactive drugs, and directly related to this consumption’ although 
they often may happen in combination with other substances such as alcohol or 
psychoactive medicines. The EMCDDA Standard protocol transforms this conceptual 
definition in practical codes and criteria to extract and report cases in a similar way 
across countries and over time, producing the closest possible set of cases to the 
conceptual definition (EMCDDA 2009). 
In 2010 the average EU mortality rate of drug-induced deaths was estimated to be 
about 20 deaths per million population aged 15-64 years. Around 7.000 drug-induced 
deaths occurred in the EU Member States and Norway in 20107. This indicates a slight 
decrease when compared to 2009. There are differences between countries and the 
estimates are conservative and the numbers are likely to be higher, as some national-
data are affected by under-reporting (EMCDDA 2012a). Estonia reports more than 110 
drug-induced deaths per million population aged 15-64 years followed by Ireland and 
Denmark.  
Drug-induced deaths in the EU are mainly caused by opioids (in particular heroin). 
11 % of the overdoses in Europe are reported among people aged under 25 years, 32 % 
25 to 35 years and 57 % aged 35 and older (EMCDDA 2012c). By far most of the drug-
                                                                                                                                         
7 
In the EMCDDA Annual Report on the state of the drugs problem in Europe 2012 Norway is included. 
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induced deaths are male (80 %), and the majority are related to the use of several 
drugs, the most common background of which is opioids (EMCDDA 2012c).  
Figure 11.4 presents the index of the number of drug-induced deaths starting from 
1995/1996. Country comparisons in Europe should be made with caution, although 
most countries provide now robust and comparable data, following the EMCDDA 
protocol. Nonetheless there are still some differences between countries in the capac-
ity to ascertain the drug-induced death cases (e.g. the coverage of autopsies and of 
toxicological examinations of ‘suspect’ deaths may vary). Furthermore, in some 
countries the capacity to ascertain the cases has changed over time i.e. the proportion 
and numbers of ‘suspect’ deaths who undergo these examinations have changed. The 
other reason for being cautious when comparing countries, are some remaining 
differences in coding, recording and extracting the drug-induced deaths cases. In 
addition, some countries are not able to cross check and therefore to validate the 
results derived from their general mortality register, with the results derived from 
alternative sources (i.e. special mortality registries like police or forensic sources). 
Finally some countries report that their reported numbers of cases might be an 
underestimate. 
Most national reporting systems have been stable over time, which allows, in the 
majority of countries, an analysis of the trends over time. Nonetheless, caution is 
needed here as well, as some countries have changed over time e.g. some upgraded 
their monitoring capacity of drug-induced deaths. Some have improved the collabora-
tion between the different national sources of information, and thus have improved the 
completeness of their reporting. Finally, many countries have ‘gap’ years, with no data 
reported, for some years. This is the case for about a third of the countries, for which 
at least one year data is missing. Bearing in mind these limitations, in some cases, of 
the reported data, it can be noted that the number of reported drug-induced deaths 
slightly increased in the 2004–09 period from around 6.450 in 2004 to around 7.000 
in 2009/2010 (EMCDDA 2012c; EMCDDA 2012d). Figure 11.4 shows that the increas-
ing trend in reported cases was mainly in the EU 128. This part of Europe has still a 
relatively small contribution in numbers though compared to the EU 159 (around one in 
ten drug-induced deaths reported in all EU Member States plus Norway is accounted 
for by the EU 12. Nevertheless is has to be states that also in the EU 15 a significant 
reduction of reported drug-induced deaths was not observed. 
                                                                                                                                         
8 
EU 12=Countries which joined the EU in 2004 or later 
9 
EU 15=Countries which joined the EU before 2004 
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Figure 11.4:  
Indexed number of drug-induced deaths in EU Member States and Norway according 
to national definitions 
 Source: EMCDDA Statistical Bulletin 2012, Table DRD-02 part V – GÖ FP own calculations;  
graphic representation: GÖ FP 
Due to the limitations stated above the trend of drug-induced deaths are analysed 
instead of rates10. Only Spain, Italy and Denmark experienced a significant decrease of 
drug-induced deaths from 2003/2004 to 2009/2010. 13 of the Member States and 
candidates countries didn’t experience significant changes; eleven countries reported a 
significant increase in the number of drug-induced death. This may partly be due to 
the rather low starting points 2003/2004 in some countries (see Figure 11.5). 
                                                                                                                                         
10 
Due to national differences it is recommended to refer to the Member States before drawing conclusions on 
reliable national trends. 
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Figure 11.5: 
Significant changes of mortality rated due to direct drug-induced deaths 2003/2004-
2009/2010 in the EU11  
 
Source: Table 13.1; graphic representation: GÖ FP 
11.4 New challenges 
11.4.1 Recent HIV-outbreaks 
In Greece the numbers of newly diagnosed drug injectors infected with HIV increased 
from 9–16 per year until 2010 (2005-2010) to 256 cases in 2011 and 314 cases in 
2012 - January till August (ECDC 2012; EMCDDA 2012e). The percentage of IDU as 
                                                                                                                                         
11  
Due to national differences it is recommended to refer to the Member States before drawing conclusions on 
reliable national trends. 
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route of infection increased from 2 to 3 % in 2010 up to 41 % in 2012. As possible 
hypothesis for the reasons behind this outbreak increasing risk behaviour among IDUs 
in Athens (changing from sniffing to injecting heroin) and low coverage of prevention 
services and low uptake of antiretroviral therapy are discussed (EMCDDA 2012e). 
In Romania the numbers of newly diagnosed drug injectors infected with HIV increased 
from 0–14 per year until 2010 (2005-2010) to 129 cases in 2011 and 102 cases in 
2012 (January till June). The percentage of IDU as way of infection increased from two 
to three percent to approximately on third in 2012 (ECDC 2012; EMCDDA 2012f). As 
possible hypothesis for the reasons behind this outbreak, increasing changes in drug 
use patterns (legal highs – new stimulants which lead to increased injection frequency) 
and low harm reduction service provision (EMCDDA 2012f) are discussed. 
Since HCV infection rates have been stated to be an indirect indicator for risky injection 
behaviour and 30 % of HCV infection rate seems to be the threshold for an increasing 
risk of HIV-outbreaks (Vickerman et al. 2010) a lot of European countries are in danger 
of similar outbreaks. 
11.4.2 New substances 
Within Europe, and globally, new drugs and new patterns of drug use are attracting 
increasing political, media and public attention (EMCDDA 2012a). Between 2005 and 
2011, 164 new psychoactive substances were formally notified through the early 
warning system of the EMCDDA. In 2012 it was over 60 substances. Most of these 
substances are sold in smart or head shops or via internet as “legal highs”. The term 
“legal highs” covers a wide range of synthetic and plant-derived substances that aim to 
imitate the effect of controlled substances like ecstasy, cocaine or cannabis. The term 
“legal highs” might be misleading as some substances are controlled by drugs legisla-
tion, medicines or food or consumer safety laws or by new, special laws for those new 
psychoactive substances. 
Prevalence data on new psychoactive substances are scarce and often suffer methodo-
logical limitations, including lack of common definitions, and use of self-selected or 
non-representative samples (EMCDDA 2012a). In the course of the EUROBAROMETER 
more than 12.000 young persons (15–24) were interviewed, about 5 % of young 
Europeans reported that they had used “legal highs” at least once. The highest esti-
mates were reported by Ireland (16 %) followed by Latvia, Poland and the United 
Kingdom  - all at nearly 10 % (The Gallup Organization 2011).  
Across Europe, measures are beginning to be developed to reduce both the demand 
for, and the supply of, new psychoactive substances. Individual Member States have 
taken initiatives to improve and accelerate their legal responses to new psychoactive 
substances, products and the establishments selling them (EMCDDA 2012a). 
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While in most of the countries the “legal highs” phenomenon is regarded a matter of 
recreational use and thus is actively addressed by prevention programmes for recrea-
tional drug users and also Drug Checking projects (see also chapter 10.3.7), in some 
countries or regions substances like mephedrone are also injected by people who used 
to inject other substances like opiates (e. g. Hungary, Romania – see stakeholder 
survey, annex 3). This shift, which might be an effect of heroin shortage in the respec-
tive regions, seems to contribute to the HIV-outbreak in Romania (see also 11.4.1). 
Whether these new patterns of use will lead to a permanent change of the drug 
situation and therefore become relevant for harm reduction remains unclear at the 
moment. 
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12 Situation concerning supply of harm 
reduction in the EU and  
candidate/acceding countries 
Harm reduction programmes for persons who inject drugs (IDUs) emerged during the 
1980s in Europe in response to the HIV epidemics. The first step was needle and 
syringe exchange programmes (NSP) and opioid substitution treatment (OST) which 
spread rapidly across Europe and gained broad acceptance to finally become an 
integral component of the EU´s drug strategy (EUROHRN 2012). Other harm reduction 
measures, like peer naloxone programmes or drug consumption rooms, are still under 
discussion or still only implemented in some European countries. Although there is a 
consensus in European policy that prisoners should have the same health support as 
the general population  - e. g. Dublin declaration on HIV/AIDS in prisons in Europe and 
Central Asia, (WHO 2007) - the situation concerning harm reduction measures in 
prison is worse than outside prison.  
That is why the sections on needle exchange (see 12.3) and opioid substitution 
treatment (see 12.4) are more detailed due to the central importance of these meas-
ures. In section 12.12 a special focus is given to harm reduction in prison. 
12.1 Methodical issues 
The following analysis covers all 27 EU Member States as well as the acceding country 
Croatia and the candidate countries the former Yugoslav Republic of Macedonia, 
Iceland, Montenegro and Turkey. Where relevant, a distinction between the EU 15 and 
the EU 12 is made. This distinction is made on one hand because the drug issue was a 
special focus of EU-funded projects in the EU 12 states (PHARE, CARDS, IPA) in the 
negotiation process to become a member, which might have strengthened the influ-
ence of EU-drug´s policy. On the other hand most of the EU 12 states (especially those 
behind the former iron curtain) faced the drug problem later (but then rapidly increas-
ing) than the EU 15 states and therefore the coverage of harm reduction measures had 
to be improved quickly. 
The following section is based on data from the previous report (Trimbos 2006), the 
policy maker survey (see section 9.3), the stakeholder survey (see section 9.4), the 
country profiles and data available at the EMCDDA (see section 9.1), from the gap-
survey (see section 9.2) and scientific literature. To properly understand the following 
graphs on data from the stakeholder survey, it has to be noted that the description of 
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the results is possible in percentages only, due to the weighting procedure (details see 
annex 3). 
The coverage of measures was asked on a Likert scale (full coverage, extensive cover-
age, limited coverage, rare coverage, not available and do not know). The change of 
coverage was measured with the following categories: strong increase, increase, no 
change, decrease, strong decrease and do not know.  
The main limitation of the data from the policy maker survey and the stakeholder 
survey is that they are based on subjective estimations of coverage and changes from 
one person or institution. Therefore, wherever possible, the assessment of the policy 
makers and the assessment of the stakeholders are supplemented with data from 
other sources. 
Figure 12.1: 
Coverage, estimated by stakeholders and policy makers 
 
HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, OST=opioid substitution 
treatment, STD=sexually transmitted diseases, TBC=tuberculosis 
Remark: data refer to Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovakia, 
Slovenia, Spain, United Kingdom; The full wording of all CRs can be found in section 15. 
Coverage: 1=not available, 2=rare, 3=limited, 4=extensive, 5=full coverage 
Source: GÖ FP, stakeholder survey, policy maker survey; graphic representation: GÖ FP 
Generally speaking the policy makers tend to report higher coverage and availability of 
harm reduction measures than the stakeholders. However, the same pattern can be 
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seen among both groups, but on different levels (see Figure 12.1). Major differences 
can be observed for harm reduction in prison. The coverage of harm reduction in 
prison is stated to be “rare” by stakeholders whereas policy maker perceive it as 
“limited”. 
To interpret the results, it has to be taken into account that data from the policy maker 
survey refer to 31 of the 32 countries (Slovakia is missing)12 and that data from the 
stakeholders are available for 24 countries only (Austria, Belgium, Bulgaria, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Latvia Luxembourg, Malta, Netherlands, Portugal, Romania, Slovakia, Slovenia, Spain, 
United Kingdom, Croatia). In the graphs below, missing data are only mentioned when 
data are missing from the 31 countries covered by the policy survey respectively from 
the 24 countries covered by the stakeholder consultation. Six countries out of the 24 
covered by the stakeholder questionnaires provide data at regional level only. 
12.2 Harm reduction as a public health objective (CR 1) 
The EU drug strategy aims at making “a contribution to the attainment of a high level 
of health protection, well-being and social cohesion by complementing the Member 
States´ action in preventing and reducing drug use, dependence and drug-related 
harm to health and society” and at “ensuring a high level of security for the general 
public” (Council of the European Union 2004, 5). For over a decade harm reduction has 
been an integral part of the EU drug action plans, giving priority to preventing trans-
mission of infectious diseases and reducing drug-induced deaths among IDUs 
(Rhodes/Hedrich 2010). The Lisbon Treaty article 168 on high level protection of 
human health strengthens the harm reduction approach, as well as the Communication 
from the Commission to the European Parliament, the Council, the European Economic 
and Social Committee and the Committee of the Regions of 26 October 2009 - Com-
bating HIV/AIDS in the European Union and neighbouring countries, 2009-2013. 
Several European networks or projects have been supporting the implementation of 
harm reduction, like Correlation network13 (development on several guidance docu-
                                                                                                                                         
12 
Slovakia did not complete the policy maker survey, for information on existence of policies the previous report 
is used. 
13 
www.correlation-net.org 
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ments on harm reduction) Connections network14 (assessed and build capacities for 
harm reduction in prisons), WHO-project “Scaling up access to high-quality harm 
reduction, treatment and care for injecting drug users in the WHO European Region”15, 
Psychonaut16 and REDNET17 (established a monitoring system for new substances) and 
NEWIP18 (guidance documents for safer nightlife and Drug Checking). 
One general problem concerning funding is that in some EU 12 states harm reduction 
projects were initially financed by the Fund to Fight AIDS, Tuberculosis, and Malaria. 
There are now problems to ensure national funding. This problem was expressed by 
policy makers and stakeholders. 
All EU Member States, Croatia, Montenegro and the former Yugoslav Republic of 
Macedonia have adopted (public health) policy objectives that aim to prevent and 
reduce health-related harm associated with drug dependence. In Turkey and Iceland, 
policies regarding some key elements of harm reduction do not exist yet. In Turkey no 
policy for the provision of appropriate access to injection materials exists. Furthermore 
the provision of drug-free treatment as well as appropriate opioid substitution treat-
ment (OST) in accordance with the individual needs of the drug abuser is not provided. 
For the latter, a respective policy is waiting for approval; OST has been available in 
Turkey since 2010. In Iceland, an official policy for the provision of appropriate access 
to injection material does not exist either, but in practice, these services are available 
to some extent.  
                                                                                                                                         
14 
www.connections.accessproject.eu 
15 
www.euro.who.int/en/what-we-do/health-topics/communicable-diseases/hivaids/activities/ec-who-project-
scaling-up-access-to-high-quality-harm-reduction 
16 
www.psychonautproject.eu 
17 
www.rednetproject.eu 
18 
www.safernightlife.org 
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Figure 12.2: 
Estimations of the impact of the CR on the relevance of the prevention of health-
related harm associated with drug dependence as a public objective in the respective 
countries  
 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Regarding the influence of the Council Recommendation 1 (CR 1) on these policies, 
more than half of the investigated countries confirm at least a medium impact. The 
rate of the impact of the CR is higher in the EU 12 than in the EU 15 (see Figure 12.2). 
12.3 Needle and injection equipment exchange (NSP) 
CR 2.10 focuses on needle exchange: “provide where appropriate access to distribution 
of condoms and injection materials, and also to programmes and points for their 
exchange.” This policy exists in all EU Member States and candidate countries with the 
exception of Turkey and Iceland. In ten countries this policy is based on the CR (see 
Figure 12.3).  
NSPs were introduced in the EU-countries in the late 1980ies or in the 1990ies of the 
last century. In most countries, specialised agency sites play a dominant role in this 
field of harm reduction. Vending machines are available in a few countries only (see 
Table 12.1). 
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Figure 12.3: 
Existence of policy CR 2.10 “provide where appropriate access to distribution of 
condoms and injection materials, and also to programmes and points for their 
exchange” 
 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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Table 12.1: 
Year of introduction of needle and syringe programmes (NSPs), types of programmes 
available in 2010 and number of sites 
Country Year first NSP 
No. of specialist 
agency sites with NSP 
No. of 
vending 
machines 
No. of 
Pharmacy-based 
NSP sites 
No. of prison-
based NSP 
sites 
Austria 1990 15 15 nd 0 
Belgium (Flem Com.) 2001 20 0 25 0 
Belgium (French 
Com.) 
1994 16 0 nd 0 
Bulgaria 1995 98 0 0 0 
Cyprus 2007 1 0 0 0 
Czech Republic 1986 55 1 0 0 
Germany 1984 185 165 nd 1 
Denmark 1986 nd nd nd 0 
Estonia 1997 13 0 0 0 
Greece 1998 4 0 0 0 
Spain 1985 1222 nd 912 70 
Finland 1997 40 0 0 0 
France 1989 116 276 29 0 
Hungary 1994 21 5 0 0 
Ireland 1989 28 0 0 0 
Italy 1990 nd nd nd 0 
Lithuania 1997 11 0 0 0 
Luxembourg 1993 4 4 0 1 
Latvia 1997 18 0 0 0 
Malta 1987 7 0 0 0 
Netherlands 1984 150 nd 25 0 
Poland 1989 24 0 0 0 
Portugal 1993 14 0 1336 2 
Romania 2000 4 0 0 3 
Sweden 1986 2 0 0 0 
Slovenia 1992 9 0 5 0 
Slovakia 1994 5 0 0 0 
UK- England 1986 nd 1 nd 0 
UK - Wales nd 30 1 192 0 
UK-Northern Ireland 2001 1 0 14 0 
UK-Scotland 1987 55 nd 200 0 
The former Yugoslav 
Republic of 
Macedonia 
nd nd nd nd nd 
Croatia nd 6 0 nd 0 
Iceland nd nd nd nd nd 
Montenegro nd nd nd nd nd 
Turkey na 0 0 0 0 
Remark: nd=no data 
Source: EMCDDA Statistical Bulletin 2012, Table HSR-4 
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12.3.1 Coverage and availability of needle and 
equipment exchange 
Figure 12.4 shows a more differentiated picture concerning the regional availability of 
NSP by breaking down the availability of at least one NSP to NUTS-2 regions.  
Figure 12.4: 
Needle and syringe programmes, geographical coverage at regional level 
 
Remark: The acronym NUTS stands for nomenclature of territorial units for statistics, following the European 
classification of territorial units for statistics defined in the Regulation (EC) No 1059/2003 of 26 May 2003. The 
current NUTS classification lists 97 regions at NUTS 1, 271 regions at NUTS 2 and 1.303 regions at NUTS 3 
level. The geographical units displayed on this graph represent NUTS level 2 regions, corresponding to larger 
administrative units or regions in the countries ('comunidades', 'oblasti‘, ‘Bundesländer’, etc). Six small Member 
States have no NUTS level 2 units but only the smaller level 3-regions (Cyprus, Estonia, Latvia, Lithuania, 
Luxembourg and Malta). 
 Source: EMCDDA trend report for the evaluation of the 2005-12 EU drugs strategy 
It has to be noted that Romania and Greece, where recent HIV-outbreaks have been 
observed, are among the countries with the highest numbers of NUTS-2 regions 
without NSP. 
Coverage in the sense of syringes distributed per IDU differs between the countries. 
Figure 12.5 shows that the numbers of needles distributed through specialised pro-
grammes in 2010, per estimated IDU, range from nearly zero to over 200. The WHO, 
       region with NSP 
       region without NSP 
       no information
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UNODC, UNAIDS criteria (WHO 2009) of 200 syringes per IDU per year for good 
coverage concerning HIV prevention is not reached by every country where respective 
data are available. This is a major obstacle, taking into account that the levels required 
for the prevention of HCV are likely to be much higher. But it has to be further taken 
into account, that EMCDDA data include needle exchange from specialised NSP only 
and it can be assumed that some IDUs also get syringes from pharmacies. Only few 
data are available about the extent of pharmacy based needle acquirement.  
Figure 12.5: 
Syringes distributed through specialised programmes in 2010 per estimated injecting 
drug user 
Remark: Syringes provided through fixed and mobile NSP points in the community and in prisons: at specialist 
drugs agencies, including through outreach work and peer-distribution, through vending machines and 
pharmacy-based NSP points 
Source: EMCDDA Statistical Bulletin 2012, Figure HSR-3 
This impression of different coverage rates in the countries converges to the estima-
tion of coverage of needle exchange from policy makers (see Figure 12.6). In addition 
the coverage in the EU 15 is estimated a bit higher than in the EU 12 and candidate 
countries see Figure 12.7. 
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Figure 12.6: 
Estimation of the coverage of distribution of injection materials for IDUs by EU 
membership status from policy makers 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Figure 12.7: 
Estimation of the coverage of needle and syringe exchange for IDUs by EU membership 
status from stakeholders (civil society organisations) 
Remark: data refer to all 24 countries from the stakeholder survey 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
Estimations of the stakeholders’ needle and syringe exchange coverage are available 
for Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, Netherlands, Portugal, 
Romania, Slovakia, Slovenia, Spain, United Kingdom. The estimates show different 
coverage rates, too. 
Example: In Portugal several programmes provide support to drug users with the 
objective to reduce the risk of infections and to minimise harm of drug use. This 
support ranges from the exchange of syringes and the distribution of aseptic material 
to therapeutic support and guidance to health and treatment units (e.g. Reunion and 
Solutions Outreach II, EDDRA) 
Example: Since 2011 Ireland provides a pharmacy needle exchange programme with 
corresponding training for pharmacy staff (country profile Ireland – see annex 1). 
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12.3.2 Change of coverage and availability of needle 
and equipment exchange 
According to the policy makers the availability/coverage increased since 2003 in most 
countries (see Figure 12.8). 
Figure 12.8: 
Estimation of the change of availability/coverage of injection materials for IDUs by EU 
membership status from policy makers 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Figure 12.9: 
Change of the numbers of syringes distributed by specialised NSP facilities 
 
Source: Table 13.1; graphic representation: GÖ FP 
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For countries where sufficient data are available to judge the increase or decrease of 
syringes exchanged in the time span 2003 to 2010 a significant increase can be 
observed in two thirds of these countries while in other countries the numbers are 
decreasing (see Figure 12.9 and Table 13.1).  
12.3.3 Influence of the CR on the change of coverage 
and availability of needle and equipment 
exchange 
The estimated influence of the CR on the development of the distribution of injection 
materials is different in the EU 12 and in the EU 15. While policy makers of half of the 
EU 15 states estimate that there was little or no impact of the CR on the coverage of 
the distribution of injection materials, over 40 percent of policy makers in the EU 12 
see a strong or very strong impact (see Figure 12.10). 
Figure 12.10: 
Estimation of the impact of the CR on the development of the distribution of injection 
materials 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
12.4 Opioid substitution treatment (OST) and 
drug free treatment (CR 2.6, CR 2.7) 
CR 2.6 focuses on treatment provision: “provide, in accordance with the individual 
needs of the drug abuser, drug-free treatment as well as appropriate substitution 
treatment supported by adequate psychosocial care and rehabilitation taking into 
account the fact that a wide variety of different treatment options should be provided 
for the drug-abuser” and CR 2.7 focuses on one special aspect of OST “establish 
measures to prevent diversion of substitution substances while ensuring appropriate 
access to treatment”. 
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A policy, according to CR 2.6, exists in all EU Member States and candidate countries 
with the exception of Turkey where this policy is pending for approval (no information 
for Romania). In seven countries this policy is based on the CR (see Figure 12.11). A 
policy, according to CR 2.7, exists in all countries investigated with the exception of 
Iceland (no information for Romania and Slovakia) and in eight countries this policy is 
based on the CR. 
Figure 12.11: 
Existence of policy concerning CR 2.6 “provide in accordance with the individual needs 
of the drug abuser, drug-free treatment as well as appropriate substitution treatment” 
 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Opioid substitution treatment has been implemented in most EU Member States in the 
80s or 90s, in the form of methadone maintenance therapy (MMT). The Netherlands 
and the UK have been the first countries in Europe implementing this form of treat-
ment. Later, in many countries, the opioids used for substitution treatment has 
diversified (e. g. buprenorphine). Slow release morphine substitution, as well as heroin 
assisted treatment, is available just in a few Member States (see Table 12.2). 
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Table 12.2: 
Year of introduction of methadone maintenance treatment (MMT), high-dosage 
buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin 
assisted treatment and slow-release morphine 
Country MMT HDBT 
Buprenorphine/
naloxone 
combination 
Heroin assisted 
treatment (including 
pilots) 
Slow-release 
morphine 
Austria 1987 1999 2008 n.a. 1998 
Belgium1 1994 2003 n.a. 2011 n.a. 
Bulgaria 1996 n.a. (2008) n.a. 2006 
Cyprus : 2007 2008 n.a. n.a. 
Czech Republic2 1998 2000 2008 n.a. n.a. 
Germany3 1992 2000 n.a. 2003 n.a. 
Denmark 1970 1999 : 2008 n.a. 
Estonia 2001 (2003) n.a. n.a. n.a. 
Greece 1993 2002 2006 n.a. n.a. 
Spain4,5,6 1990 (1996) : 2003 n.a. 
Finland 1974 1997 2004 n.a. n.a. 
France 1995 1996 n.a. n.a. : 
Hungary 1995 n.a. 2007 n.a. n.a. 
Ireland 1992 (2002) (2007) n.a. n.a. 
Italy 1975 1999 2007 n.a. : 
Lithuania 1995 2002  n.a. n.a. 
Luxembourg 1989 2002  n.a. 2006 
Latvia 1996 2005  n.a. n.a. 
Malta 1987 2006  n.a. : 
Netherlands7 1968 1999  1998 : 
Poland 1993 n.a. (2008) n.a. n.a. 
Portugal 1977 1999 : n.a. n.a. 
Romania 1998 (2007) 2008 n.a. n.a. 
Sweden8 1967 1999 n.a. n.a. n.a. 
Slovenia 1990 2005 2007 n.a. 2005 
Slovakia 1997 (1999) 2008 n.a. 2005 
United Kingdom9 1968 1999 2006 1920s n.a. 
The former 
Yugoslav Republic 
of Macedonia 
     
Croatia10 1991 2004 2009 n.a. : 
Iceland      
Montenegro      
Turkey n.a. n.a. 2009 n.a. n.a. 
Remarks: n.a. indicates that the treatment is not available in the country; (...) indicates that the treatment 
substance is legally available in the country but there are no reported clients.  
When data are not available for a country, the table entry is left empty. Buprenorphine/naloxone combination 
date of issue of marketing authorisation valid throughout the European Union: 26 September 2006 (EMEA).  
(1) A heroin assisted treatment pilot project has started in 2011 in the city of Liège (Belgium). (2) A first 
unofficial substitution programme was already implemented in 1992, see Czech Republic National Report 2000. 
(3) First methadone maintenance trial in Germany took place in the mid-1970s in Hannover, but only in 1987 
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did the first large-scale pilot project in North Rhine Westphalia begin. Official introduction of MMT through 
change in narcotics law in 1992 (4) After its introduction in 1983, methadone substitution was prohibited again 
between 1985 and 1990. Heroin assisted clinical trials are ongoing in Catalonia and Andalucia. (5) HDB is a 
legally recognised medication for opioid substitution treatment in Spain, yet it is not commercially available. (6) 
Buprenorphine-naloxone is commercially available in Spain although it is not financed by the national drug 
funding system. (7) The Central Committee on the Treatment of Heroin Addicts was already established in 
December 1996 and preparations for the heroin pilot in the NL started in 1997. Clients were admitted from July 
1998 onwards. Heroin prescription became a regular scheme in the Netherlands in 2006. (8) Methadone 
maintenance treatment began on trial basis in 1967 and was introduced on a permanent basis in 1981 in 
Sweden. (9) In the UK, slow release morphine has been used for a long time for the management of pain but is 
not licensed for the treatment of opiate dependence. (10) Buprenorphine substitution therapy was introduced in 
2004 while the financing of treatment costs has been legally regulated in 2006. In 2009 buprenorphine was 
replaced by the buprenorphine/naloxone pharmacotherapy. 
Source: EMCDDA Statistical Bulletin 2012, Table HSR-1 
12.4.1 Coverage and availability of opioid substitution 
treatment and drug free treatment 
Figure 12.12: 
Opioid substitution treatment clients as a percentage of the estimated number of 
problem opioid users, 2010 or most recent year available 
Remark: The graphic shows the estimated or reported number of opioid maintenance clients as a proportion of 
the number of problem opioid users, estimated by various methods, in each country with available data. The 
symbol indicates a point estimate, a bar indicates an uncertainty interval. Based on countries' estimates of 
problem opiate use (POU), estimates or estimates of problem drug use and injecting drug use, where case 
definitions in the country's estimates correspond to POU. Finland, Poland: data on POU estimates are for 2005 
and the latest available estimates of OST clients data are from 2009 for Finland and 2010 for Poland. Ireland: 
data on POU estimates are for 2006 and the latest available estimates of OST clients data are from 2010. 
Luxembourg, Lithuania: data on POU estimates are for 2007 and the latest available estimates of OST clients 
data are from 2010. Netherlands, Hungary, Norway: data on POU estimates are for 2008 and the latest available 
estimates of OST clients data are from 2010. Germany, Austria, Spain: data on POU estimates are for 2009 and 
the latest available estimates of OST clients data are from 2010. 
 Source: EMCDDA Statistical Bulletin 2012, Figure HSR-1 part I 
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The coverage of OST differs between the countries. Figure 12.2 shows that the per-
centage of problem opioid users in OST in countries, when the respective data are 
available, ranges from below 20 percent to over 60 percent. 
According to policy makers, OST, psychosocial care and rehabilitation supporting 
substitution treatment and drug free treatment is available in all countries investi-
gated. Coverage for all three interventions seems to be slightly higher in the EU 15. 
Generally, coverage of psychosocial care supporting OST is estimated to be lower than 
coverage of OST. 
Figure 12.13: 
Estimation of OST coverage, psychosocial care and rehabilitation supporting 
substitution treatment (PSC) and drug free treatment (DFT) by EU membership status 
from policy makers 
OST=opioid substitution treatment, PSC=psychosocial care and rehabilitation supporting OST, DFT=drug free 
treatment 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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Example: In Austria, OST is offered throughout the country by general practitioners 
(GPs) as well as special services, mainly outpatient but increasingly also inpatient 
services. Methadone, buprenorphine as well as slow release morphine is available for 
maintenance therapy. GPs who want to provide OST have to participate in a special 
education programme. Over 50 % of problem opioid users receive OST in Austria, 
which is regarded as a success concerning the prevention of DRID and drug-induced 
deaths (NFP-Austria 2012). 
Example: In Germany a special relapse prevention training programme is provided, to 
teach effective coping strategies for situations with acute danger of relapse (EDDRA). 
Example: In Slovakia, a methadone maintenance programme is part of the complex 
Multimodal Centre for Treatment of Drug Dependencies (CTDD), which provides 
several interconnected programmes. Clients can choose and change the programme 
according to their needs. They can also participate in several programmes at the same 
time, for example methadone maintenance and detoxification/treatment for metham-
phetamine dependence (EDDRA). 
Example: A study in the Netherlands on the effects of high doses of methadone 
maintenance treatment showed more favourable outcomes in the high dosage group 
than in the lower dosage group (EDDRA). 
Example: In the Czech Republic, especially in the capital city Prague, there is also a 
low-threshold methadone programme. This programme does not have such strict rules 
for clients entering treatment as other OST programmes, but it also does not provide 
“take-home” doses (country profile Czech Republic – see annex 1). 
Figure 12.14: 
Estimation of coverage of OST, psychosocial care and rehabilitation supporting OST, 
drug free treatment and heroin assisted treatment from stakeholders (civil society 
organisations) 
 
Remark: data refer to all 24 countries from the stakeholder survey 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
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According to stakeholders, OST, psychosocial care and rehabilitation supporting 
substitution treatment and drug free treatment is available in all countries investi-
gated. Similar to the policy makers, stakeholder estimate the coverage of psychosocial 
care and rehabilitation supporting OST lower than the coverage of OST (see Figure 
12.14). In addition to the questions above, civil society organisations were asked about 
the coverage of heroin assisted treatment (see Figure 12.14). Heroin assisted treat-
ment is available in very few countries (see also Table 12.2). 
Example: In Germany diamorphine-assisted therapy is provided for heavily dependent 
opioid users. It is defined over the disorder-relevant main substance, but is linked to a 
series of psychosocial & health interventions (country profile Germany – see annex 1). 
12.4.2 Change of coverage and availability of OST and 
drug free treatment 
According to the policy makers in almost all countries, the availability/coverage of OST 
increased since 2003. Psychosocial care and rehabilitation supporting OST increased in 
two thirds of the countries. 
Figure 12.15: 
Estimation of change of coverage of opioid substitution treatment (OST), psychosocial 
care (PSC) and rehabilitation supporting OST and drug free treatment (DFT) by EU 
membership status from policy makers 
 
OST=opioid substitution treatment, PSC=psychosocial care and rehabilitation supporting OST, DFT=drug free 
treatment 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
5
4
3
3
3
1
2
2
1
8
6
2
7
4
3
8
4
3
2
1
4
3
1
4
3
1
1
1
2
1
0% 20% 40% 60% 80% 100%
EU 15 OST
EU 12 OST
candidate/acceding countries OST
EU 15 PSC
EU 12 PSC
candidate/acceding countries PSC
EU 15 DFT
EU 12 DFT
candidate/acceding countries DFT
strong increase increase no change decrease strong decrease do not know
VI / Main report - long version  113 
The picture of improved coverage of OSTs painted by the policy makers corresponds to 
the epidemiological data on the numbers of clients in substitution treatment, where an 
increase can be observed in almost all countries (see Figure 12.16). 
Figure 12.16: 
Change of the numbers of clients in opioid substitution treatment from 2003 to 2010 
 
Source: Table 13.1; graphic representation: GÖ FP 
12.4.3 Influence of the CR on the overall development 
of treatment, care and rehabilitation services 
for drug users 
The estimated influence of the CR on the development of the overall development of 
treatment, care and rehabilitation services for drug users in the EU 15 is slightly lower 
than in the EU 12. 40 % of the policymakers in the EU 15 see a medium impact while 
over half of the policymakers in the EU 12 estimate a medium or strong impact (see 
Figure 12.17). 
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Figure 12.17: 
Estimation of the impact of the CR on the overall development of treatment, care and 
rehabilitation services for drug users 
Remark: data refer to all 31 countries from the policy maker survey 
 Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
12.4.4 Measures to prevent diversion of substitution 
substances (CR 2.7) 
A policy, according to CR 2.7, which focuses on avoidance of distribution of substitu-
tion treatment medications to the black market, exists in 29 of the investigated 
countries but not in Iceland (no information for Romania and Slovakia). In eight 
countries the policy is based on the CR. While in all EU 15 at least extensive coverage is 
estimated, in one third of the EU 12 countries the coverage is estimated to be limited 
or rare (see Figure 12.18). 
 
Figure 12.18: 
Estimation of coverage of measures to prevent diversion of substitution substances  
(CR 2.7) 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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Example: In Austria, a cooperation project to control the abuse of substitution medi-
cines exists in the capital Vienna and involves police and public health services of the 
city as well as the Institute for Addiction Diagnostics. A special procedure was estab-
lished for the cases of reports to the police because of suspected trafficking of substi-
tution medicines (NFP-Austria 2010). 
In the opinion of policy makers, the coverage of more than half of the countries 
increased in the time span from 2003 to 2010 (see Figure 12.19). 
Figure 12.19: 
Estimation of change of coverage of measures to prevent diversion of substitution 
substances (CR 2.7) 
 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
12.5 Prevention of risk behaviour - Information, 
education and communication (CR 2.1; CR 2.2.) 
CR 2.1 “provide information and counselling to drug users to promote risk reduction 
and to facilitate their access to appropriate services” and CR 2.2 “inform communities 
and families and enable them to be involved in the prevention and reduction of health 
risks associated with drug dependence” are related to this topic. A policy, according to 
CR 2.1, exists in 31 investigated countries but not in Iceland. In nine countries the 
policy is based on the CR. A policy, according to CR 2.2, exists in 31 of the investi-
gated countries but not in Iceland; in ten countries it is based on the CR (details for 
both CRs see annex 4). 
Services according to CR 2.1 and CR 2.2 exist in all of the investigated countries. 
Extensive coverage of information and counselling of drug users related to harm 
reduction is reached in over 80 percent. Extensive coverage of information to families 
and communities related to harm reduction is reached just in 39 % of the countries 
(see Figure 12.20). 
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Figure 12.20: 
Estimation of coverage of information and counselling services to drug users related to 
harm reduction (CR 2.1) and information measures targeted to families and 
communities related to harm reduction (CR 2.2)  
 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
In the opinion of policy makers the coverage of information and counselling services 
for drug users related to harm reduction increased in the time span from 2003 to 2010 
in almost 90 % of the countries; for information measures targeted to families and 
communities related to harm reduction in over half of the investigated countries (see 
Figure 12.21). 
Figure 12.21: 
Estimation of change of the coverage of information and counselling services to drug 
users related to harm reduction (CR 2.1) and information measures targeted to families 
and communities related to harm reduction (CR 2.2) 
 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
In addition to the general questions above, one special question on Pill Testing / Drug 
Checking has been implemented in the investigation of the stakeholders. 
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Figure 12.22: 
Estimation of availability/coverage of services for information, education and 
communication in the field of harm reduction in percent (n=24) 
 
Remark: data refer to all 24 countries from the stakeholder survey 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
According to the opinion of stakeholders, information and counselling services for 
drug users are widely available in their countries but still far away from full coverage. 
Similar to policy makers, stakeholders estimate the coverage of information measures 
targeted to families and communities lower than for counselling of drug users. Drug 
Checking is still very rare (see Figure 12.22). 
Example: In Ireland outreach workers assess each individual’s current situation with 
respect to injecting use, and provide appropriate advice. Each contact with clients is 
used to provide information to increase the safety of the individual’s current injecting 
practices. In addition, safer injecting classes are operated. These activities are sup-
ported by booklets, which were developed partly together with the target group and 
adapted to the clients’ needs (country profile Ireland – see annex 1). 
Example: In Belgium, the project “Drugs, risk less (DR-)” wants to raise the awareness 
among drug users concerning the risks related to the use of psychotropic substances. 
It is based on a health promotion approach by promoting knowledge together with 
individual and social skills (EDDRA). 
12.6 Drug-related outreach work and peer 
involvement (CR 2.3; CR 2.4; CR 2.5) 
CR 2.3 “include outreach work methodologies within the national health and social 
drug policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-oriented 
activity undertaken in order to contact individuals or groups from particular target 
populations, who are not effectively contacted or reached by existing services or 
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through traditional health education channels”, CR 2.4 “encourage, when appropriate, 
the involvement of, and promote training for, peers and volunteers in outreach work, 
including measures to reduce drug-related deaths, first aid and early involvement of 
the emergency” and CR 2.5 “promote networking and cooperation between agencies 
involved in outreach work, to permit continuity of services and better users' accessibil-
ity” are related to this topic. A policy, according to CR 2.3, exists in 29 countries but 
not in Croatia and Iceland (no information for Romania). In nine countries the policy is 
based on the CR. A policy, according to CR 2.4, exists in 27 of the investigated coun-
tries but not in Croatia, Slovakia (it is not a priority task for the national government of 
these two countries), Hungary and Iceland (no information for Romania). In seven 
countries, the policy is based on the CR. A policy, according to CR 2.5, exists in 26 of 
the investigated countries but not in Greece, Croatia, Iceland, Latvia and Slovakia (no 
information for Romania). In nine countries the policy is based on the CR (details see 
annex 4). 
Figure 12.23: 
Estimation of coverage of outreach work targeted to drug users (CR 2.3), peer 
involvement in outreach work (CR 2.4) and networking and cooperation between 
agencies involved in outreach work (CR 2.5) 
 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Outreach work (CR 2.3) and networking and cooperation between agencies involved in 
outreach work (CR 2.5) are available in all of the investigated countries, and peer 
involvement in outreach work (CR 2.4) in all countries but one. The coverage of 
outreach work (CR 2.3) and of networking and cooperation between agencies involved 
in outreach work (CR 2.5) is estimated to be extensive in half of the countries investi-
gated; involvement of peers (CR 2.4) in outreach work is estimated to be extensive in 
just one third (see Figure 12.23). Policymakers of two thirds of the countries investi-
gated report an increase in services/activities related to CR 2.3, CR 2.4 and CR 2.5 (see 
Figure 12.24). 
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Figure 12.24: 
Estimation of change of coverage of outreach work targeted to drug users (CR 2.3), 
peer involvement in outreach work (CR 2.4) and networking and cooperation between 
agencies involved in outreach work (CR 2.5) 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Figure 12.25: 
Estimation of availability/coverage of services of drug-related outreach work in the 
field of harm reduction in percent 
ORW=outreach work 
Remark data refer to all 24 countries from the stakeholder survey  
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
In the stakeholders’ view, the coverage of outreach work (ORW) is lower compared to 
services for information, education and communication (see Figure 12.25 and Figure 
12.22); this may be due to the fact that outreach work is more often implemented in 
urban areas where the target group might be easier to reach by this form of interven-
tion. As the coverage of outreach work is rather low, networking and cooperation 
between organisations involved in outreach work might be low as those organisations 
might be active in different regions. Peer involvement in outreach work is not very 
common. 
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Example: In Belgium, peers are trained within the snowball operations project to 
provide information and harm reduction material among injecting drug users and other 
drug users with rare contacts to drug help services. The training is carried out in six 
sessions of approximately two hours. The peers are asked to contact around ten drug 
users and recruit new volunteers among them (EDDRA). 
Example: In Finland active participation of substance abusers is seen as crucial to 
reach the most excluded and most concealed client groups and to provide access to 
services with a low threshold. This approach is used for example by the project Osis, a 
centre of excellence in peer support for drug users in the Greater Helsinki area (coun-
try profile Finland – see annex 1). 
12.7 Screening and treatment of drug-related 
infectious diseases, HBV vaccination, condom 
distribution, safer injection training and 
paraphernalia distribution (CR 2.9, CR 2.10) 
CR 2.9 “promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as well 
as screening for all the aforementioned diseases among injection drug users and their 
immediate social networks, and take the appropriate medical actions” is related to this 
topic. A policy, according to CR 2.9, exists in 30 countries but not in Iceland (no 
information for Romania). In ten countries, the policy is based on the CR (details see 
annex 4). For CR 2.10 (condom distribution and paraphernalia distribution are relevant 
for this section) see chapter 12.3. 
Coverage of HBV vaccination for IDUs is estimated to be at least extensive in just half 
of the countries and for condom distribution in two thirds of the countries. 
Screening and treatment of drug-related infectious diseases are available in all of the 
countries providing information on the topic. Coverage for HIV screening of IDUs (81 % 
at least extensive) and medical treatment of HIV/AIDS of IDUs (80 % at least extensive) 
is higher than for HCV (58 % and 55 % - see Figure 12.26). 
With the exception of vaccination of HBV for IDUs in around two thirds of the countries 
policymakers see an increase of activities in this area (see Figure 12.27). 
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Figure 12.26: 
Screening and treatment of drug-related infectious diseases, HBV vaccination and 
condom distribution (CR 2.9 and CR 2.10)  
HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, IDU=injecting drug users, 
STD=sexually transmitted diseases, TBC=tuberculosis 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Figure 12.27: 
Estimation of change of the coverage of screening and treatment of drug-related 
infectious diseases, HBV vaccination and condom distribution (CR 2.9 and CR 2.10) 
HCV hepatitis C virus, HIV=human immunodeficiency virus, IDU=injecting drug user 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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Just one third of the stakeholders estimate the coverage of HBV vaccination of IDUs to 
be at least extensive. Also coverage of screening for drug-related infectious diseases 
is quite low in their opinion (e. g. HIV: 32 %, HCV: 26 % - coverage at least extensive). 
In accordance with policy makers, the coverage of medical treatment of HIV/AIDS of 
IDUs (58 % at least extensive) is higher than for HCV (26 %). Concerning prevention 
measures, the coverage of safer injection training (21 % at least extensive) and para-
phernalia distribution for sniffing (10 % at least extensive) is very low (see Figure 
12.28). 
Figure 12.28: 
Estimation of coverage of prophylactic measures other than NSP, screening and 
treatment of drug-related infectious diseases (CR 2.9) of stakeholders (n=24) 
HCV=hepatitis C virus, HIV=human immunodeficiency virus, IDU=injecting drug user, STD=sexually transmitted 
diseases 
Remark: data refer to all 24 countries from the stakeholder survey 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
Example: In Portugal, a national network of harm and risk reduction structures (RRMD) 
was established in 2001, which provides alternative paths leading to stabilisation and 
treatment. One element is early identification and prevention of HIV/AIDS among drug 
users (Program Klotho), which should be finally integrated in local healthcare struc-
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tures. Meanwhile this programme is incorporated in all RRMD structures (country 
profile Portugal – see annex 1). 
Example: In France, screening for DRID is provided free of charge and anonymously by 
specific centres. While screening for HIV and hepatitis C is covered by the French 
health insurance, screening for hepatitis B is covered to some extent only. Systematic 
activities in all services visited by drug users shall improve the awareness of the 
importance of screening and the efficacy of treatments – especially among unstable 
and migrant drug users (country profile France – see annex 1). 
Example: In Denmark free vaccination against hepatitis A and B is offered to drug 
abusers (country profile Denmark – see annex 1). 
12.8 Prevention of drug-induced deaths other than 
OST (CR 2.11, CR 2.10) 
CR 2.11 “ensure that emergency services are trained and equipped to deal with over-
doses” is related to this topic. A policy, according to CR 2.11, exists in 30 countries 
but not in Iceland (no information for Romania). In eleven countries the policy is based 
on the CR (details see annex 4). For CR 2.10 (drug consumption rooms are relevant for 
this section) see chapter 12.3 
Figure 12.29: 
Estimation of the coverage of emergency services are trained and equipped to deal 
with overdoses (CR 2.11) 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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Figure 12.30: 
Estimation of change of the coverage of emergency services are trained and equipped 
to deal with overdoses (CR 2.11) 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Policy makers of 85 % of the countries estimated the coverage of this measure to be at 
least extensive (see Figure 12.29); in half of the countries they see an increase (see 
Figure 12.30). 
Figure 12.31: 
Estimation of the availability/coverage of services other than opioid substitution 
treatment for the prevention of drug-induced deaths in percent 
Remark: data refer to all 24 countries from the stakeholder survey 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
The questions concerning measures targeted to prevent drug-induced deaths, which 
were asked to the stakeholders, also included some other concrete measures. Accord-
ing to stakeholders, ambulances are not equipped with naloxone in all countries or 
regions, and the coverage of emergency staff’s training to deal with overdoses is 
astonishingly low (27 % at least extensive). Full or extensive coverage of release 
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management in the context of drug free treatment is reported by 20 % only. Naloxone 
“take home” programmes are still extremely rare (see Figure 12.31). 
Only a small number of European countries report the existence of community-based 
programmes that prescribe naloxone to drug users at risk of opioid overdose, accord-
ing to the EMCDDA (EMCDDA 2012a). Naloxone prescribing is accompanied by com-
pulsory training in recognising overdoses and providing basic life-support techniques 
in most countries (see Chapter 10.3.2). Programmes for the distribution of naloxone 
are reported by Italy (where 40 % of drugs agencies provide the substance), Germany 
and the United Kingdom (England and Wales). New initiatives are reported by Bulgaria, 
Denmark and Portugal. In Scotland, provision of 'take-home-naloxone' to all at-risk 
individuals leaving prison was introduced nationally in 2010, and the government is 
supporting a national “take-home” naloxone programme for those deemed to be at 
risk of opioid overdose and those who may come in contact with them (EMCDDA 
2012a). 
Drug consumption rooms are available in 77 cities in five Member States (Denmark, 
Germany, Luxembourg, Netherlands and Spain) (EMCDDA 2012d) but also in Switzer-
land and Norway. 
Example: In Germany, 28 drug consumption rooms exist with the objective to secure 
survival and stabilisation of the health conditions of drug users as well as to reach 
those drug users, who are not in contact with the drug help system otherwise. Drugs 
are brought along to the drug consumption rooms by the drug users, infection pro-
phylaxis is systematically provided by the staff. Minimum standards are defined in the 
Narcotics Act (NFP-Germany 2011).  
Example: In Belgium, emergency departments provide crisis beds for the treatment of 
substance-related disorders. During a maximum stay of five days a range of interven-
tions are carried out, including assessment of the acute somatic situation and intensive 
treatment. Continuity of care afterwards is guaranteed, which lies in the responsibility 
of a case manager (country profile Belgium – see annex 1). 
Example: In the UK, the project “Take Home Naloxone” (THN) provides training on the 
administration of naloxone and first-aid in case of an overdose event. After the 
training is completed, THN kits are issued to opiate users and their carers (EDDRA). 
Example: In Slovakia, a new system of first aid emergency was created, which increased 
the availability of healthcare for urgent drug-related health threats. Throughout the 
country a network of emergency healthcare stations was established. In this context 
medical education of drug users became an important part of prevention and protec-
tion of health for this target group (NFP-Slovakia 2010). 
126 GÖ FP, Sogeti, Report on the current state of play of the 2003 CR on harm reduction  
12.9 Co-operation, training and education of staff 
(CR 2.12, CR 2.13) 
CR 2.12 “promote appropriate integration between health, including mental health, 
and social care, and specialised approaches in risk reduction” and CR 2.13 “support 
training leading to a recognised qualification for professionals responsible for the 
prevention and reduction of health-related risks associated with drug dependence” are 
related to this topic. A policy, according to CR 2.12, exists in 28 countries but not in 
Bulgaria, Iceland and Turkey (no information for Romania). In Turkey this policy is 
pending for approval. In six countries the policy is based on the CR (details see annex 
4). 
A Policy, according to CR 2.13, exists in 30 countries but not in Iceland (no information 
for). In ten countries the policy is based on the CR (details see annex 4). 
The coverage of appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction is estimated in half of the 
countries to be at least extensive: Training leading to a recognised qualification for 
professionals responsible for the prevention and reduction of health-related risks 
associated with drug dependence exists in over two thirds of the countries (see Figure 
12.32). Over 70 percent of policymakers see improvements in both fields of action. 
Figure 12.32: 
Estimation of the coverage of measures according to CR 2.12 and CR 2.13  
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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Figure 12.33: 
Estimation of change of the coverage of measures according to CR 2.12 and CR 2.13 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
The picture drawn by the stakeholders, who were asked for their estimate of the 
coverage of training in several areas, shows strong indication for improvement in one 
fifth of the countries covered (The coverage is estimated as lower than “limited” – see 
Figure 12.34). 
Figure 12.34: 
Estimation of availability/coverage of training in different areas of harm reduction 
OST=opioid substitution treatment, ORW=outreach work 
Remark: data refer to all 24 countries from the stakeholder survey 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
Example: In Austria, the cooperation between the healthcare system and the drug help 
system is strengthened by CONTACT, a liaison service for hospitals. This service is 
provided in Vienna with the objective to stabilise drug users, who are in hospital care 
after non-fatal overdoses, by connecting them with a suitable service of the drug help 
system (EDDRA). 
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12.10 Housing (not included in CR) 
Housing seems to be a field of harm reduction where still a lot of improvement is 
necessary as all measures are described to have a rather low coverage (stakeholder 
consultation). For night shelters - the measure with the highest coverage - only 24 % 
report full or extensive coverage (see Figure 12.35). 
Example: In Austria, supervised housing provides accommodation for persons with 
drug-related problems. Clients targeted are those who are homeless but relatively 
stable in their drug use and live in Vienna. This includes also couples and people with 
children. After a maximum of two years within this programme clients are able to 
move into their own accommodation (EDDRA). 
Example: In Ireland, the Dublin Simon Emergency Hostel offers short term emergency 
accommodation for homeless people, including heroin using persons. Within a pilot 
project of the Safetynet Service, a methadone programme was implemented in the 
hostel, to reduce heroin use and the high-level of hospital admissions among this 
specific target group (EDDRA). 
Figure 12.35: 
Estimation of the availability/coverage of services for housing in percent 
 Remark: data refer to all 24 countries from the stakeholder survey 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
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Although no new studies are available, except for a smaller evaluation from Switzer-
land (Bücheli et al. 2010 and Hungerbuehler et al. 2011) which shows that “party drug 
users” are not a homogenous group, some important developments can be reported in 
this field:  
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Due to the fact that the projects not only focus on ecstasy tablets any longer but also 
on other substances like cocaine and new psychoactive substances (e. g. so called 
“research chemicals”) the term “Drug Checking” is now more common. Drug Checking 
programmes are today available in more European countries than in 2006 namely in 
Austria, Belgium, France, the Netherlands, Portugal, Spain and Switzerland. Drug 
Checking is seen as an integrated service that always combines the chemical analysis 
with advice or counselling (TEDI 2011). In their self-perception (VWS 2012) Drug 
Checking programmes often define themselves as information and counselling pro-
grammes that also provide drug-checking (in this order of importance). 
Example: In Austria counselling and Drug Checking has been implemented by checkit! 
at large music festivals in Vienna and the surrounding areas for many years. Bits of 
tablets or powders are analysed by the checkit! staff in a mobile laboratory (using 
high-performance liquid chromatography and liquid chromatography–mass spec-
trometry). In the year 2011 only a third of the analysed samples contained the ex-
pected psychoactive substance without additional pharmacological active ingredients 
(country profile Austria – see annex 1). 
Simple colour reaction tests and the use of pill-lists are not common anymore; the 
programmes use at least thin layer chromatography but many use also laboratory 
analysis, which helps not only with identifying more substances but also gives a better 
input for early warning and monitoring systems. In many programmes peers are 
involved, partially high standards for professional counsellors like advanced education 
in motivational interviewing are reported. Drug Checking programmes regard them-
selves being cost effective as they reach drug users at an early stage which gives the 
possibility of early interventions. Moreover, the analyses can provide beneficial results 
to general public health (TEDI 2011). Through the use of modern social media Drug 
Checking projects are able to gain a broader but nevertheless targeted public than 
some ten years ago. 
In the course of the EU-financed project Nightlife Empowerment & Well-being Imple-
mentation Project (NEWIP) all European Drug-Checking programmes work together in 
the TEDI (Trans European Drug Information) workgroup on a common database and 
focus on: 
» Standardising the various processes related to Drug Checking 
» Making recommendations to help improve first-line project field interventions 
» Monitoring the evolution of new substances and new trends throughout Europe 
(http://www.safernightlife.org) 
130 GÖ FP, Sogeti, Report on the current state of play of the 2003 CR on harm reduction  
12.12 Prison - a special setting for harm reduction 
(CR 2.8) 
The selected issue “prisons and drugs in Europe” (EMCDDA 2012h) demonstrates that 
harm reduction of harm related to drug use in prison is a very relevant issue. Between 
2001 and 2010 the prison population increased from 582.000 to 635.000 in the 27 EU 
Member States. Offences related to the use, possession or supply of illicit drugs are 
the main reasons for the imprisonment of between 10 % and 25 % of all sentenced 
prisoners. To interpret these numbers, it has to be taken into account that on one 
hand, not all of them necessarily have experience of or problem with drug use. But on 
the other hand not all prisoners with problem drug use have been imprisoned for a 
drug law offence (e. g. imprisonment for other leading offences like burglary, shoplift-
ing, etc.). Estimates suggest that around 50 % of the prisoners in the EU have a history 
of drug use and a high proportion of them with problem drug use (WHO 2007) – see 
also chapter 10.4). 
12.12.1 Coverage and availability of harm reduction 
measures provided to drug users in prison 
Although a consensus exists in European policy that prisoners should have the same 
health support as the general population  - e. g. Dublin declaration on HIV/AIDS in 
prisons in Europe and Central Asia, (WHO 2007) the situation concerning harm reduc-
tion measures in prison is worse than outside prison.  
OST was introduced in prison later (see Figure 12.36) and needle exchange is available 
in prison in only five of the investigated countries (see Table 12.1 in section 12.3.1). 
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Figure 12.36: 
Cumulative number of European countries that had officially launched OST as a 
recognised method of treatment in community and prison settings 
Source: EMCDDA Selected issue 2012 – prisons and drugs in Europe, page 22 
Figure 12.37: 
Estimation of the coverage of harm reduction measures provided to drug users in 
prison 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
A policy, according to CR 2.8, exists in 31 countries with the exception of Iceland (no 
information for Romania). In Lithuania this policy is pending for approval. In eleven 
countries the policy is based on the CR (details see annex 4). 
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Coverage of harm reduction measures in prison is estimated to be limited or worse in 
many countries, especially in the EU 12 (see Figure 12.37). 
In addition to the questions above, civil society organisations were asked more details 
about the coverage of different harm reduction measures in prison. According to the 
opinion of stakeholders, harm reduction measures for prisoners reach limited coverage 
in less than one third of the countries covered. OST and medical treatment of HIV/AIDS 
are the only measures which are at least extensively available in half of the countries 
(see Figure 12.38). 
Example: In Spain needle exchange programmes are running in 41 prisons and the 
majority of prisoners who need syringes are covered by the programmes (EMCDDA 
2012h). HIV prevalence among prisoners decreased from 24 % in 1992 to 7 % in 2009 
(Arroyo-Cobo 2010).  
Example: In France, a national programme (Departmental (sub-regional) Justice and 
Health conventions of objectives, CDO) was initiated and re-launched in the late 
1990s, with the purpose of offering the same level of treatment and prevention 
services to drug users within the criminal justice system as in the community. As a 
result of this programme and the better identification of health problems, the number 
of drug users in contact with care services increased from 9.000 in 1999 to 36.000 in 
2002 (EDDRA). 
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Figure 12.38: 
Estimation of the coverage of several harm reduction measures in prison 
DRID=drug-related infectious diseases, HCV=hepatitis C virus, HIV=human immunodeficiency virus, 
IDU=injecting drug user, OST=opioid substitution treatment, STD=sexually transmitted diseases 
Remark: data refer to 22 countries of the 24 countries covered by the stakeholder survey. Malta and Slovakia 
are missing. 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
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12.12.2 Change of coverage of harm reduction 
measures in prison 
According to the policy makers, in more than two thirds of the EU 15 and candidate 
countries and in two thirds of the EU 12 the availability/coverage of harm reduction 
measures in prison increased since 2003.  
Figure 12.39: 
Estimation of change of the coverage of harm reduction measures in prison 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
12.12.3 Influence of the CR on the change of coverage 
and availability of harm reduction measures 
in prison 
Figure 12.40: 
Estimation of the impact of the CR on the change of coverage and availability of harm 
reduction measures in prison 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
The estimated influence of the CR on the development of the change of coverage and 
availability of harm reduction measures in prison in the EU 15 is slightly lower than in 
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the EU 12. One third of policy makers in the EU 15 see at least a medium impact while 
over half of the policy makers in the EU 12 see this impact (see Figure 12.40). 
12.13 Harm reduction and scientific evidence, 
monitoring & evaluation and (CR 3)19 
Council Recommendation 3 focuses on scientific evidence, monitoring and evaluation. 
Questions concerning CR 3 were not included in the stakeholder survey. All referred 
data originate from the policy maker survey.  
CR 3: Member States should consider, in order to develop appropriate evaluation to 
increase the effectiveness and efficiency of drug prevention and the reduction of drug-
related health risks: 
CR 3.1: using scientific evidence of effectiveness as a main basis to select the appro-
priate intervention; 
A policy, according to CR 3.1, exists in 28 countries but not in Bulgaria, Hungary and 
Latvia (no information for Romania). In Hungary and Latvia this policy does not exist 
because this topic is not a task of the national government. 
Still, scientific evidence is widely used as basis for the development of guidelines and 
standards in Europe. While many countries have guidelines and standards for drug 
treatment, they are less available for the area of harm reduction (see Best Practice 
Portal; http://www.emcdda.europa.eu/themes/best-practice/standards). 
Example: In the UK, quality standards for drug use disorders, which are based on 
scientific evidence, are provided by the National Health Service (NHS). According to the 
NHS, these quality standards describe markers of high-quality, cost-effective care that, 
when delivered collectively, should contribute to improving the effectiveness, safety 
and experience of care for people with drug use disorders. The NHS recommends 
though, to consider also national and local guidelines on training and competencies, 
for example competencies set out in the Drugs and Alcohol National Occupational 
Standards (DANOS) (NHS; http://publications.nice.org.uk/quality-standard-for-drug-
use-disorders-qs23/introduction-and-overview). 
Example: In the Czech Republic, a certification system was developed and imple-
mented, which includes certification standards and a defined certification process. 
These standards refer to professional competencies for facilities and programmes 
                                                                                                                                         
19  
All information concerning Slovakia in this chapter is based on the previous report (Trimbos 2006) 
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providing professional services to problem substances users and persons with a 
substance addiction. To consider scientific evidence, the standards were based on 
WHO guidelines and guidelines from the UK (NFP-Czech-Rebublic 2009). 
CR 3.2: supporting the inclusion of needs assessments at the initial stage of any 
programme; 
A policy, according to CR 3.2, exists in 27 countries but not in Bulgaria, Hungary, the 
Netherlands (no information for Romania). In Bulgaria and Slovakia it is pending for 
approval, in Hungary and the Netherlands this policy does not exist because this topic 
is not a task of the national government. 
CR 3.3: developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes; 
A policy, according to CR 3.3, exists in 21 countries but not in Austria, Bulgaria, 
Hungary, Latvia, Malta, the Netherlands, Slovakia, Iceland and Turkey (no information 
for Romania and Slovakia). In Malta and Slovakia it is pending for approval, in the other 
countries this policy does not exist because this topic is not a task of the national 
government or because of other undisclosed reasons. 
CR 3.4: establishing and implementing evaluation quality criteria, taking into account 
the recommendations of the European Monitoring Centre for Drugs and Drug Addic-
tion (EMCDDA); 
A policy, according to CR 3.4, exists in 22 countries but not in Austria, Croatia, France, 
Hungary, Malta, the Netherlands, Slovakia and Turkey (no information for Romania and 
Iceland). In Slovakia it is pending for approval, in the other countries this policy does 
not exist because this topic is not a task of the national government or because of 
other undisclosed reasons. 
CR 3.5: organising standardised data-collection and information dissemination 
according to the EMCDDA recommendations through the REITOX national focal points; 
A policy, according to CR 3.5, exists in 30 countries but not in Iceland (no information 
for Romania). In Iceland this policy does not exist because of undisclosed reasons. 
In all EU Member States as well as in the acceding resp. candidate countries, a national 
REITOX Focal Point was established to organise and ensure standardised data-
collection and information dissemination according to the EMCDDA recommendations 
(see EMCDDA; http://www.emcdda.europa.eu/about/partners/reitox-network. 
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CR 3.6: making effective use of evaluation results for the refining and development of 
drug prevention policies; 
A policy, according to CR 3.6, exists in 27 countries but not in Austria, Bulgaria, 
Hungary and Iceland (no information for Romania). In Bulgaria it is pending for ap-
proval, in Hungary this policy does not exist because this topic is not a task of the 
national government. In Austria and Iceland this policy does not exist because of 
undisclosed reasons. 
Several countries evaluate (regularly) their national drug strategies or plans to refine 
and develop drug prevention policies. 
Example: In Denmark, on the basis of a national action plan 19 specific and new 
initiatives were launched in October 2010, including initiatives in the area of harm 
reduction. These initiatives are monitored on an ongoing basis and evaluated with the 
purpose to adjust the national drug policy (NFP-Denmark 2011). 
CR 3.7: setting up evaluation training programmes for different levels and audiences; 
A policy, according to CR 3.7, exists in 22 countries but not in Bulgaria, Croatia, 
Hungary, Iceland, Latvia, Malta, and Slovakia (no information for Romania, Turkey and 
France). In Hungary and Latvia this policy does not exist because this topic is not a 
task of the national government, in Slovakia because it is not a priority and in the other 
countries because of other undisclosed reasons. 
CR 3.8: integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation; 
A policy, according to CR 3.8, exists in 21 countries but not in Austria, Bulgaria, 
Croatia, France, Hungary, Iceland, Latvia, the Netherlands, and Slovakia (no information 
for Romania and Turkey). In Bulgaria this policy is pending for approval. In Austria, 
Hungary and Latvia this policy does not exist because this topic is not a task of the 
national government, in Slovakia because it is not a priority and in France, Iceland and 
the Netherlands it does not exist because of other undisclosed reasons. 
CR 3.9: encouraging, in collaboration with the Commission, the exchange of pro-
gramme results, skills and experience within the European Union and with third 
countries, especially the applicant countries. 
A policy, according to CR 3.9, exists in 28 countries but not in Austria and Iceland (no 
information for Romania and Ireland). In Austria this policy does not exist because this 
topic is not a task of the national government. In Iceland this policy does not exist 
because of other undisclosed reasons. 
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Many countries support the initiatives of the Commission to exchange programme 
results, skills and experiences by participating in various programmes for candidate 
countries (e. g. NFPs as REITOX coaches within the IPA programme) or in EU funded 
projects or conferences - e. g. conference on European Minimum Quality Standards 
(EQUS) in Brussels. 
Table 12.3 gives an overview about the existence of the respective policies in the 
countries investigated (for more details see annex 4). 
Concerning the implementation of Council Recommendation 3 standardised data 
collection CR 3.5 is estimated to be implemented to a large extent by 26 of 31 coun-
tries. Using scientific evidence of effectiveness as a main basis to select the appropri-
ate intervention CR 3.1 is estimated to be implemented to a large extent by 18 coun-
tries (2nd highest rating concerning implementation). Only five countries estimate a 
high rate of implementation for the involvement of actors and stakeholders in evalua-
tion (CR 3.8). Figure 12.41 shows the policy makers’ estimation of the level of imple-
mentation concerning CR 3.1 to CR 3.9 For all sub recommendations of CR 3 more 
than half of the policy makers estimate an increase or a strong increase in the level 
implementation since 2005 (Figure 12.42). 
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Table 12.3: 
Council Recommendation 3 – overview of existence 
Recommendation 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 total 
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Austria 1   1   0 NT 0 NT 1   0 OT 1 0 NT 0 NP 4 
Belgium 1   1 1 1   1   1 1 1 DIV 1   1   1   9 
Bulgaria 0 0 PA 0 OT 1 1 1 1 0 PA 0 0 PA 1 1 3 
Croatia 1 1    1   0 1 1 0 0 1    6 
Cyprus 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Czech Republic 1   1 1 1 1 1 1 1   1   1   1 1 1   9 
Denmark 1   1   1   1   1   1   1   1   1   9 
Estonia 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Finland 1   1   1 1 1   1   1   1   1   1   9 
France 1   1     OT 0 OT 1   1       0 OT 1   5 
The former Yugoslav 
Republic of Macedonia 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Germany 1 1 1   1 1 1 1 1 1 1   1   1   1 1 9 
Greece 1   1   1   1   1   1   1   1   1   9 
Hungary 0 NT 0 NT 0 NT 0 NT 1   0 NT 0 NT 0 NT 1   2 
Ireland 1   1   1   1   1   1   1   1   8 
Iceland 1   1   0 OT     0 OT 0 OT 0 OT 0 OT 0 OT 2 
Italy 1   1 NT 1 NT 1   1   1 NT 1 1 1 1 1   9 
Latvia 0 NT 1 1 0 NT 1 1 1 1 1 1 0 NT 0 NT 1 1 5 
Lithuania 1 1 1   1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Luxembourg 1   1   1 OT 1   1   1   1   1   1 1 9 
Malta 1   1   0 PA 0 OT 1   1   0 OT 1 1 1   6 
Montenegro 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Netherlands 1   0 NT 0 OT 0 NT 1   1   1   0 OT 1   5 
Poland 1   1   1   1   1   1   1   1   1   9 
Portugal 1   1   1   1   1   1   1   1   1   9 
Romania 
Slovakia 1 1 0 PA 0 PA 0 PA 1 1 1 NP 0 NP 0 NP 1 1 4 
Slovenia 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 9 
Spain 1   1   1   1   1   1   1   1   1   9 
Sweden 1   1   1   1   1   1   1   1   1   9 
Turkey 1 1 1    0 OT 0 OT 1 1 1 1 1 1 5 
UK 1   1   1 1 1 1 1   1   1 1 1 1 1   9 
Total  28  27  21  22  30  27  22  21  28    
Remarks: 0=no; 1=yes; blank=no information 
Reasons why not based on Council Recommendation: OT=other reason | NP=not a priority | NT=not task 
national government | PA=pending for approval | NA=not available | DIV=diverging answers. 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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Figure 12.41: 
Council Recommendation 3 - estimation of implementation 
 Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
Figure 12.42: 
Council Recommendation 3 - estimation of change of implementation 
Remark: data refer to all 31 countries from the policy maker survey 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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12.14 Most efficient measures to reduce drug-related 
harm according to the opinion of stakeholders 
12.14.1 Prevention of drug-related infectious diseases 
Figure 12.43: 
Harm reduction measures whose implementation / expansion would have the biggest 
effect in reduction of prevalence of DRID among IDUs (opinion of stakeholders) 
DRID=drug-related infectious diseases, IDU=injecting drug user, NIROA=non injecting route of administration, 
NSP=needle and syringe exchange programme, OST=opioid substitution treatment,  
STD=sexually transmitted diseases; 
The exact formulation of the question was: “Please indicate the harm reduction measures whose 
implementation / expansion - to your opinion - would have the biggest effect in reduction of prevalence of 
infectious diseases among injecting drug users in your country/region. Please indicate 10 measures at 
maximum!” 
Remark: data refer to 23 countries from the 24 countries covered by the stakeholder survey. Latvia is missing. 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
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Asked for harm reduction measures whose implementation/expansion would have the 
biggest effect in reduction of prevalence of infectious diseases among injecting drug 
users (IDUs) in the respective country/region, needle and syringe exchange and harm 
reduction measures in prison were the most often quoted, followed by paraphernalia 
distribution for injecting drug users and safer injection training. Taking into account 
the rank given to the measures needle and syringe exchange for injecting drug users, 
paraphernalia distribution for injecting drug users and drug consumption rooms were 
quoted most often on rank 1 to 3 (see Figure 12.43,  more details see annex 3).  
12.14.2 Prevention of drug-induced deaths  
Asked for measures whose implementation/expansion would have the biggest effect in 
reducing drug-related deaths (due to overdoses) in the respective country/region, first 
aid training for drug users and naloxone “take-home” programmes are quoted most 
often followed by information and counselling services to drug users focusing on harm 
reduction and prison release management. The measures naloxone “take-home” 
programmes, drug consumption rooms and first aid training for drug users were 
quoted most often on rank 1 to 3 (see Figure 12.43, more details see annex 3).  
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Figure 12.44: 
Harm reduction measures whose implementation / expansion would have the biggest 
effect in reduction of drug-induced deaths according the opinion of stakeholders 
OST=opioid substitution treatment, NIROA=non injecting route of administration; 
The exact text of the question was: “Please indicate the harm reduction measures whose implementation / 
expansion - to your opinion - would have the biggest effect in reduction of drug-related deaths (deaths due to 
overdoses) in your country/region. Please indicate 10 measures at maximum!” 
Remark: data refer to 23 countries from the 24 countries covered by the stakeholder survey. Latvia is missing. 
Source: GÖ FP, stakeholder survey; graphic representation: GÖ FP 
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13 Modelling the relation between harm 
reduction measures and drug-related 
harm in the EU and candidate/acceding 
countries 
The aim of this chapter is to provide a comprehensive overview of the available 
epidemiological data and the information on the coverage of harm reduction measures 
in the EU and candidate countries deriving from the policy questionnaires. This chapter 
brings together epidemiological data (see chapter 11), the effectiveness of harm 
reduction measures (see chapter 10) and the coverage/availability as reported by the 
policy makers (see chapter 12). Since the stakeholder survey only provides national 
data for 16 countries, the stakeholder data are not included (see chapter 12.1 and 
annex 3). 
The aim of this chapter is to get some insight into the complex relationships between 
the supply of harm reduction measures and the treatment availability on the one side 
and the indicators for drug-related harm (epidemiological data) on the other. The 
leading questions were:  
» Did the Council Recommendation have an impact on the coverage/availability of 
harm reduction measures in the countries investigated?  
» What is the impact of the coverage/availability of harm reduction measures on 
drug-related harm (indicated by drug-induced deaths) and HIV infections via in-
jecting drug use (IDU)? 
In the first step, the main epidemiological and harm reduction data available from the 
EMCDDA standard tables were analysed regarding the trends from 2003 (the year of 
the Council Recommendation) till the most recent year (generally 2010 – for some data 
2011).  
In the second step, the association between two key indicators for drug-related harm 
(HIV infection rates via IDU and drug-induced deaths rates) is discussed.  
In the third step, the different coverage reported in the policy questionnaire is com-
prehensively analysed according to the already introduced differentiation between 
EU 15 and EU 12 as well as candidate/acceding countries. In addition to the already 
introduced way of analysing the data, the data are looked at in the context of epidemi-
ological trends. This provides first insights into the association of harm reduction 
measures and harm related to drug use.  
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In the fourth step, the association between the impact of the Council Recommendation 
and the Member States is discussed.  
The final step brings together the information from the policy questionnaire on the 
impact of the Council Recommendation and the coverage of harm reduction measures 
and drug-related harm. For this purpose, a structural equation modelling approach 
(SEM) using AMOS was used. The use of multivariate analysis tools such as SEM or 
Logistic Regression allows identifying relevant aspects in a model holding other factors 
(covariates) on a constant level. This is essential to level out the effects of subpopula-
tions and to identify the influence of the implementation. 
Data remarks 
There are several limitations and data remarks that must be kept in mind when 
conducting the analysis and interpreting the data. 
The coverage/availability of harm reduction measures is a subjective assessment made 
by the policy makers. In chapter 12.1, the reliability of the data compared to stake-
holder answers is discussed and the same pattern but different estimates concerning 
coverage were attributed. 
The quality of epidemiological data varies dramatically among the countries. For 
example the rate of drug-induced deaths in the UK is more than six times higher than 
in France, which cannot be fully explained by harm reduction measures or low preva-
lence rates. It can be assumed that the data collection process varies significantly and 
the interpretation of the data should be made with caution. Apart from the raw data 
limitations, the correlation needs to be interpreted with caution. For example high 
coverage of needle exchange programmes can reduce the numbers of HIV infections 
via IDU (negative correlation), but high HIV rates could also cause an expansion of the 
needle exchange programmes (positive correlation). 
Due to the concerns regarding the coverage of the available data, the focus was put on 
trend analysis. However, there are several limitations to this approach as well. The 
comparison of 2009/2010 data and 2003/2004 data within the same countries 
ignores the variability between the analysed countries. Furthermore, the very low 
absolute numbers (in particular among drug-induced deaths) hinders significant 
changes. Another important limitation about the association of coverage and signifi-
cant changes is that it combines single-point measures (the coverage estimated in 
2012) and trend data (from 2003 to 2010). 
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13.1 Comprehensive overview of the changes in drug-
related harm and harm reduction measures 
2003-2010 
The country comparison in Europe should be made with caution, since there are still 
some differences between countries in their capacity to ascertain the drug-induced 
death cases (see chapter 11). Another major limitation is the remaining differences in 
coding, recording and extracting the drug-induced death cases. Ireland, for instance, 
has implemented a procedure of checking a special register, which probably partly 
explains the high rate of drug-induced deaths. Most national reporting systems have 
been stable over time, which allows, in the majority of countries, an analysis of the 
trend over time. Nonetheless, caution is needed here as well, as some countries have 
changed over time (e.g. the upgrade of the monitoring system). 
Table 13.1 provides an overview of the trends of HIV (HIV infections newly diagnosed 
and AIDS diagnosed among injecting drug users according to ECDC), the number of 
drug-induced deaths, the needle exchange rates and the number of patients in opioid 
substitution treatment. A statistical test for significant differences between pooled 
2003/2004 data and pooled 2009/2010 data was performed20. The aim was to see if 
the Council Recommendation resulted in a decrease in drug-related harm (drug-
induced death and HIV) and increases in harm reduction measures. The table should 
also provide clear patterns of countries (e. g. showing a decrease in drug-related harm 
and an increase in harm reduction measures) that could be used for further analysis. 
For example Lithuania has experienced an increase of HIV infections among IDUs and 
an increase in drug-induced deaths and at the same time the needle exchange de-
clined. In Romania, the situation concerning HIV and drug-induced death has also 
worsened but the numbers of needle exchange and numbers of OST have increased. It 
is important to note that significant changes in drug-induced deaths and changes in 
HIV rates do not follow the same trends in most of the countries. Only seven countries 
(Bulgaria, Czech Republic, Italy, Lithuania, Romania, Spain, Croatia) report the same 
trends (or no significant changes) for HIV and drug-induced deaths.  
                                                                                                                                         
20 
After a consultation with the EMCDDA, a Poisson distribution for the incidence and symmetric confidence 
intervals were assumed. A 5 % alpha error confidence interval for 2003/2004 data was calculated.  
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Table 13.1: 
Trends in DRD, HIV, Needle Exchange, OST (significant differences between 2003/2004 
and 2009/2010 data) 
Country DRD HIV 
drug users 
Needle  
Exchangei 
OST 
Austria  ii n.a.  
Belgium n.a.   iii
Bulgaria    
Cyprus iv n.a.  n.a.
Czech Republic    v
Denmark vi  n.a.  
Estonia    
Finland    vii
France viii  ix x
Germany   n.a.  
Greece  xi  xii
Hungary  n.a.  xiii
Ireland xiv  n.a.  
Italy  xv n.a.  
Latvia    
Lithuania    n.a
Luxembourg  n.a.  xvi
Malta  n.a.  
Netherlands   n.a. xvii 
Poland xviii xix  xx
Portugal n.a.xxi   xxii
Romania  xxiii xxiv xxv
Slovakia xxvi n.a.  xxvii
Slovenia  n.a. n.a. n.a 
Spain xxviii xxix  xxx
Sweden xxxi  xxxii n.a
United Kingdom    n.a. n.a 
Croatia  xxxiii  
The former Yugoslav 
Republic of Macedonia 
n.a. n.a. n.a. n.a.
Iceland n.a. n.a. n.a. n.a.
Montenegro n.a. n.a. n.a. n.a.
Turkey xxxiv n.a. n.a. n.a
Remarks: =no significant change, =significant increase, =significant decrease, n.a.=data not available (or 
only partial data), DRD=drug-induced deaths, HIV=human immunodeficiency virus, OST=opioid substitution 
treatment 
Source: EMCDDA Statistical Bulletin 2012, Table DRD-2, ECDC/WHO 2011 data collection, EMCDDA Statistical 
Bulletin 2012, Table HSR-3; EMCDDA Statistical Bulletin 2012, Table HSR-5; GÖ FP-own calculation 
graphic representation: GÖ FP 
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For more methodological and data remarks, please refer to the EMCDDA Tables in annex 4. 
i No data collection 2004 
ii No 2003 data, 2004/2005 data used 
iii No data 2004 and 2010 available, only 2003 and 2009 data used 
iv No data for 2003, data 2004/2005 used 
v No data for 2004, only 2003 data used 
vi No data for 2003/2004 available, data 2005/2006 used, no data for 2010 available, 2008/2009 data used, 
due to a change in the national definition in 2006, earlier data are not strictly comparable with more recent data 
vii No data for 2010 available, only 2009 data used 
viii No data for 2010 available, 2008/2009 data used 
ix No data for 2005 and 2009 available, only 2003 and 2010 used 
x No data for 2004, only 2003 data used 
xi In order to cover the drastic increase of HIV infections, data for 2010 and 2011 used 
xii No data for 2004, only 2003 data used 
xiii No data for 2004, only 2003 data used 
xiv No data for 2010 available, 2008/2009 data used 
xv Regional data, no data for 2003, 2004/2005 data used 
xvi No data for 2004, only 2003 data used 
xvii No data 2004 and 2010 available, only 2003 and 2009 data used 
xviii No data for 2010 available, 2008/2009 data used 
xix No 2003 data, 2004/2005 used 
xx No data for 2004 available, only 2003 data used 
xxi Data starting 2008 
xxii No data for 2004, only 2003 data used 
xxiii In order to cover the drastic increase of HIV infections, data for 2010 and 2011 used  
xxiv No data for 2003, only 2005 data used 
xxv No data for 2004, only 2003 data used  
xxvi No 2003 data, 2004/2005 used 
xxvii No data for 2004, only 2003 data used 
xxviii No data for 2010 available, 2008/2009 data used 
xxix Regional data 
xxx No 2004 and 2010 data available, only 2003 and 2009 data used 
xxxi No data for 2010 available, 2008/2009 data used 
xxxii No 2003 and 2010 data available, only 2005 and 2009 data used 
xxxiii No 2009 data, 2008/2010 data used 
xxxiv No 2003/2004 data, 2005/2006 data used 
VI / Main report - long version   149  
Table 13.1 shows that most of the countries have either experienced an increase in 
drug-induced deaths or not recorded any significant changes. Only Denmark, Spain 
and Italy have experienced a significant decrease comparing 2009/2010 to 
2003/2004. Looking at the HIV data, there seems to be a more positive trend and 
most countries have experienced a decrease or no significant changes. Only Bulgaria, 
Greece, Lithuania and Romania show a significant increase in HIV infections among 
injecting drug users.  
13.1.1 Association of HIV and drug-induced deaths 
As already indicated in Table 13.1, an increase (or decrease) in HIV infections among 
injecting drug users is not associated with an increase (or decrease) of drug-induced 
deaths in most countries (only Bulgaria, Romania and Lithuania show an increasing 
trend in drug-induced death and HIV rates). This does not come as a surprise, as the 
literature review reveals (see chapter 10) that infectious diseases among injecting drug 
users and drug-induced deaths are influenced partly by different harm reduction 
measures. Only OST is found to be effective in reducing HIV infection rate and in 
reducing the numbers of drug-induced deaths. 
The correlation of the numbers of drug-induced deaths per 100.000 inhabitants in the 
EU countries with the available data and the numbers of HIV infections acquired via IDU 
per 100.000 inhabitants in EU countries with the available data is low. The association 
between HIV rates and drug-induced deaths rates varies between 2003 and 2010 from 
0,265 in 2004 to 0,567 in 2007 (Spearman-correlation). Generally speaking, it is 
difficult to identify countries, where low HIV rates are accompanied by low drug-
induced deaths rates and vice versa for most of the years. 
This correlation analysis and the results from Table 13.1 show that the numbers of 
drug-induced deaths and the numbers of newly diagnosed HIV infections among IDUs 
do not follow the same trends and are probably not influenced by the same factors (in 
accordance with results from the literature review – see above).  
13.2 Coverage of harm reduction measures  
As the first step, the coverage of harm-reduction measures in the EU is presented 
according to the definition of the EU 15 and the EU 12, as well as the candi-
date/acceding countries. The same differentiation but a different form of presentation 
was used in chapter 12. In order to provide a quick overview, the mean data for 
coverage/availability of CR 3 and CR 2.9 (infectious diseases) are presented. Figure 
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13.1 shows clearly that the EU 15 Member States report a broader coverage for all 
harm reduction measures stated in the Council Recommendation. The highest cover-
age is reported for counselling from the EU 15 and the EU 12 as well as the candi-
date/acceding countries. The harm reduction in prison is broadly lacking in particular 
in the EU 12. The coverage of harm reduction among the candidate/acceding countries 
does not provide a clear picture: the coverage/availability of some harm reduction 
measures is higher than in the EU 15, other harm reduction measures have a lower 
coverage/availability than in the EU 12.  
Figure 13.1: 
Coverage of harm reduction measures in EU 15 and EU 12 and candidate/acceding 
countries 
  
DRID=drug-related infectious diseases, OST=opioid substitution treatment 
Remark: Data refer to: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, 
Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, Croatia, the former Yugoslav Republic of 
Macedonia, Montenegro, Iceland, Turkey; The full wording of all CRs can be found in section 15. 
Coverage: 1=not available, 2=rare, 3=limited, 4=extensive, 5=full coverage 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
As mentioned above, the comprehensive overview of harm reduction measures and 
drug-related harm did not produce a consistent pattern of countries (see Table 13.1). 
In order to identify the association of drug-related harm and the coverage of available 
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measures, the following figures present the coverage of harm reduction measures 
(results from the policy questionnaire) according to countries with different trends of 
drug-induced deaths resp. HIV between 2003/2004 and 2009/2010.  
Figure 13.2: 
Coverage of harm reduction measures in countries with increasing, stable or 
decreasing numbers of drug-induced deaths 
 
DRID=drug-related infectious diseases, DRD=drug-induced death, OST=opioid substitution treatment 
Remark: Data refer to: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Romania, Slovakia, 
Slovenia, Spain, Sweden, United Kingdom, Croatia, Montenegro, Turkey; The full wording of all CRs can be 
found in section 15. 
Coverage: 1=not available, 2=rare, 3=limited, 4=extensive, 5=full coverage 
Source: GÖ FP, policy maker survey, Table 13.1; graphic representation: GÖ FP 
Figure 13.2 shows that countries that have experienced a significant decrease in drug-
induced deaths (Denmark, Spain and Italy; see Table 13.1) report the highest coverage 
of harm reduction measures. The pattern is less consistent comparing increasing and 
stable trends to the coverage/availability of harm reduction measures, but countries 
with an increase in the numbers of drug-induced deaths (Bulgaria, Estonia, Finland, 
France, Ireland, Lithuania, Poland, Romania, Sweden, United Kingdom and Turkey) tend 
to have a little lower coverage/availability than those with stable trends (Austria, 
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Cyprus, Czech Republic, Germany, Greece, Hungary, Latvia, Luxembourg, Malta, 
Netherland, Slovakia, Slovenia, Croatia).  
Looking at the differences of coverage, in particular “integration of services” (CR 2.12), 
the availability of “drug treatment” (CR 2.6) and “harm reduction in prison” (CR 2.8) 
indicate the biggest gaps. A direct causal association between a high coverage of harm 
reduction measures in these fields and a decrease in the number of drug-induced 
deaths cannot be deducted, but it gives a strong hint for the direction of further 
research and analysis.  
Figure 13.3: 
Coverage of harm reduction measures in countries with increasing, stable or 
decreasing numbers of HIV acquired via IDU 
DRID=drug-related infectious diseases, OST=opioid substitution treatment 
Remark: Data available for: Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Spain, Sweden, 
United Kingdom, Croatia, Montenegro; The full wording of all CRs can be found in section 15. 
Coverage: 1=not available, 2=rare, 3=limited, 4=extensive, 5=full coverage 
Source: GÖ FP policy maker survey, Table 13.1; graphic representation: GÖ FP 
Figure 13.3 shows the reported coverage of harm reduction measures in the EU (from 
the policy questionnaire) according to increasing, decreasing or stable trends of newly 
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diagnosed HIV infections among injecting drug users. The picture is less consistent 
than for the trend concerning drug-induced deaths. Countries with a significant 
increase in HIV-infections via IDU (Bulgaria, Greece, Lithuania, Romania) report lower 
coverage/availability of most harm reduction measures than countries with stable or 
decreasing rates. The “integration of services” (CR 2.12) again shows the greatest 
differences, with the lowest coverage reported in those countries that show an increas-
ing trend in IDU-related HIV infections, followed by harm reduction in prison. It is 
important to note that harm reduction measures associated with infectious diseases in 
particular (e. g. screening) in CR 2.9 show higher coverage for countries with stable or 
decreasing trends than those with HIV increase, but the differences are rather slim.  
13.3 Influence of the Council Recommendation 
on harm reduction measures 
Figure 13.4: 
Impact of the Council Recommendation on the coverage of harm reduction measures in 
the EU and candidate countries 
 
Data available for: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, the former Yugoslav Republic of 
Macedonia, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, 
Croatia, Iceland, Montenegro, Turkey; The full wording of all CRs can be found in section 15. 
Impact: 1=no impact, 5=very strong impact 
Source: GÖ FP, policy maker survey; graphic representation: GÖ FP 
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The impact of the Council Recommendation on the coverage/availability of harm 
reduction measures was higher (reported by the policy makers) in the EU 12 than in the 
EU 15. In the EU 15 the Council Recommendation was mainly considered to have had 
little impact, whereas in the EU 12 a medium impact was described. Again, the candi-
date/acceding countries show no clear picture, but the impact of the Council Recom-
mendation was higher in the candidate countries than in the EU 15. It is important to 
keep in mind that the EU 15 report a higher coverage of harm reduction measures (see 
Chapter 12 and Figure 13.1) and have a higher “starting point”, for example regarding 
needle exchange and OST.  
The highest impact of the Council Recommendation was measured on the coverage of 
“condom distribution” in the candidate and acceding countries and in “counselling” and 
“distribution of injection material” in the EU 12. The impact of the Council Recommen-
dation in the EU 15 was on average “little”, for instance almost no impact on the 
prevention of diverting the substitution medications to the black market and no impact 
on the prevention of diversion of substitution medications to the black market and 
availability of naloxone in emergency services was reported. 
13.4 Modelling the influence of the Council 
Recommendation on harm reduction 
As discussed in chapter 13.1.1, the numbers of drug-induced deaths and the number 
of HIV infections via IDU show no stable correlation. This means that a high number of 
drug-induced deaths is not necessarily associated with a high number of HIV infec-
tions. Additionally, the literature review (see chapter 10) identified partly different 
influencing factors for overdoses and HIV infections. Due to these theoretical and 
empirical restraints, it was assumed that a general model including drug-induced 
deaths and HIV as an indicator of the effectiveness of harm reduction measures will 
not provide solid results. Therefore two models to measure the influence of the 
Council Recommendation on harm reduction were developed: one for HIV and one for 
drug-induced deaths. The models are calculated based on population rates and trend 
data. As stated above (see chapter 11), the quality of the numbers of drug-induced 
deaths and newly diagnosed HIV infections among injection drug users reported to the 
EMCDDA and ECDC varies dramatically and modelling the coverage of harm reduction 
services on low and high rates would be based on potentially biased data. It is as-
sumed that the data collection systems in place did not change dramatically over the 
last few years and therefore conclusions regarding valid trends can be drawn from the 
provided data. 
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13.4.1 Modelling the influence of the Council 
Recommendation on harm reduction 
measures and drug-induced deaths 
Factors that influence the risk of (opioid) overdoses identified by Darke and Hall 
(Darke/Hall 1997) - see also chapter 10.3) are opioid substitution treatment (OST), 
reducing risk factors (risk factor counselling in particular at prison release), improving 
responses at overdoses (i.e. cardiopulmonary resuscitation, ambulance services and 
police agreements), provision of naloxone, interventions to change the route of 
administration, medically supervised injecting rooms and heroin maintenance. 
The Council Recommendation includes OST (CR 2.6), harm reduction in prisons 
(CR 2.8), preparation of emergency services to deal with overdoses (CR 2.11), integra-
tion of services (CR 2.12) and professional training on the reduction of health-related 
risks associates with drug dependence (CR 2.13). Those recommendations cover partly 
the above mentioned influencing factors of drug-induced deaths. However, major 
impact factors, such as peer naloxone provision (see chapter 10.3.2), are not covered 
by the Council Recommendation explicitly and therefore cannot be modelled.  
In the first step, a regression analysis for the stated variables on significant changes on 
the number of drug-induced deaths was performed (R2=0,665). Only integration of 
services showed a significant (alpha=0,05) impact.  
The general model for the impact of the Council Recommendation, the coverage of 
OST, harm reduction in prison, the preparation of emergency services and the profes-
sional training on the numbers of drug-induced deaths among people aged 15-64 
shows a high probability level (chi-square: 206; df: 96; Figure 13.5). However, the 
model does not produce any significant association between the latent variables (drug-
induced deaths rates in Europe, the impact of Council Recommendation and the 
coverage of selected harm reduction measures). The impact of the Council Recommen-
dation shows a negative association to the overdose rate (suggesting that high impact 
would lead to lower drug-induced death rates), but the association is not significant. 
No significant association between “coverage of harm reduction measures” and “drug-
induced deaths” was found.  
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Figure 13.5: 
Model impact of the Council Recommendation and coverage of harm reduction on 
rates of drug-induced deaths21 
 
Impact: 1=no impact, 5=very strong impact; Coverage: 1=not available, 5=full coverage; DRD rate: drug-
induced deaths among 15-64 aged population per 100.000 
Source: GÖ FP policy maker survey; EMCDDA Statistical Bulletin 2012, Table DRD-2;  
graphic representation: GÖ FP 
                                                                                                                                         
21 
Country included in the analysis: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, United Kingdom, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, 
Poland, Romania, Slovenia, Spain, Sweden, Croatia and Turkey. For policy makers stating that the impact of the 
Council Recommendation was unclear, the impact was considered “no impact”. This was necessary to overcome 
the substantial missing data concerning the impact of the Council Recommendation. If the coverage of 
treatment was unknown no coverage was assumed in order to minimize missing data. Drug-induced death 
rates (DRD): only 2004 to 2009 data used. Turkey: the drug-induced deaths rates for 2004 were taken from 
2005 for DRD rates 2007 the mean of 2006 and 2008 data used. Denmark: the DRD rates for 2004 were taken 
from 2005. 
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As already detected in an earlier factor analysis, the different coverage of harm reduc-
tion measures show rather low correlations. This can be seen in particular for the 
variable “availability/coverage of emergency services adequately prepared to deal with 
overdoses”: The “coverage of emergency services” is not explained/influenced by the 
latent variable “coverage of services”. The availability of harm reduction measures in 
prison also shows a very low squared multiple correlation with “coverage of services”. 
This (together with the conducted factor analysis) indicates that a high (or low) cover-
age of emergency services and harm reduction in prisons is not correlated with high 
(or low) coverage of OST or integration of services. On the contrary, a high (or low) 
impact of one part of the Council Recommendation is correlated with a respectively 
high (or low) influence of other parts of the Council Recommendation.  
Figure 13.6: 
Model: Coverage of harm reduction on changes in drug-induced deaths22 
Coverage: 1=not available, 5=full coverage; drug-induced deaths (DRD): 1=significant increase from 2003 to 
2010, 2=no significant change, 3=significant decrease from 2003-2009 
Source: GÖ FP policy maker survey; Table 13.1; graphic representation: GÖ FP 
A model just for the coverage and the significant changes in the number of drug-
induced deaths (see Figure 13.6) was also calculated. The model analyses the effect of 
low or high coverage of harm reduction measures associated with drug-induced 
                                                                                                                                         
22 
Country included in the analysis: Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, United Kingdom, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 
Netherlands, Poland, Romania, Slovenia, Spain, Sweden and Turkey. If the coverage of treatment was unknown 
no coverage was assumed in order to minimise missing data 
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deaths (as stated by the policy makers) and significant increases, decreases or stable 
trends among drug-induced deaths. 
The model shows a significant influence of “Coverage of harm reduction measures” on 
the trends of drug-induced deaths (32 % of the variance in the trends of drug-induced 
deaths are explained by the factor “coverage”). When the coverage goes up, the 
chances of a stable or decreasing number of overdoses goes up. As mentioned above, 
the latent variable “coverage” mainly explains the variations within the “integration of 
services”, “professional training on the reduction of health-related risks associates 
with drug dependence” and “OST”.  
13.4.2 Modelling the influence of the Council Recom-
mendation on harm reduction and HIV infec-
tions acquired via IDU 
Harm reduction measures aimed at reducing HIV infections among injecting drug users 
include (see also chapter 10.2) OST, needle exchange programmes and prophylactic 
and treatment measures, as well as needle exchange in prison. The Council Recom-
mendation covers OST (CR 2.6), prophylactic and treatment measures (CR 2.9) and 
distribution of injection materials and condoms (CR 2.10). Those variables are analysed 
in order to model the effect of these harm reduction measures on HIV. As stated 
above, the analysis is conducted in order to study the impact of the Council Recom-
mendation and the impact of the harm reduction measures on the HIV rates and the 
HIV-trends. All models show a good model fit, but looking at the factor loadings, the 
results are rather inclusive. The baseline model focuses on the influence of the Council 
Recommendation and harm reduction measures on the HIV rates. Countries that report 
a high impact of the Council Recommendation on the distribution of injecting materials 
report higher HIV rates and therefore a high impact is significantly associated with 
high HIV rates23. A high impact of CR 2.9 (prophylactic measures), in turn, is associ-
ated with a significant negative influence on HIV rates. The OST coverage shows a 
significant negative association with HIV rates. If the same model is calculated without 
the impact of the Council Recommendation, OST is again negatively associated with 
HIV rates (the high OST coverage leading to lower HIV rates) and no significant asso-
ciation between the distribution of injecting material and other prophylactic measures 
(e. g. screening) is found. 
                                                                                                                                         
23 
This can partly be explained by the higher impact of the Council Recommendation in the EU 12, which also 
report higher HIV infection rates.  
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Figure 13.7: 
Model: Coverage of harm reduction on changes in drug-related HIV infections24 
Coverage: 1=not available, 5=full coverage; Land_HItrend: 1=significant increase from 2003 to 2010, 2=no 
significant change, 3=significant decrease from 2003-2009 
Source: GÖ PF policy maker survey; Table 13.1; graphic representation: GÖ FP 
When looking at the significant changes in HIV rates from 2003 to 2010, the picture 
changes. Now, a high coverage of injecting materials and prophylactic measures 
associated with a decrease in the number of newly diagnosed HIV infections and high 
rates of OST coverage and treatment options show negative associations (e. g. high 
coverage implies stable or increasing trends). Due to these different outcomes refer-
ring either at the rates or the trends, a general conclusion for the impact of harm 
reduction on new HIV infections among IDUs cannot be drawn from this model.  
                                                                                                                                         
24 
Country included in the analysis: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, United Kingdom, Greece, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, 
Romania, Spain, Sweden. If the coverage of treatment was unknown, no coverage was assumed in order to 
minimise missing data. 
160  GÖ FP, Sogeti, Report on the current state of play of the 2003 CR on harm reduction 
14 Conclusions and recommendations 
This report provides an overview of the availability and coverage of harm reduction 
measures in the EU, Croatia, the former Yugoslav Republic of Macedonia, Iceland, 
Montenegro and Turkey and discusses the evidence of their effectiveness. A special 
focus was put on the impact of the Council Recommendations and on developing 
recommendations for improvements in the field of harm reduction. The following 
conclusions and recommendations are based on the literature review, the analysis of 
the current situation and the recommendations of the stakeholders for future interven-
tions. First, general conclusion on the effectiveness of the interventions are presented 
and discussed. In a second step, concrete recommendations have been elaborated, 
addressing the EU level, the national level and the harm reduction sites.  
There exists strong scientific evidence for the effectiveness of opioid substitution 
treatment (OST) to reduce the infection risk in connection with drug-related infectious 
diseases as well as mortality. Interruptions of OST are a risk factor for drug-induced 
deaths. Challenges for the future are to clarify how the coverage can be increased 
further (e. g. to avoid waiting lists), how interruptions can be avoided and how OST 
concerning substances and regimes can be diversified to meet the needs of different 
subgroups of opioid addicts. As for the syringe provision through specialised pro-
grammes, there is strong scientific evidence concerning the reduction of infection risk, 
too. Challenges include improving the coverage and dealing with other routes of 
administration. On the one hand, it has to be clarified if and how needle exchange 
programmes (NSPs) can be used to promote other ways of administration than IDU. On 
the other hand, there are signs that injecting as a route of administration is decreas-
ing, while delivering safer use materials and information for other routes of admini-
stration gets more relevance. Information, education and communication are effective 
when the setting is appropriate and messages are provided in an adequate form by 
trustable persons. One possibility to assure the right setting is outreach work. Since 
peers are the most trustable persons in many aspects peer involvement which has 
proven to be effective is a good strategy. In the last decade, the evidence on heroin 
assisted treatment as a second line intervention, drug consumption rooms and peer 
naloxone programmes has increased a lot. Based on this evidence, it can be assumed 
that these interventions are effective, but they should be further monitored and 
evaluated. There is strong evidence concerning the effectiveness of harm reduction in 
prison. Vaccination for hepatitis B, treatment of HIV, HBV and HCV in IDUs are effective 
measures. The treatment for HCV is a particularly effective instrument of infection 
prevention for others, too. Drug Checking is considered an integrated service that 
always combines chemical analysis with advice or counselling. Although there is no 
new evidence on the effectiveness of Drug Checking programmes, it might be worth to 
conduct new studies; on the one hand, because Drug Checking/counselling might be a 
reaction to the emerging of new psychoactive substances on the markets, on the other 
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hand, because professionalisation took place concerning testing and counselling 
methods during the last few years. The possible benefit of measures to avoid shifting 
from other routes of administration to injecting drug use (IDU) and to foster shifting 
from IDU to other routes of administration is pointed out in scientific literature. 
However, there is hardly any evidence on concrete projects 
To summarise the epidemiologic situation concerning drug-related harm, it can be 
stated that a significant reduction of HIV infections among IDUs in most countries has 
been achieved but infection rates of hepatitis C are still high in many countries. Recent 
HIV-outbreaks in Greece and Romania show that HIV infection rates can increase 
rapidly under specific conditions including low coverage of harm reduction measures. 
High rates of HCV infection can be seen as an indicator for the risk of a HIV-outbreak. 
It was not possible to reduce direct drug-induced deaths since 2003 in most countries, 
although coverage of OST has increased. On the one hand, measures to improve 
retention rates in OST and to avoid interruptions (e. g. prison, attempts to become 
drug-free with no adequate indication) are necessary. On the other hand, interventions 
focusing on overdose risk, such as drug consumption rooms and peer naloxone 
programmes, should be considered. Prison release is a risk factor for overdoses. 
Adequate throughcare including prison release management and continuation of OST 
in prison as well as over the period of release is crucial. 
The situation concerning harm reduction measures has improved significantly in most 
countries. Coverage of OST and NSP has increased considerably but especially NSP is 
still far from having full coverage in all countries. While OST is now available in many 
prisons, NSP is not. Therefore, prisons still constitute a high risk environment for 
infections with HIV or HCV and a driving factor for infectious diseases among injecting 
drug users (IDUs). Therefore, improvements in the prison setting are very urgent. 
Heroin assisted treatment as a second line intervention, Drug Checking, peer naloxone 
programmes and drug consumption rooms have been implemented only in a few 
countries. In the times of economic crises, the financing of the status quo and the 
expansion of harm reduction is an important issue in all countries. Some EU 12 
Member States (e. g. Bulgaria and Romania), where harm reduction projects were 
initially funded by the Global Fund to Fight AIDS, Tuberculosis, and Malaria, are 
currently struggling to ensure national funding. 
The role of the Council Recommendation on harm reduction can be judged as impor-
tant, especially in the countries joining the EU in 2004 or later (EU 12). A further 
support on the EU level is requested from organisations involved in harm reduction. A 
clear new statement on harm reduction can help to foster the expansion of harm 
reduction measures. These EU recommendations should include in particular new 
measures, like drug consumption rooms and peer naloxone programmes related to the 
reduction of drug-induced death, and give a special focus to prisons (OST, NSP and 
adequate throughcare). In addition, the new recommendations should cover new areas 
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like housing, social re-integration and occupation because these are the main factors 
for stabilisation (or de-stabilisation if lacking). However, also existing harm reduction 
measures such as OSP and NSP as the backbone of any harm reduction strategy need 
to be strengthened. 
There has been very good progress in data availability in the time-span from 2003 to 
2010. Thanks to the continuous efforts of the EMCDDA towards the harmonisation and 
expansion of data collection, a lot of comparable data that allow describing the 
epidemiology of the drug situation and harm reduction measures are available. 
Unfortunately, data for time-series are not available for all countries; even basic data 
to analyse drug-related harm and availability of measures of harm reduction are 
missing in some countries. It has to be taken into account that absolute numbers (e. g. 
number of drug-induced deaths) are influenced by the quality of the respective 
monitoring system, too. Therefore country-specific comparisons have to be made with 
caution and should be avoided for some countries entirely. The implementation of 
adequate evaluation protocols for all drug prevention and risk reduction programmes, 
as well as the involvement of all actors and stakeholders in evaluation could be 
improved.  
Based on the literature review and the analysis of the situation concerning harm 
reduction, the following concrete recommendations have been elaborated. These 
recommendations implicate activities on different levels: EU-policy-level, national-
policy-level and the level of practical implementation in the field. 
14.1 Political strengthening of harm reduction 
Harm reduction still does not remain politically undisputed. While in many countries 
harm reduction measures have become well-implemented in the last decade, in some 
countries steps backwards can either be observed or are feared. Moral barriers and the 
prioritisation of abstinence-orientated services by some decision makers remain major 
obstacles for harm reduction services (stakeholder survey). Many stakeholders express 
concerns regarding the financing of harm reduction measures in the future due to the 
financial crisis. However, there are also objections by uninformed or despondent 
decision makers. The harm reduction approach should be strengthened further in a 
follow-up policy work at the EU level. 
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14.2 Syringe provision through specialised 
programmes 
Syringe exchange for injecting drug users (IDUs) is an integral part of drug policies in 
all EU Member States and candidate countries, with the exception of Turkey. However, 
nearly all countries where respective data are available miss the WHO, UNODC, UNAIDS 
criteria of 200 syringes per IDU per year for good coverage concerning HIV prevention. 
This is a major obstacle, given that the levels required for the prevention of hepatitis C 
(HCV) are likely to be much higher. Activities to improve the coverage of the availability 
of sterile needles and syringes especially in rural areas are needed. Especially countries 
with an increase of HCV prevalence (Austria, Bulgaria, Cyprus, Greece and Romania) or 
of newly diagnosed HIV or high HIV rates among IDUs (Bulgaria, Estonia, Latvia, 
Lithuania, Greece, Portugal, Romania) are called upon to take some actions. 
14.3 OST improvement of coverage and organisation 
Coverage of OST has increased significantly since 2003. However, not in all countries 
coverage is regarded as full or extensive, and waiting lists for OST are common. Other 
challenges for practice and research are the diversification of OST according to sub-
stances used and of routes of administration and regimes (e. g. OST via drug treatment 
centres versus OST via general practitioners) in order to meet the needs of different 
groups of clients. The main purpose should be to avoid interruptions which are a risk 
factor, especially concerning drug-induced deaths. In this respect, clear indications for 
the change from OST to drug-free treatment are needed because failed attempts to 
become drug-free might increase the risk of overdoses. Another factor in avoiding 
interruptions is that the parallel consumption of other drugs should not be a reason to 
suspend someone from OST. Only Spain, Italy and Denmark have experienced a 
significant decrease in drug-induced deaths during the last decade. Thus, improve-
ments in this field seem to be necessary in almost all countries. In addition, heroin 
assisted treatment should be expanded as a second line intervention. 
14.4 Harm reduction in prison 
While OST is now available in many prisons, syringe provision through specialised 
programmes (NSP) is not. The coverage of harm reduction in prison is estimated to be 
very low in general. Therefore, prisons are still a high risk environment for infection 
with HIV or HCV and a driving factor for infectious diseases among IDUs. There is a 
high risk of fatal overdoses after prison release which shows the importance of ade-
quate prison release management (throughcare). The conclusion is that a lot has to be 
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done in this area. The implementation of NSP, which is possible and effective (see 
Spain for example), as well as the improvement of OST coverage and adequate 
throughcare including prison release management (assuring continuation of OST in 
prison and after prison release) is necessary. To speed up the full implementation of 
harm reduction measures in prison, this issue should be especially highlighted in a 
follow-up policy work at the EU level.  
Example: Spain provides a high standard and elaborated prison-based harm reduction 
programme that includes also pre-release education and post-release treatment 
referral to community services (WHO 2010).  
Example: Models of good practice in pre-release counselling on overdose risks or 
overdose prevention training were identified in Belgium (Flemish prisons) and Portugal. 
14.5 Naloxone “take-home” programmes 
Asked which implementation/expansion of harm reduction measures would have the 
biggest effect on reducing the numbers of drug-induced deaths (due to overdoses) in 
the respective country/region, first aid training for drug users and naloxone “take-
home” programmes were quoted most often by civil society organisations. Based on 
the results from the evaluation studies, the recommendations from experts and the 
analysis of the objections against naloxone, it can be concluded that naloxone is a safe 
drug to use and peer naloxone programmes – in combination with emergency training 
– should be expanded in Europe to decrease the number of drug-induced deaths.  
Example: In the United Kingdom, the project “Take Home Naloxone” (THN) provides 
training on the administration of naloxone and first-aid in case of an overdose event. 
After the training has been completed, THN kits are issued to opiate users and their 
carers (EDDRA). 
14.6 Use of emergency services 
The use of emergency services is an important aspect in preventing drug-induced 
deaths. However, the use of emergency services and its impact on harm reduction is 
hardly studied. One major aspect is the (perceived) risks of police arrests associated 
with calling emergency services or the fear of violating conditions of probation. More 
research is needed to identify and overcome obstacles (e. g. legal implications) when 
calling ambulance services during an overdose in Europe. Furthermore, it is important 
that expenses for the hospital stay as well as for the rescue effort are paid by the 
health insurance and not by the patient. 
VI / Main report - long version  165 
Example: In Luxembourg, a law exempts drug users who call for assistance in case 
another user is in need of medical help from prison sentences and from fines in certain 
circumstances. In general, witnesses meeting these conditions are not prosecuted. As 
an accompanying measure, an information flyer has been elaborated jointly with field 
agencies and the Ministry of Health and broadly distributed. The flyer contains useful 
information on safer injection and advice in case of overdose events (NFP-Luxembourg 
2011).  
14.7 Drug consumption rooms 
It was not possible to reduce the number of drug-induced deaths in most of the 
countries from 2003 to 2009 (see section 11.3). Additional measures focusing on 
preventing drug-induced deaths are necessary. According to the stakeholders, the 
implementation of drug consumption rooms would be the second most effective 
measure to reduce drug-induced deaths after peer naloxone programmes. Based on 
evidence from recent literature on the effectiveness to reduce mortality and on the 
absence of negative consequences of consumption rooms, this measure can be 
recommended. Implementation should be accompanied by adequate monitoring and 
evaluation in order to strengthen the scientific base. 
Example: In Germany, 28 drug consumption rooms exist with the objective to secure 
survival and stabilisation of the health conditions of drug users, as well as to reach 
those drug users, who are not in contact with the drug help system otherwise. Drugs 
are brought along to the drug consumption rooms by the drug users and infection 
prophylaxis is systematically provided by the staff. Minimum standards are defined in 
the Narcotics Act (NFP-Germany 2011). 
14.8 Counselling, outreach and peer involvement 
Counselling and outreach are mainly part of other interventions and proved to be 
effective when the setting is appropriate and messages are provided by trustable 
persons. In particular, peer delivered counselling including outreach fulfils these 
criteria (see section 10.2.3). The coverage of outreach is estimated to be at least 
extensive in roughly half of the countries and peer involvement in just one third of the 
countries (see section 12.6). The coverage of outreach and peer involvement in coun-
selling should be improved. 
Example: In Finland, an active participation of substance abusers is seen as crucial to 
reach the most excluded and most concealed client groups and to provide access to 
services with low threshold. This approach is used for example by the Osis project, a 
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centre of excellence in peer support for drug users in the Greater Helsinki area (coun-
try profile Finland – see annex 1). 
Example: In Belgium, peers are trained within the snowball operations project to 
distribute information and harm reduction material among injecting drug users and 
other drug users who rarely have contact with drug help services. The training is 
carried out in six sessions of approximately two hours. The peers are asked to contact 
about ten drug users and recruit new volunteers among those (EDDRA). 
14.9 Access to HCV treatment 
Only 31 % of the countries in the stakeholder survey rate the coverage of medical 
treatment of HCV for injecting drug users as full or extensive. Many stakeholders state 
that increasing the coverage of HCV screening and treatment is a great challenge 
today. Scientific studies show that an integrated approach using needle exchange as 
well as HCV treatment is needed to reduce the prevalence of HCV, especially in high 
prevalence countries. The expansion of coverage of HCV screening and treatment 
should be improved. 
14.10 HBV vaccination 
HBV vaccination is effective for IDUs and especially important if there is already an HCV 
infection, because this leads to additional complications (see section 10.2.6). Taking 
into account the high rates of HCV infections among IDUs in most countries (see 
section 11.2.2), the low coverage of HBV vaccination (only 7 countries report full 
coverage; see section 12.7) is critical. Measures to improve HBV vaccination coverage 
are necessary. 
Example: In Denmark free vaccination against hepatitis A and B is offered to drug 
abusers (country profile Denmark – see annex 1). 
14.11 Housing 
Housing was not covered by the Council Recommendation but is a relevant issue for 
improving the quality of life and stabilisation. Housing seems to be a field of harm 
reduction where still a lot of improvement is necessary, as all measures (night shelters, 
assisted living, “housing first” approach) are described to have a rather low coverage 
(stakeholder survey). For night shelters, which is the measure with the highest cover-
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age, only 24 % report full or extensive coverage. The problem of housing should be 
considered in follow-up policy work. 
Example: In Austria, Supervised Housing provides accommodation for people with 
drug-related problems. Targeted clients are those who are homeless, but relatively 
stable in their drug use, and who live in Vienna. This also includes couples and people 
with children. After a maximum of 2 years within this programme, clients are able to 
move into their own accommodation (EDDRA). 
14.12 Integration of services 
The integration of services between health, social care and risk reduction is reported to 
be full or extensively covered in most countries. However, countries that have experi-
enced significant increases in drug-induced deaths report limited, rare or no coverage. 
The integration of services such as hospital release management (integrating health 
and social care) and treatment release management should be considered a priority in 
order to reduce the number of fatalities due to overdoses. Throughcare and prison 
release management are also very important issues (see above). 
Example: In Portugal, a national network of harm and risk reduction structures (RRMD) 
has been established since 2001, which provides alternative paths leading to stabilisa-
tion and treatment. One of its elements is the early identification and prevention of 
HIV/AIDS among drug users (the Klotho Programme), which should be finally inte-
grated in local healthcare structures. Meanwhile, this programme is incorporated in all 
RRMD structures (country profile Portugal – see annex 1). 
Example: In Austria, the cooperation between the healthcare system and the drug help 
system is strengthened by CONTACT, a liaison service for hospitals. This service is 
provided in Vienna with the objective to stabilise drug users who are in hospital care 
after non-fatal overdoses by connecting them with a suitable service of the drug help 
system (EDDRA). 
Example: The “Through the gate” scheme in Wales includes “in-reach”, prison gate 
pick-up, assertive outreach, local networking and enhanced engagement with support 
services (EMCDDA 2012h). 
14.13 Research 
There has been very good progress in data availability in the time-span from 2003 to 
2010. Thanks to the continuous efforts of the EMCDDA towards the harmonisation and 
expansion of data collection, a lot of comparable data that allow describing the 
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epidemiology of the drug situation are available. Unfortunately, the data for time-
series are not available for all countries, not even the basic data to analyse drug-
related harm and the availability of measures of harm reduction can be found. The 
following priority areas where measures for improvement and targeted research 
related to harm reduction are necessary have been identified: 
» The improvement of coverage of estimates for the prevalence of problem drug use, 
especially the injecting drug use 
» The mortality rates directly related to overdoses (drug-induced deaths) differ to a 
large extent between countries. Research is needed to get insight if these differ-
ences are real (important information for policy evaluation) or due to the different 
quality of data collection systems 
» More standardised data and longitudinal research to follow the development of 
HCV epidemics are needed 
» The proportion of injecting as a route of administration of opioids differs a lot 
between countries. Research is needed to get insight into the reasons behind this 
and based on the results, measures to shift away from injection or to avoid shifting 
to injection from other routes of administration should be developed – if possible 
» The implementation of adequate evaluation protocols for all drug prevention and 
risk reduction programmes that involve all actors and stakeholders in evaluation is 
needed 
Example: In the United Kingdom, quality standards for drug use disorders, which are 
based on scientific evidence, are provided by the NHS.  According to the NHS, these 
quality standards describe markers of high-quality, cost-effective care that, when 
delivered collectively, should contribute to improving the effectiveness, safety and 
experience of care for people with drug use disorders. The NHS recommends though, 
to consider also national and local guidelines on training and competencies, for 
example competencies set out in the Drugs and Alcohol National Occupational Stan-
dards (DANOS) (NHS; http://publications.nice.org.uk/quality-standard-for-drug-use-
disorders-qs23/introduction-and-overview). 
Example: In Denmark, on the basis of a national action plan, 19 specific and new 
initiatives were launched in October 2010, including initiatives in the area of harm 
reduction. These initiatives are monitored on an ongoing basis and evaluated with the 
purpose to adjust the national drug policy (NFP-Denmark 2011). 
14.14 Priorities for a new Council Recommendation 
The Council Recommendation (CR) helped to foster harm reduction in the EU, but the 
coverage is still far from sufficient in most of the areas. These calls for political 
strengthening of harm reduction which can be achieved by a new or revised CR. Based 
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on the analysis of the situation and scientific evidence, the following priorities shall be 
addressed:  
Priority A: The reduction of drug-induced deaths 
Reasoning: It has not been possible to reduce the number of drug-induced deaths 
since 2003. 
Target: significant reduction of the number of drug-induced deaths in the next ten 
years. 
Proposed measures: Improvement of coverage (for specific subgroups of opioid 
addicts, low threshold access to OST, comprehensive health insurance covering OST) 
and organisation of opioid substitution treatment (avoid interruptions, avoid waiting 
lists), facilitating the use of emergency services, peer naloxone programmes, integra-
tion of services (especially prison and treatment release management), drug consump-
tion rooms, outreach, peer involvement and family support. 
Relevance for public health: Drug-induced deaths remain one of the major causes of 
deaths among young adults, which call for immediate action. In particular, easy-to-
adopt and cost-effective measures, such as facilitating the use of emergency services 
should be addressed and supported on the European level in order to save young lives.  
Priority B: The improvement of harm reduction in prison 
Reasoning: The coverage of harm reduction measures in prison lies far behind cover-
age outside prison. Therefore prison is a high-risk environment for injecting drug 
users (IDUs) to get infected with drug-related infectious diseases. Prison release 
without adequate throughcare is one of the main risk factors for drug-induced deaths. 
Target: harm reduction measures in prison should be assured as a comprehensive 
response, equivalent to the community in the next ten years.  
Proposed measures: Opioid substitution treatment (OST), syringe provision through 
specialised programmes (introduction in all prisons), release management, through-
care into and out from prison (regarding OST continuity), housing for released prison-
ers, health assessments including infection prevention.  
Relevance for public health: Harm reduction in prison is still very rare or limited in 
Europe, leading to high infections rates and increased mortality after prison release. 
Around 15 % of all drug-related deaths could be avoided with adequate prison release 
management only (Frisher et al. 2012) 25. High infection rates (e. g. HIV, hepatitis) of 
prison population threaten the health of the general population, too. Good prison 
health is good public health (WHO 2007). Action in this field promises instant results 
                                                                                                                                         
25 
In 2005, 1.506 drug users died in England from ‘overdose’ or poisoning, drug abuse or drug dependence. 
Around 15% of these deaths occur in people after release from prison. Those fatalities might be avoided with 
adequate and coordinated prison release management (Department of Health 2007; Frisher et al. 2012). 
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and can be implemented cost-effectively (e. g. syringe provision through specialised 
programmes).  
Priority C: The reduction of harm caused by drug-related infections 
Reasoning: Existing harm reduction measures have been sufficient to decrease HIV 
prevalence in injecting drug users (IDUs) significantly in most countries covered with 
this research. Recent HIV outbreaks show that this situation can change very fast when 
harm reduction is not appropriate. Hepatitis C (HCV) rates are still on a high level and 
will lead – if reaction is not adequate – to enormous individual (e. g. death due to 
consequences of HCV) and public costs. 
Target: Significant reduction of HCV prevalence among IDUs in the next five years, 
significant reduction of HIV incidence in countries with high rates or increasing trends 
(Bulgaria, Estonia, Latvia, Lithuania, Greece, Portugal, Romania) in the next five years, 
treatment (especially HCV treatment) of infected IDUs shall reach full coverage in the 
next five years (treatment should be available for everyone who needs it), HBV vaccina-
tion of IDUs shall reach full coverage in the next five years. 
Proposed measures: See priority B, improvement of coverage of syringe provision 
through specialised programmes (NSP), HIV and HCV treatment programmes, im-
provement of HCV surveillance, hepatitis B vaccination programmes, outreach, peer 
involvement and family support. 
Relevance for public health: Infection diseases are one of the major drug-related 
diseases and can be easily and cost-effectively influenced by widely available syringe 
provision through specialised programmes. It has been proven that OST is associated 
with a 50 % reduction of HIV infection among IDUs (MacArthur et al. 2012). HIV and 
HCV treatment decrease the risk of infections for others and are therefore cost-
effective interventions to avoid individual harm and prevent further infections, which 
could lead to a substantial health burden for drug users and the society as whole. 
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15 Council Recommendation of 18 June 
2003 on the prevention and reduction 
of health-related harm associated with 
drug dependence (2003/ 488/ EC) 
THE COUNCIL OF THE EUROPEAN UNION, 
Having regard to the Treaty establishing the European Community, and in particular 
the second subparagraph of Article 152(4) thereof, 
Having regard to the proposal from the Commission(1), 
Having regard to the opinion of the European Parliament(2), 
Having regard to the opinion of the European Economic and Social Committee(3), 
Having regard to the opinion of the Committee of the Regions(4), 
Whereas: 
(1) In accordance with Article 3(1)(p) of the Treaty, Community action is to include a 
contribution towards the attainment of a high level of health protection. The third 
subparagraph of Article 152(1) of the Treaty also makes provision for action in reduc-
ing drugs-related health damage, including information and prevention. 
(2) The European Council, meeting in Helsinki on 10 and 11 December 1999, endorsed 
the European Union Drugs Strategy 2000 - 2004 that covers all European Union drug-
related activities and sets main targets. These targets include a substantial reduction 
over five years of the incidence of drug-related health damage (such as HIV, hepatitis B 
and C and tuberculosis) and the number of drug-induced deaths. 
(3) The European Council, meeting in Santa Maria da Feira on 19 and 20 June 2000, 
endorsed the European Union Action Plan on Drugs 2000 - 2004 as a crucial instru-
ment for transposing the European Union Drugs Strategy 2000 - 2004 into concrete 
actions which provide an effective integrated and multi-disciplinary response to the 
drug problem. 
(4) The Commission, in its Communication to the European Parliament and the Council 
on the European Union Action Plan to Combat Drugs (2000 - 2004), considered a 
comprehensive approach that should cover all areas of drug abuse prevention, from 
discouraging the initial use to reducing the negative health and social consequences as 
the best strategy. 
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(5) The European Parliament, in its Resolution on the abovementioned Communication 
welcomed the objective of reducing the number of deaths among addicts and called on 
the European Union and its Member States to encourage and develop damage limita-
tion policies, without debarring individual Member States from adopting measures and 
pilot schemes in this area. 
(6) The programme of Community action on the prevention of drug dependence within 
the framework for action in the field of public health and the programme of Commu-
nity action on the prevention of AIDS and certain other communicable diseases within 
the framework for action in the field of public health have supported projects aimed at 
preventing and reducing the risks associated with drug dependence, in particular by 
encouraging cooperation between the Member States, supporting their action and 
promoting coordination between their policies and programmes. Both programmes 
have been contributing to improving information, education and training aimed at 
preventing drug dependence and the associated risks, in particular, for young people 
and particularly vulnerable groups. 
(7) The decision of the European Parliament and of the Council adopting a programme 
of action in the field of public health (2003 - 2008) includes the development of 
strategies and measures on drug dependence, as one of the important lifestyle-related 
health determinants. 
(8) Since, according to research, the morbidity and the mortality associated with drug 
dependence affects a sizeable number of European citizens, the health-related harm 
associated with drug dependence constitutes a major problem for public health. 
(9) In accordance with the principle of subsidiarity, any new measure taken in an area 
which does not fall within the exclusive competence of the Community, such as 
prevention and reduction of risks associated with drug dependence, may be taken up 
by the Community only if, by reason of the scale or effects of the proposed action, the 
objectives proposed can be better achieved by the Community than by Member States. 
Prevention and reduction of risks associated with drug dependence cannot be confined 
to a geographical region or Member State and action therefore requires coordination at 
Community level. 
(10) Provisions should be made on reporting at national and Community level to 
monitor the measures taken by the Member States in this area, and the results thereof, 
and the way these Recommendations have been implemented. 
(11) The most important measure to reduce the risk associated with drug abuse is to 
prevent the abuse itself. 
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HEREBY RECOMMENDS THAT: 
1. Member States should, in order to provide for a high level of health protection, set 
as a public health objective the prevention of drug dependence and the reduction of 
related risks, and develop and implement comprehensive strategies accordingly. 
2. Member States should, in order to reduce substantially the incidence of drug-related 
health damage (such as HIV, hepatitis B and C and tuberculosis) and the number of 
drug-related deaths, make available, as an integral part of their overall drug preven-
tion and treatment policies, a range of different services and facilities, particularly 
aiming at risk reduction; to this end, bearing in mind the general objective, in the first 
place, to prevent drug abuse, Member States should: 
1. provide information and counselling to drug users to promote risk reduction 
and to facilitate their access to appropriate services; 
2. inform communities and families and enable them to be involved in the preven-
tion and reduction of health risks associated with drug dependence; 
3. include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from particu-
lar target populations, who are not effectively contacted or reached by existing 
services or through traditional health education channels; 
4. encourage, when appropriate, the involvement of, and promote training for, 
peers and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services; 
5. promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility; 
6. provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide variety 
of different treatment options should be provided for the drug-abuser; 
7. establish measures to prevent diversion of substitution substances while ensur-
ing appropriate access to treatment; 
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8. consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison; 
9. promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions; 
10. provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange; 
11. ensure that emergency services are trained and equipped to deal with over-
doses; 
12. promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction; 
13. support training leading to a recognised qualification for professionals respon-
sible for the prevention and reduction of health-related risks associated with drug 
dependence. 
3. Member States should consider, in order to develop appropriate evaluation to 
increase the effectiveness and efficiency of drug prevention and the reduction of drug-
related health risks: 
1. using scientific evidence of effectiveness as a main basis to select the appropri-
ate intervention; 
2. supporting the inclusion of needs assessments at the initial stage of any pro-
gramme; 
3. developing and implementing adequate evaluation protocols for all drug pre-
vention and risk reduction programmes; 
4. establishing and implementing evaluation quality criteria, taking into account 
the Recommendations of the European Monitoring Centre for Drugs and Drug Ad-
diction (EMCDDA); 
5. organising standardised data-collection and information dissemination accord-
ing to the EMCDDA recommendations through the REITOX national focal points; 
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6. making effective use of evaluation results for the refining and development of 
drug prevention policies; 
7. setting up evaluation training programmes for different levels and audiences; 
8. integrating innovative methods that enable all actors and stakeholders to be in-
volved in evaluation, in order to increase acceptance of evaluation; 
9. encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries. 
4. Member States should report to the Commission on the implementation of this 
Recommendation within two years of its adoption and subsequently on request by the 
Commission with a view to contributing to the follow-up of this recommendation at 
Community level and acting as appropriate in the context of the European Union 
Action Plan on Drugs. 
HEREBY INVITES the Commission to: 
- cooperate with the Pompidou Group of the Council of Europe, the World Health 
Organisation, the United Nations International Drug Control Programme and other 
relevant international organisations active in the field, 
- prepare a report, in accordance with the European Union Action Plan on Drugs and 
with the technical support of the EMCDDA, with a view to the revision and updating of 
this Recommendation, on the basis of the information submitted by the Member States 
to the Commission and the EMCDDA, and the latest scientific data and advice. 
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Abbreviations 
 
AIDS acquired immune deficiency syndrome 
CI confidence interval 
CR Council Recommendation 
DFT drug free treatment 
DRD drug-induced deaths 
DRID drug-related infectious diseases 
DG JLS Directorate-General for Justice, Security and Freedom 
DG SANCO Directorate-General for Health and Consumers 
EAHC Executive Agency for Health and Consumers 
EC European Commission 
ECDC European Centre for Diseases Prevention and Control 
EDDRA Exchange on Drug Demand Reduction Action 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EU European Union 
EUROHRN European harm reduction network 
EU 12 countries which joined the EU in 2004 or later 
EU 15 countries which joined the EU before 2004 
GÖG Gesundheit Österreich GmbH 
GP general practitioner 
HBV hepatitis B virus 
HCV hepatitis C virus 
HDB(T) high-dosage buprenophine (treatment) 
HIV human immunodeficiency virus 
IDM interactive domain model 
IDPC International Drug Policy Consortium 
IDU injecting drug user, injecting drug use 
IEC information, education and communication 
IPA Instrument for Pre-Accession Assistance 
MMT methadone maintenance therapy 
Abbreviations 177 
NIROA non injecting route of administration 
NFP national focal point 
NHS National Health Service 
NSP needle (and syringe) exchange programme 
NUTS nomenclature of territorial units for statistics 
ORW outreach work 
OST opioid substitution treatment 
PDU problem drug use 
PHARE Poland and Hungary: Assistance for Restructuring their Economies 
PICO population-intervention-comparison-outcome 
POU problem opiate use 
PSC psychosocial care 
RCT randomised controlled trial 
REITOX Réseau Européen d ́Information sur les Drogues et les Toxicomanies 
RR relative risk 
SQ standard questionnaire 
ST standard table 
STD sexually transmitted diseases 
TB(C) tuberculosis 
TEDI Trans European Drug Information 
UNAIDS United Nations Programme on HIV/AIDS 
UNODC United Nations Office on Drugs and Crime 
UK United Kingdom 
WHO World Health Organization 
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